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ABSTRACT
Genetics and epigenetics are widely expected to revolutionise our understanding of health and 
disease.  However  any  attempt  to  extract  relevant  information  from  noisy  data  requires  a 
combination of modelling and statistical techniques. Given the number of genes and the complexity 
involved in the genome, sophisticated methods will be needed to properly capture the information 
that is contained.
Many mechanisms and variables can affect and control the expression of a gene. In this 
thesis, it is specifically spatially coherent variations in transcription which are investigated. Several 
different areas were examined, producing a broad set of results. Important findings include the 
demonstration of spatial coherence as the result of epigenetic effects, the creation and validation of 
a technique to detect spatial coherence, and the extension of spatial modelling to epigenetic data. 
Other important results include the detection of spatial coherence variation due to confounding 
variables  (PMI  and  neuronal  concentration)  and  the  development  of  new  spatial  modelling 
techniques. The results indicate that spatial modelling provides a useful approach to investigating 
unusual and unknown aspects of epigenetic and transcriptional regulation.
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1. Structure and original contributions to this thesis
The majority of this thesis makes use of the 'Chromowave' software and methodology (Turkheimer 
et  al.  2006). Despite its publication in two papers,  Chromowave modelling represents a fringe 
method for modelling transcription, and looks at a distinctly different aspect of transcription to other 
methods. The overall intention of the thesis is to 
• Validate further the wavelet/spatial  approach of  modelling transcription by applying it  to 
large series of genomic data and test the consistency of its findings across experiments 
and platforms.
• Verify  using  independent  metrics  (e.g.  Hurst  exponent)  the  existence  of  coherence  in 
genomic data to justify the use of Chromowave as a basic tool for genomic research.
• Apply Chromowave to non-transcriptional genomic data to assess its potential in modelling 
genomic variations with spatial coherence, particularly those of epigenetic origin.
• Expand  the  power  of  the  approach  by  using  other  multivariate  approaches  (e.g. 
Independent Component Analysis).
Chapter  2  –  Introduction: This  chapter  introduces the basic  biology of  transcription  and the 
concept  of   'spatial  coherence'  used here.  The reasons this coherence are expected are then 
justified. An introduction is also made to some of the mathematics used both in the literature and 
specifically in this thesis. Some explanation for the primary methods are made and discussed. 
Chromowave results published before the start of this PhD are analysed to demonstrate how to 
interpret results and to give the former 'state of the art' of spatial modelling. 
Chapter  3  –  Materials  and  methods: This  chapter  discusses  the  practical  application  of 
Chromowave and discusses the various materials used in the different investigations. It includes 
information  about  pre-processing  of  data  and  database  information  for  where  data  can  be 
acquired. 
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Chapter 4 - Results 1: This chapter attempts to firstly demonstrate that spatial variations exist due 
to epigenetic modifications. This was claimed in a previous publication (Anderson et al. 2008), but 
needed further  testing  due to that  papers reliance on  assumptions  about  the pathogenesis  of 
Huntington's disease (HD). Consequently in this chapter simpler data from cell lines treated with 
DNA methylation and histone acetylation modifiers is analysed. These experiments are entirely lab 
based and so represent a purer approach to verify the detection of epigenetic events. Additionally 
a frequent question from colleagues was whether  Chromowave results were due to confounding 
factors  such  as  pH  or  postmortem  interval  (PMI).  Some  standard  confounding  factors  were 
therefore investigated with some significant patterns detected. 
This  chapter  does  not  represent  strongly  novel  work,  though  data  on  epigenetic 
modifications have not been analysed in this way previously and the results contained are different 
from any published elsewhere. Choice of datasets and investigation areas were performed by the 
author. Some novel aspects do exist in this chapter, for example the usage of SVD to summarise 
the  neuronal  concentration  is  unique  (to  our  knowledge)  to  this  thesis.  It  represents  an 
improvement over the common method of using the mean (Bossers et al. 2009), which is not a 
suitable summary of noisy expression data. Results are similar to using the mean (associations 
can be detected) but it appears more sensitive. The findings are also unique and novel. 
Chapter 5 - Results 2: This chapter investigated whether spatial modelling was applicable to other 
non-transcription genomic data. Some data (e.g. copy number data) are routinely analysed in a 
spatial fashion. Other data (e.g. epigenetic data) are not thought of as being spatially organised. To 
determine whether these data had significant spatial components, new tests were developed to 
detect  spatial  coherence,  using  Hurst  exponent  models.  Data  were  then  analysed  where 
appropriate using a modified Chromowave procedure. Chromowave was then applied to interesting 
datasets,  to  determine  the  ability  to  detect  relevant  variations  as  well  as  test  the  findings, 
reproducibility  and  generality.  These  studies  showed  how  widespread  spatially  coherent 
methylation changes were, and some discussion is made on the potential uses of this approach for 
17
prediction and diagnosis. 
The  results  and  methods  in  this  chapter  are  unique  to  this  thesis  as  is  approaching 
epigenetic data in a spatial way. Data was acquired partially (copy number data) from collaborators 
and partially from publicly available sources (epigenetic data).  The pre-processing of both was 
done by others, but the analysis and the development of software to analyse these (or in the case 
of Chromowave the addition of those microarrays) were developed by the author. The other main 
result for the chapter was a final demonstration of the ability of Chromowave to detect transcription 
variations due to chromosomal deletions or gains.      
Chapter 6 - Results 3: This chapter applies some alternatives to  Chromowave to transcription 
data.   Three alternatives  are investigated.  The first  replaces the singular  value decomposition 
analysis technique in Chromowave with a more modern independent component analysis.  This 
makes it possible to apply Chromowave like modelling to situations which were poorly modelled 
before, such as those with non-orthogonal components. The second method is a supplement to 
Chromowave, providing different, though related information. This applies a Hurst exponent based, 
long-range correlations model to spatial modelling. This enbles detection of changes in the amount 
of spatial coherence, though not their location. The third is a non-spatial analysis technique. This 
technique aimed to remove the spatial coherence part of the data and analyse only the individual 
probe  components.  It  is  shown  that  this  makes  an  important  impact  on  gene-expression 
measurements and in situations where the spatial component is not wanted, it is argued that this 
method is better than traditional techniques.
These  three  softwares  are  based  on  Chromowave concepts  and  make  use  of  some 
Chromowave code,  however  they  are  unique  to  this  thesis  and  have  not  been  developed 
elsewhere.  Two of them use models which are extensively different from that in  Chromowave, 
while the third can be seen as an extension of  Chromowave to non-orthogonal components. All 
show advantages and disadvantages over the normal model.
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Chapter 7 - Results 4: This chapter returns to the spatial analysis of non-transcription data using 
a  method  based  on  Chromowave.  Unlike  Chromowave the  method  discussed  in  this  chapter 
analyzes  multiple  data  types  simultaneously.  This  chapter  applies  a  technique  (simultaneous 
component analysis – SCA) to the wavelet space representation of the data. This enables it to 
detect simultaneously modified regions in cases where data is acquired using multiple modalities 
on the same subjects. Other uses and methods for applying this method are briefly discussed. 
The application of SCA in wavelet space has not been published elsewhere and is a novel 
application. The application of SCA to problems involving comparative genomic hybridisation and 
expression,  or  methylation  and  expression  also  are  unique  to  this  thesis.  The  method  was 
developed by the author using original code combined with that obtained from Chromowave. This 
represents a novel development in the thesis. 
Chapter 8 - Discussion: This chapter concludes the thesis by revisiting some of the findings from 
the previous chapters, and discussing various options for future developments.  
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2. INTRODUCTION
This thesis explores modelling gene transcription in novel ways. The concept of ‘spatial coherence’ 
mentioned in the title therefore needs explanation.  In the physics of  lasers ‘spatial  coherence’ 
refers to the correlation between the phases of light at different points in space (often along 1-
dimensional lines) (Telle et al. 2007). Transcription data does not have a phase component, and so 
the definition we use is not identical with this. Instead we refer to correlated behaviour of genes 
across space, in particular nearby regions. Time and data constraints mean that this thesis limits 
itself to similar behaviour along linear chromosomes. Gene expression data is inherently complex 
and noisy, and all but the simplest experiments have multiple factors. Consequently the behaviour 
can be a reflection of any variable. If during a genes progression a set of adjacent genes show 
increased expression, then this would count as an example of spatial coherence. There can be 
various  reasons  for  spatial  coherence,  but  one  expected  reason  is  that  adjacent  genes  are 
sometimes  co-regulated  together.  The  aims  of  this  thesis  revolve  around  exploring  this 
phenomenon. These aims can be simplified into justifying spatial modelling, as a useful technique 
and develop improvements/extensions to the models  enabling  more data and situations to be 
analysed. Background on the biology of transcription and why coherent expression of this type 
would be expected is included in the next few sections. 
The importance of genetics in both health and disease is widely known. However the ways 
in which genetic information reflect disease states is complex. Gene expression is one part of the 
functional process that links DNA at the microscale to the organism at the macroscale. Rather than 
genes themselves it  is  their  products and the higher  level  networks which typically  interact  to 
produce  the  overall  phenotype  (Strohman  2002).  Regulation  of  the  gene  expression  state  is 
therefore important, allowing cells to maintain the specific set of genetic instructions that forms the 
organism.  In  this  thesis  it  is  “spatially  coherent”  gene  expression  that  is  investigated.  Since 
spatially coherent gene expression is a rarely investigated phenomenon the thesis also focuses on 
the development of mathematical tools which can be used to investigate it. In order to understand 
why  spatially  coherent  expression  exists  it  is   first  necessary  to  introduce  some of  the  basic 
biology.
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DNA is  made of  four  bases,  adenine  (A),  cytosine  (C),  guanine   (G)  and thymine  (T) 
(Claverie and Notredame 2007; Isaev 2004). These four bases are then arranged in a specific 
sequence along the DNA strand to create genes (Dawkins 2006). The utility of the word gene is 
debated  (Pearson 2006), since it is now known that they are not discrete units and instead can 
overlap, however genes can be viewed as codes representing proteins and other products (Oram 
and Wilson 2007, 218). How these codes become expressed as gene products is an important 
area in biology and some of the ways in which 'gene expression' can be regulated is the focus of 
this thesis. 
At  the pH normally found in  cells,  the phosphate  backbone of  DNA carries  a negative 
charge  which  creates  an  electrostatic  repulsion  between  different  parts  of  the  DNA strands 
(Bloomfield 1997). The entire length of DNA is on the order of a metre, and is packaged into the 
nucleus, a volume of just a few micrometers  (Yamasaki,  Teramoto, and Yoshikawa 2001). The 
efficient packaging of DNA into chromosomes within the nucleus, is therefore a necessity. Most 
eukaryotes2, including humans, make use of positively charged histone proteins to facilitate this 
compaction.  The  DNA strand  is  wrapped  around  groups  of  eight  such  histones  to  form  a 
nucleosome, the building block of 'chromatin' (see figure 1). The proteins carry a positive charge 
(Strahl and Allis 2000), which cancels out the negative charge of the DNA and holds the strand 
tightly together, maintaining a 3D conformation. By varying these charges the compaction level can 
be altered and controlled. As will be discussed in a later section (2.2.2.2 Histone tail changes), the 
level  of  chromatin  compaction  is  used  by  many  eukaryotes  to  regulate  the  levels  of  gene 
expression. 
Of particular interest is the role of genes in disease, since their understanding may lead to 
the development of therapies. However there is no generic mechanism by which genes cause or 
participate in pathogenesis. It is known that different diseases involve genes in different ways and 
that diseases vary in complexity. Some 'simple' diseases are caused by mutations in a single gene 
(Antonarakis  and  Beckmann  2006) and  typically  follow  simple  rules  of  inheritance.  'Complex 
disorders'  instead often involve familial  risk rather than outright  inheritance  (Ptak and Petronis 
2 Not all eukaryotes as is sometimes thought, in fact there are many exceptions to the rule (Bendich and 
Drlica 2000).
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2008). It is thought that the disease processes for complex disorders involve multiple interacting 
genes  (Dipple  and  McCabe  2000) and  environmental  signals  (Ptak  and  Petronis  2008). 
Environmental signals are believed to be incorporated into genetics through what are known as 
epigenetic control mechanisms (Jaenisch and Bird 2003), which regulate gene expression. Gene 
expression can be controlled at various stages of the expression process,  (Dever 2002), but this 
PhD  focuses  on  mechanisms  which  operate  at  the  transcription  stage,  and  hence  can  be 
measured using standard transcription arrays.
2.1 Gene Transcription.
Transcription  is  the  first  step  in  the  gene  expression  process.  Transcription  involves  a  DNA 
sequence being used as a template by ribonucleic acid (RNA) polymerase enzymes to create a 
'complementary'  sequence of  RNA  (Perdew, Heuvel,  and Peters 2006,  52). Like DNA, RNA is 
made of four bases, each of which is associated ('complementary') with one of the bases making 
up DNA. Consequentially each sequence of DNA is associated with a unique sequence of RNA 
and vice versa. Transcription starts in a so called promoter region. These promoter regions are 
areas of the DNA sequence upstream from the actual gene, which act as a binding site for RNA 
polymerase  enzymes  when  there  are  'transcription  factors'  present  (Ferrai  et  al.  2010). The 
presence of transcription factors and RNA polymerase molecules at the promoter region initiates 
the transcription  process3.  The process stops when the RNA polymerase molecule  reaches a 
transcription  terminator  (a  genetic  sequence  which  marks  the  end  of  the  the  region  whose 
transcription is controlled by that promoter region). The number of genes controlled by a single 
promoter region can be a single gene or multiple genes (Blumenthal 2004). If several genes are 
controlled by a single promoter region, they are co-regulated, since regulation of the transcription 
factors will affect all associated genes simultaneously. These sets of co-regulated genes can be 
located together along a chromosome and are then known as operons. 
Depending on the function of a specific gene, the RNA produced is referred to in different 
3 This is not quite the whole picture since RNA polymerase II, which is often associated with transcriptional 
control, can be modified post-translation, some modifications are then associated with non-transcribed or 
minimally transcribed genes. (Brookes and Pombo 2009).
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ways. In the case of genes coding for proteins, the RNA molecules are referred to as messenger  
RNA (mRNA) and after transcription they proceed to move to the ribosomes, where proteins are 
synthesised. Alternatively the products of transcription may be ribosomal RNA (rRNA, the main 
component of the ribosomes), transfer RNA (tRNA, which transfers specific amino acids to the 
sites of protein synthesis)  or various other factors which are involved in protein synthesis and 
assembly. The expression process is completed with the next stage which involves the translation 
of the RNA into gene products (such as proteins) and therefore into the components that make up 
the organism. 
Changes in the rate of gene transcription represent one of the main ways in which gene 
expression  can  be  actively  controlled  in  living  organisms.  It  is  also  possible  to  control  gene 
expression  through  the  translation  process  (Dever  2002),  however  here  we  are  focussing  on 
mechanisms which affect the level of transcription for genes. 
2.2 Controlling the rate of transcription
Transcription  can be controlled  at  a  range of  different  scales,  from single  genes operated by 
transcription  factors  to  the  large  scale  folding  of  chromatin  and  the  global  positioning  of 
chromosomes (Ferrai et al. 2010; Branco et al. 2008; Branco and Pombo 2007) and association 
with the nuclear lamina (Guelen et al. 2008; Finlan et al. 2008). In this thesis we are focussing on 
those mechanisms which  can operate in  a  spatial  way,  upon multiple  genes that  are  located 
sequentially along the DNA sequence. However, this too can occur at a range of scales due to a 
variety of mechanisms that will be discussed below.
2.2.1 Transcription factors
Transcription factors can be separated into 2-types. The first type is general transcription factors 
which  are  associated  with  the  transcription  of  many  different  genes.  The  second  type  of 
transcription factor is sequence specific factors  (Kim and Mullet 1995; Dutton, Johns, and Miller 
1997) that  operate  on specific  promoter  regions.  While  gene  expression  is  regulated  through 
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transcription  factors,  transcription  factors  are  also  gene  products,  and  this  leads  to  complex 
networks of co-regulation. 
2.2.2 Epigenetic Mechanisms
Epigenetics can be defined as “a system of  inheritance that  does not  involve changes in  the  
primary  DNA sequence but  that  can nevertheless  be transmitted through cell  and organismal  
lineages and can result in changes in gene expression.”  (Ling and Hoffman 2007). There are a 
large number of different epigenetic mechanisms, and many of them involve changes in the local 
state of chromatin. Chromatin exists in a range of states from the loosely bound euchromatin, to 
highly  condensed  heterochromatin.  Euchromatin  is  associated  with  relatively  high  levels  of 
expression,  whereas  heterochromatin  is  associated  with  repressed  states  of  gene  expression 
(Tsankova et al. 2007). The reason for this is thought to be that the more condensed the chromatin, 
the harder it is for the transcription factors to access the promoter regions and consequently there 
will be a reduced rate of transcription (see figure 1).                                                                  
2.2.2.1 DNA methylation 
The best known epigenetic mechanism is DNA methylation. When DNA becomes methylated, a 
hydrogen atom in a cytosine base within the DNA strand is replaced with a methyl group. If this 
occurs in a promoter region, this inactivates the gene by making it  harder for the transcription 
factors  to  bind  to  the  DNA strand  and  also  compacting  the  local  chromatin  state  (Bock  and 
Lengauer  2008) making it  harder  for  the transcription  factor  to  access the promoter  region.  It 
occurs almost exclusively in CpG dinucleotides; parts of the DNA sequence where a cytosine ('C') 
is followed by a guanine ('G'). Because cytosine and guanine are complementary pairs, this CG 
can be read on either strand and so is inactivated independent of which strand is read (Jones and 
Laird 1999). The eukaryote genome shows a very low rate of CG dinucleotides4 while prokaryote 
4 Approximately 42% of the Human genome is made up of cytosine-guanine pairs  (Jabbari and Bernardi 
2004). Assuming a random distribution of DNA bases, we therefore would expect CG to occur around 
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sequences tend to show no suppression of the CG sequence. It is therefore often argued that the 
majority of the silenced CG dinucleotides represent parasitic DNA elements (due to insertions by 
retroviruses and mutations) which need to be silenced to both stop them spreading through the 
genome and stop them causing disruptions  such as  translocations  (Yoder,  Walsh,  and Bestor 
1997; Robertson and Wolffe 2000). A similar protective role for DNA methylation exists in some 
plants which use methylation as a form of immune system (Waterhouse, Wang, and Lough 2001). 
Not  all  CpG dinucleotides are methylated however,  with the majority of  non-methylated 
CpGs occuring in  'CpG islands'.  A CpG island is  a  region  of  the  genome which contains  an 
abnormally large number of CpGs which are also relatively unmethylated. These CpG islands often 
become methylated  in  cancer  cells  (Bradbury  2003).  It  is  also  possible  for  genes  which  are 
normally methylated to become demethylated  (Esteller and Herman 2002), representing another 
potential component in disease since these gene inactivations may be detrimental.
More recently it  has been suggested that methylation occurring outside of the promoter 
region can also have an effect on expression levels  (Hellman and Chess 2007; Zilberman et al. 
2007). This extra-promoter methylation is known as 'body methylation' (because it occurs in the 
'body'  of  a  gene)  and is  associated with  highly  active  genes,  rather  than inactive  genes (like 
promoter  region  methylation).  This  is  a  recent  finding,  and  it  is  not  certain  whether  body 
methylation  increases  gene  expression  or  has  a  different  relationship  with  transcription. 
Consequently its significance is not yet understood (Suzuki and Bird 2008). 
4.41% of the time ((0.42/2)2), whereas for Humans the percentage is actually closer to 1  (Jabbari and 
Bernardi 2004). The rate of GC however is 4.3%, which is close to the predicted value. CG however is not  
suppressed in other lifeforms such as most prokaryote sequences (Campbell, Mrázek, and Karlin 1999). 
25
Figure  1,  diagram of  chromatin structure.  Chromatin is made up of  sets of  8 histone proteins  
(green circles) with the DNA helix (grey line) wrapped around them ('beads on a string'). Chemical  
modifications to the tails  of  the  histone proteins  (blue lines)  allows the charge carried  by the  
histone-DNA complex to vary. By changing the charge the level of compaction can be varied from  
open  euchromatin  (top)  to  compact  heterochromatin  (bottom).  Transcription  factors  can easily  
access the DNA in open euchromatin, but are blocked by the compact nature of heterochromatin.  
Consequently euchromatin is associated with high levels of expression while heterochromatin is  
associated with repressed genes.
 
2.2.2.2 Histone tail changes
As mentioned the primary function of histone proteins is to compact DNA, allowing for long lengths 
of DNA to fit inside the cell nucleus. The compaction status controls the accessibility of promoter 
regions and hence controls gene expression. The primary way that this compaction status can be 
regulated is through chemical changes to the tails of the histone proteins. Chemical changes to the 
tails of histones change the charge carried by the histone proteins making it bind together more or 
less tightly, which in turn changes how compact the chromatin is (Bloomfield 1997). 
A number  of  chemical  changes  can  affect  the  tails  of  histones.  Different  expression 
changes can occur depending on which of the eight histones is affected (each octamer of histones 
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contains two copies of each histone labelled H2A, H2B H3 and H4) (Tsankova et al. 2007; Luger et 
al.  1997). The total collection of different changes and the effects they have on expression, is 
called the histone code (Strahl and Allis 2000). Some of the changes which can occur to the tails 
include,  acetylation,  methylation,  ubiquination,  SUMOlation and phosphorylation  (Cheung,  Allis, 
and Sassone-Corsi 2000; Gill 2004; Kouzarides 2002; Kuo and Allis 1998). Some of these changes 
(e.g. histone acetylation) are associated with increased expression and others (e.g. SUMOloation 
(Shiio and Eisenman 2003)) are associated with reduced expression. 
2.2.2.3 Genetic Dosage and Dosage Control Mechanisms
Gene expression may also vary because of copy number variations (CNV). Healthy individuals nor-
mally carry two copies of each autosome (chromosome other than the sex chromosomes, X & Y) 
and so generally carry two copies of each gene located on an autosome. However, it is possible for 
the number of copies of a gene or a region of a chromosome to be either higher or lower than two.  
Both duplications and deletions are possible, and may occur on any chromosome (including the 
sex chromosomes). Because the number of copies is different, the amount of expression may be 
different, although dosage control mechanisms may stop this difference from occurring. 
Dosage control mechanisms act on individual genes or on whole chromosomes, mainly by 
epigenetic means. In mammals, ChrX undergoes both inactivation in females (females carry two 
ChrX with one inactivated) and upregulation in males of the single active ChrX, bringing expression 
up to autosomal levels (Nguyen and Disteche 2006).
X-inactivation is regulated by Xist gene and implemented through methylation. Xist  is a 
gene that is activated in females but not in males. Activation of this gene occurs when the two 
copies of Xist in women become colocalised (Bacher et al. 2006) in the nucleus. One of the two 
Xist copies becomes unmethylated (Panning and Jaenisch 1996) and the chromosome containing 
the active Xist gene then becomes covered in RNA product, and relocates to the outside of the 
nucleus. The nuclear periphery is often associated with low levels of gene expression (see 2.2.2.4
Lamina Associated Domains).  It  is  not only the Xist gene which follows this pattern of change 
(colocalisation  followed  by  inactivation  of  one  allele  (Schlesinger  et  al.  2009))  and statistical 
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models have been created to explain this mechanism (Nicodemi and Prisco 2007), although this is 
deemed to be work in progress towards a clearer understanding of the process .
The X which remains active is selected randomly for different cells, but remains constant 
throughout the woman's lifetime. This means that as an overall dosage, women get a mixture of 
the  different  alleles  from different  chromosomes  providing  protection  against  certain  disorders 
located on chromosome X (Migeon 2008). This can be seen as an extra risk factor for males due to 
low zygosity. 
Gene dosage is closely related to the concept of zygosity. Zygosity is a measure of how 
many different copies of a gene, gene region or chromosome there are. Autosomal genes come in 
two copies, one on the maternal allele and one the paternal allele. In males there is only one copy 
of the genes on chromosome X and in the autosomes, if both alleles are the same gene variant, 
that  gene also  exists  in  only  one form.  Genes that  are  present  in  only  one form are  termed 
homozygous.  Large numbers  of  homozygous genes usually  reflect  in-breeding in  the  parental 
populations (Balloux, Amos, and Coulson 2004) although there are other reasons for homozygous 
genes. Deletions of DNA if they occur in heterozygous regions can also lead to homozyous regions 
and this process is known as a loss of heterozygosity (LOH). 
Chromosome X dosage can also vary from tissue to tissue. It has been shown that there 
are tissue dependent mechanisms which underly X-expression. For example in brain tissues, the 
expression of x-linked genes is higher than in other tissues (Nguyen and Disteche 2006)
There are several important points about epigenetic mechanisms such as DNA methylation 
and  dosage  control  mechanisms.  Firstly  they  can  be  (but  are  not  necessarily)  inherited  from 
parents.  Additionally, unlike genes which are identical in all cells of the body, they can vary from 
tissue to tissue (Ladd-Acosta et al. 2007; De Bustos et al. 2009) and across time (Bjornsson et al. 
2008). This allows for epigenetic mechanisms to be far more dynamic than the essentially static 
DNA, which explains how they can help integrate environmental signals into the gene activity. This 
explains why it has been suggested that epigenetics may be important in complex diseases (see 
2.3 Relevance in disease). 
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2.2.2.4 Lamina Associated Domains
The nuclear lamina is a network of proteins lying just inside the nuclear membrane (Gruenbaum et 
al. 2005; Guelen et al. 2008) making up the inner part of the nuclear membrane (see figure 2). The 
lamina is associated with gene repression, due to its lack of RNA polymerase II and chromatin 
being in the compact heterochromatin state (Ferrai et al. 2010). In section 2.2.2.3 Genetic Dosage
and Dosage Control Mechanisms, it  was mentioned that the inactive X-chromosome in women 
moves to the periphery of the nucleus, effectively becoming a lamina associated domain (LAD). A 
LAD is defined as a region of chromosome that is associated with the nuclear lamina (Guelen et al. 
2008). Lamina associated domains (LADs) represent a recently identified variable associated with 
gene deserts (regions with relatively few genes) and low levels of expression, with LADs showing 
lower expression than other regions (Guelen et al. 2008). Association with the lamina causes the 
reduced transcription and is not just an indicator for it (Reddy et al. 2008; Finlan et al. 2008). It is 
expected that  LAD maps will  vary between different  cell  types,  and that  LADs contain  genes 
involved in tissue differentiation  (Shevelyov et al. 2009) so that the genes contained within the 
known LADs are not always inactive. 
Because a LAD is an extended region potentially encompassing multiple genes, it is clear 
that the reduced transcription it causes is spatially coherent, and so is highly relevant to this thesis. 
LADs themselves are believed to be involved in stabilising the 3D positioning of the chromosomes, 
by providing a  scaffold  for  the chromosomes to bind to  (Dechat,  Adam, and Goldman 2009), 
leading  to  a  role  in  the  3D  structure.  The  regions  associated  with  the  lamina  are  made  of 
heterochromatin, which demonstrates that these different processes are not truly independent but 
interact in some incompletely understood way.
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Figure  2, diagram of  the outer edge of  the nucleus.  The nucleus is  where chromatin (DNA &  
histone proteins) reside in the body. The nucleus is surrounded by the nuclear membrane (grey)  
and  the  nuclear  lamina  (blue).  The  lamina  is  a  network  of  proteins  and  is  associated  with  
transcriptional silence. Regions of chromatin localised at the lamina (red) are known as lamina  
associated  domains  (LADs)  and  show  reduced  levels  of  transcription.  Chromosomes  occupy  
specific locations in the nucleus  (Bolzer et al. 2005; Branco et al. 2008) and this is one way in  
which transcription (and hence expression) is regulated. Figure inspired by (Guelen et al. 2008)
2.3 Relevance in disease
Gene expression changes caused by any mechanism can be important in disease. For example, 
many tumours are believed to occur when 'tumour suppressor genes' become deleted (Green et al. 
2010).  CNVs  have  been  implicated  in  diseases  such  as  Schizophrenia  (Mulle  et  al.  2010; 
Stefansson et al. 2008) and Prader-Wili syndrome (Buiting et al. 1995). Other similar disruptions 
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such as translocations (where a piece of chromosome becomes detached and reattaches in an 
incorrect place, such as a different chromosome) are also important in cancers and other disorders 
(Buonincontri et al. 2010; Zhang et al. 2010). This sort of abnormality clearly operates on a spatial 
region, since it extends over a certain amount of chromatin.
Zygosity also has a role in disease. Loss of heterozgyosity (LOH), is caused by deletions of 
genes or regions on part of one chromosome (See figure 3), which are present in many cancers. It 
has been argued that loss of heterozygosity represents an important factor in cancer development 
(Green et al. 2010). Additionally the availability of only a single variant of a gene (homozygosity) 
places the subject at risk of various recessive mutations and general reduced genetic fitness  (Mi-
geon 2008; Balloux, Amos, and Coulson 2004).
Mutations in transcription factor proteins have also been implicated in a variety of disorders 
such as, Rett's syndrome (Moretti and Zoghbi 2006; Chadwick and Wade 2007) and the autoim-
mune disease IPEX (van der Vliet and Nieuwenhuis 2007). These mechanisms do not seem re-
lated to spatial expression control, since they operate on individual genes, or a set of genes distrib-
uted over the genome. However as already discussed operons can include multiple spatially asso-
ciated genes, in which case a small region of the chromosome is co-regulated and so spatially co-
herent.
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 Figure 3, illustrates a region that has been deleted and so only contains the B alliele (red) variants  
of the genes. This illustrates how a deletion, shows up as a region of low heterozygosity, which  
may represent  a loss  of  heterozygosity  (LOH).  The figure also  illustrates  the simplest  way of  
describing (very roughly) the location of a gene on a chromosome. Healthy chromosomes have  
two parts, the small arm (at the top of the figure on the left) referred to as the 'p-arm' and the  
longer arm referred to as the 'q-arm
Disruption  of  epigenetic  mechanisms have  also  been  implicated  in  a  wide  range  of  diseases 
(Tsankova et al. 2007; Esteller 2007; Petronis 2003; Blalock et al. 2004). For example, although 
cancer is considered mainly a genetic disease (Vogelstein and Kinzler 2004)  CpG islands (regions 
of DNA containing large numbers of unmethylated CpG dinucleotides) often become methylated in 
cancer cells (Bradbury 2003). The inactivation of tumour suppressor genes associated with these 
CpG islands can lead to tumorigenesis. Methylation of a gene is therefore functionally equivalent to 
a  deletion  of  that  same  gene.  Cancer  is  also  associated  with  widespread  deregulation  of 
transcription and these can result from long-range epigenetic mechanisms (Stransky et al. 2006) 
32
such as DNA methylation and histone modifications. These epigenetic changes are believed to be 
important in cancer progression and tumorigenesis  (Esteller 2007). Similarly Hutchinson–Gilford 
progeria syndrome is caused by mutation in the LMNA gene, but includes widespread changes in 
methylation patterns (Capell and Collins 2006) and the disruption of the nuclear lamina5 which is 
why it is known as a laminopathy. 
In Huntington's disease (HD), it is thought that the mutant Huntingtin protein affects RNA 
globally by either a direct interaction with DNA, which then alters the DNA conformation genome 
wide or by causing a change in higher order chromatin organisation due to unknown structural role 
for the protein  (Benn et al. 2008). Additionally, the mutant form of the Huntingtin protein collects 
into poorly soluble aggregates  (DiFiglia  et  al.  1997). These aggregates sequester transcription 
factors  (Sadri-Vakili  and Cha 2006) and interfere  with histone deacetylation  (Butler  and Bates 
2006) which  in  turn  affects  chromatin  conformation.  The  aggregates therefore  interfere  with 
transcription globally in tissues where they occur. These aggregates for neuronal inclusions which 
damage the neurons and represent a hall mark of Huntington's disease and conditions caused by 
similar  mutations  (Becher et al.  1998;  DiFiglia et al.  1997). This marks HD out as an unusual 
disease, which is likely to contain spatially coherent features of multiple origins. This is thought to 
cause the widespread transcription changes which can be detected in HD subjects and suggests 
that spatially coherent epigenetic changes can occur at high levels of genomic organisation. 
It  has even been suggested that  the way in which epigenetic changes can incorporate 
environmental signals (López-Maury, Marguerat, and Bähler 2008), can explain how environmental 
risk factors can be incorporated into complex diseases  (Rodenhiser and Mann 2006; Ptak and 
Petronis  2008).  All  of  these  points  and  examples  together  show that  changes  in  expression 
patterns  caused  by  a  variety  of  disruptions  can  be  extremely  important  in  disease,  and  can 
potentially be used both in understanding and diagnosing disorders.
5 The  LMNA gene codes for the proteins making up the nuclear lamina, so this is a direct result of the 
mutation which occurs. 
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2.4 Experimental Analysis techniques
To analyse gene expression the primary data type that is investigated is likely to be transcription, 
though other information such as measures of epigenetic markers may also be useful. The main 
ways of investigating expression and related markers involve either microarrays, or sequencing. 
Microarrays and sequencers effectively perform thousands of  experiments simultaneously.  The 
majority of data used in this thesis is from transcription microarrays. Transcription arrays measure 
the levels of gene transcription and hence get a good idea of the levels of gene expression from 
each measured gene. Other microarrays can be used to measure methylation status, or a host of  
other epigenetic marks using techniques such as Chromatin Immunoprecipitation (ChIP)  (Collas 
2010). Another type of microarray which is used here are single nucleotide polymorphism (SNP) 
microarrays, which detect the presence of different gene variants. This means that they can be 
used to perform Comparative Genomic Hybridisation (CGH) analysis to measure the amount of 
different alleles present, allowing measurements of the copy number and the heterozygosity (ratio 
of different alleles). Sequencer technology is an alternative to microarrays, often allowing for more 
genes to be measured and is capable of  measuring the various features that  microarrays can 
detect. Sequencers were developed after microarrays and currently fewer data-sets are available 
from these than from microarrays.
The  majority  of  arrays  used  in  this  thesis  are  Affymetrix  expression  arrays.  These 
expression arrays use a set of “spots” each of which represents a set of experiments (a probeset)  
which overall test a small length of mRNA. Each spot is made up of millions of identical nucleotide 
probes,  which hybridize to a specific  transcript  (Okoniewski  and Miller  2008),  the transcription 
product binds to the spots, and the amount of product that binds can be measured giving a reading 
of the transcriptional activity.  On Affymetrix arrays,  each of these perfect match (PM) spots, is 
associated with a nearby mis-match (MM) spot, where part of the residue is altered  (Wu et al. 
2004). The MM-spots provide a measure of background levels for that particular probe, since they 
do not hybridise directly, but are similar in all other ways. Each probeset is made up of a set of 
PM/MM  pairs,  which  makes  up  the  gene  probe  (Okoniewski  and  Miller  2008).  Background 
correction  is  therefore  one  of  the  primary  pre-processing  activities  for  gene  expression 
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microarrays. One signal represents the binding to the transcript of interest the other represents the 
ambient  signal  (Ritchie et  al.  2007).  Several  different  methods exist  for  correcting background 
(Ritchie et al. 2007), however the most popular two are likely to be either the Affymetrix method 
which  subtracts  the  background  values  directly  (Gautier  et  al.  2004) or  the  more  complex 
estimation method used for RMA background correction  (McGee and Chen 2006), which is also 
similar in the various offshoot methods such as GCRMA (Wu et al. 2004). These methods involve 
the deconvolution of signal and noise distributions and hence estimate the correction needed.
Once  background  correction  is  made,  and  the  transcripts  have  been  combined  into 
probesets, the next step is normalisation. The purpose of normalisation is to remove non-biological 
variability between arrays (Bolstad et al. 2003), this can be introduced by having different amounts 
of RNA or different hybridisation efficiencies in different arrays for example. Once again there are 
numerous  methods  for  normalising  arrays,  and  the  most  popular  are  likely  again  to  be  the 
Affymetrix MAS 5.0, and quantile methods  (Bolstad et al. 2003).  Affymetrix MAS 5.0 takes each 
'good'  gene  and  calculates  a  robust  average  of  the  log  of  each  probe  and  then  scales  all 
microarrays  to  have  the  same  median  intensity.  The  quantile  method  in  contrast  takes  the 
distribution  of  all  probes  and  calculates  the  distribution  of  the  quantiles  for  each  array.  The 
quantiles are then transformed so that all arrays have the same distribution (Bolstad et al. 2003). It 
is generally thought that this latter method is the more reliable, but both are widely used.
2.4.1 Traditional Microarray Analysis
Traditional microarray techniques primarily aim to detect which individual genes are significantly 
differentially expressed between two or more groups. Originally analysis used logged fold change, 
a measure of the difference in the expression of a gene between two groups (see equation  1) 
rather than statistical tests (McCarthy and Smyth 2009; Murie et al. 2009). Now though statistical 
tests  are  now frequently  used.  One commonly used analysis  technique is  called  'Significance 
Analysis of Microarrays' (SAM)  (Tusher, Tibshirani, and Chu 2001). This uses both fold changes 
and p-values, the latter calculated using resampling. There is an argument  (Murie et al.  2009) 
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amongst users of microarrays as to which is more useful a concept, fold change or significance 
testing. However, since significance testing takes into account the error, while fold change does 
not, the view in this thesis is that the p-value is a more useful measurement.
logged fold change=log2(
treated samples expression value
untreated samples expression value
)  (1)
Because of the large number of results a microarray experiment produces and the larger 
probability of false positives there is a need for a multiple comparisons correction. The traditional 
Bonferroni method solves this problem by producing a corrected significance level, calculated as  
the uncorrected alpha divided by the number of independent tests. This test is widely known to be 
too conservative  (Tusher, Tibshirani, and Chu 2001), particularly since the genes exist in families 
and so are not independent. The Bonferroni test controls the family-wise error rate (FWER). This is 
the probability of detecting a type 1 error (a “false discovery”) however, this is not the only measure 
that  can  be  controlled  when  dealing  with  multiple  comparisons. A less  conservative  approach  
involves controlling the false discovery rate (FDR) (Reiner, Yekutieli, and Benjamini 2003) i.e. the 
proportion of false discoveries that are made. This approach has become one of the most common 
ways of dealing with this issue in microarrays, and basically involves limiting the percentage of  
false  positives, rather  than limiting  the  probability  of  any  individual  false  positive . The  FDR  
analogue of p-values are known as q-values and are normally fixed at 0.05 (in analogy to p-values) 
but can be raised to higher values  (Efron 2007). This is particularly useful  since by looking at  
known genetic pathways it is possible to identify some of the likely false positives using biological 
knowledge  (Slonim 2002).
There  are  alternative  methods  for  analysing  microarray  data,  which  take  into  account 
concept of gene pathways and that genes are therefore not independent (Slonim 2002). One such 
method is referred to in this thesis as probe-SVD, and makes use of singular value decomposition 
(SVD, see 2.5.2 Singular Value Decomposition (SVD)) to factorise the dataset into a series of case 
loadings and gene-vectors (Alter, Brown, and Botstein 2000). Often when this sort of factorisation 
is performed the vectors will be of biological significance, though this is not assured. The case 
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loadings  can  therefore  be  tested  for  significance  and  the  gene-vectors  associated  with  case 
loadings of interest selected. This approach is applied here, as a contrast to the Chromowave 
method;  a  pre-existing  method  of  modelling  spatially  coherent  gene  expression  which  is 
investigated in detail here and also makes use of SVD (see  2.5 Chromowave). Other methods 
which take into account interactions between genes aim to use clustering methods to reduce the 
effective number of variables to be used in the analysis (Lazzeroni and Owen 2002; Slonim 2002). 
These methods look for  functional  coherence,  while  this thesis  investigates spatial  coherence, 
which requires different tools that take into account the spatial arrangement of probes. 
2.5 Chromowave
Before this PhD was started, the only method of modelling spatially coherent gene expression was 
the software package (and methodology) Chromowave developed by Dr Turkheimer  (Turkheimer 
et al. 2006; Anderson et al. 2008), and written in MATLAB (The Mathworks Inc., Natick MA, USA). 
This program and its approach is the primary basis for this PhD, and it will be discussed in the 
methods  section.  Chromowave  uses  a  mixture  of  the  wavelet  transform  and  singular  vector 
decomposition (SVD), both of which will now be explained.
2.5.1 Wavelet transform
Gene expression profiles can be pictured as values plotted along chromosomes. Each value would 
be unrelated to nearby values except that they all fluctuate randomly around a mean value. Some 
genes would not be expressed in a given sample (tissue specific), the rest would show a range of  
expression values in different subjects.
Concepts such as copy number, chromatin folding and LADs add coherent features along 
the chromosome6. We model these features as providing a bias to a regions transcription (see the 
top part of figure 4). For example a region with a higher copy number than another region would 
show higher mean expression (Aggarwal et al. 2005). These regional biases are what is meant by 
6 Other features (de Laat and Grosveld 2003; Branco and Pombo 2007; Xiao, Wang, and Khodursky 2011), 
may add 3D structure. However, there was no time to investigate this during this PhD.
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'spatial coherence'. If these regions had a specific scale, then they could be analysed using spatial 
filtering,  however,  since  this  would  not  be  expected  (given  the  many  different  biological 
mechanisms behind their existence and the non-equidistant nature of the probes) they are better 
analysed using methods which can handle a variety of scales.
The Fourier transform is a widely used method for analysing periodic datasets. However, 
this  transform  provides  only  frequency  information,  with  no  spatial  information.  It  is  good  for 
analysing periodic functions, but not for analysing transient events, such as hammer blow or a non-
periodic signal of any form. Given the biological mechanics behind coherence in transcription and 
the non-uniform placement of probes, it would be expected that genomic mRNA patterns would be 
transient rather than periodic7.  The two main ways to get over this limitation are using short time 
Fourier  transforms  (STFT,  essentially  applying  the  Fourier  transform  on  windowed  data)  and 
wavelets. Of the two, wavelets are the superior method, since coherent expression is expected to 
occur at a range of different scales and STFTs are limited to a set scale (Canal 2008).
Wavelets were originally identified by Haar,  and they are functional forms that can carry 
both frequency and spatial information. The discrete wavelet transform (DWT) converts a real-
space signal into a wavelet space representation. Wavelet space is made up of a series of wavelet 
coefficients which represent the difference in expression between adjacent samples at the first 
level,  then the difference between the mean of  two pairs  of  samples  and then the difference 
between the means of two sets of four probes at the third level etc. Figure 4 shows an example of 
a simple (noisy) signal converted into wavelet space.
Analysing  data  in  wavelet  space  has  several  advantages  over  traditional  methods. 
Advantages  of  the  wavelet  representation  include  the  fact  that  the  representation  is  normally 
sparse, that  additive Gaussian noise still has a Gaussian distribution and is spread amongst all 
coefficients while signal is concentrated in a few and that the DWT tends to decorrelate the data 
(Van De Ville et al. 2007; Silverman 1999). As a result, the DWT increases the signal to noise ratio 
7 It has been suggested that there are periodicities in the expression along chromosomes due to the helical  
nature of DNA (Xiao, Wang, and Khodursky 2011; Hanin et al. 2009). This represents a different model of 
spatial coherence which is not examined in this thesis. However given the limited size of chromosomes 
and  the  potentially  transient  nature  of  the  events,  wavelets  would  seem a  more  robust  model  than 
spectral analysis.
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and  renders  coefficients  approximately  independent  from  each  other  simplifying  statistical 
treatment. For example, multiple comparisons tests such as the Bonferroni are more likely to be 
preserve specificity and sensitivity in wavelet space than in real space  because of the reduced 
correlation amongst variables. 
 The power of wavelets to detect a differentially expressed region is related to both the 
value of the difference and the spatial size of the variation. This means that features involving 
similar activation of a large number of nearby probes can be easily detected, even if none of those 
probes showed significantly high expression individually. In a multi-individual cohort, there would 
be many regions (some overlapping) which would have a bias of this kind. They would exist for 
many  reasons  often  unrelated  to  any  biology  of  interest.  Consequently  statistical  analysis  is 
required to seperate these and to detect significant association with any biological variables (e.g.  
disease state). Numerous statistical techniques could be used to model the processes in wavelet 
space, however Chromowave makes use of a standard unsupervised technique known as Singular 
Value Decomposition (SVD). This method will be discussed in the next section. 
The Application of the DWT to microarray data has some specific technical issues, the main 
one being that the probes used in transcription microarrays are not equally spaced as required by 
the technique. Probes can be overlapping, or even duplicated, while other times there may be a 
large distance between probes. This will likely cause the data to be heteroscedastic or have non-
stationary covariance structure (Silverman 1999). Other problems occur in the assumptions behind 
wavelets and their intrinsic disadvantages. For example the standard transform has a bias towards 
certain sizes (those which are powers of 2)  (Aggarwal et al. 2005) and when denoised exhibits 
effects  such  as  'Gibbs  ringing'  near  discontinuities  (Coifman  and  Donoho  1995).  These 
methodological limitations are avoided in the method used here by the choice of  a  translation 
invariant transform. This class of transform is designed to avoid artefacts caused by discontinuities 
in the data and therefore offer more accurate denoising. Chromowave adopts the 'cycle spinning' 
method to create the translation invariant wavelet transform; effectively averaging the data over 
many different distance shifts. Other potential problems of wavelet denoising include correlated 
noise, which although not applied here can be solved using level dependent thresholds (Silverman 
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1999). Wavelet denoising procedures assume that the noise is white Gaussian noise. In order to 
'correct' the raw data, which has a non-Gaussian noise distribution, it is log transformed prior to 
analysis. This method is widely used in microarray experiments to overcome non-normality.
Figure  4,  a  simulated  example  of  a  chromosomal  signal  (top  image)  and  its  wavelet  space  
representation or scalogram (bottom image). The signal (1024 probes) represents a simple step  
function (1 for the first 512 points, zero for the final 512), with a small amount of Gaussian noise  
added. This simulation is converted into a wavelet space representation in the bottom image, it can  
be seen that most of the image is valued close to 0 (green) due to the sparsifying effect of the  
transform. This justifies wavelet denoising as the spatial signal is often held in a small number of  
coefficients while the noise is distributed amongst all of them.
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2.5.2 Singular Value Decomposition (SVD)
Singular  Value  Decomposition  (SVD)  is  a  mathematical  technique,  closely  related  to  principle 
component analysis (PCA)8. Equation 2 represents the singular value decomposition of a m x n, 
data-set (X) into a m x n matrix of case loadings (U) a n x n matrix of eigenvectors (VT) and a 
diagonal matrix (n x n) of singular values (S).
X =USV T  (2)
The amount of variance (var) explained by the ith component (of n components) can be quantified 
using the singular  values (S) as in equation  3. This helps to judge the importance of  a given 
eigenvector, while its significance to a set of variables is determined by applying the appropriate 
statistical test to the case loadings. There is a set of case loadings (one for each case or subject) 
associated with each eigenvector. Interpretation of SVD relies on utilising both the case loadings 
(to determine importance and direction) and the eigenvectors to determine the pattern detected.
var (i)=
S ii
∑ j=1
n
S jj
(3)
SVD decomposition is subject to the constraint of the components being orthogonal. These are 
equivalent to principle components and are (as in PCA) calculated as the axis that maximise the 
variance explained for each component. The eigenvectors are ordered so that the first represents 
the majority of the variance, the second the next largest amount and so on. This then motivates the 
usage of SVD as a dimension reduction method. The majority of the variation in the data can be 
explained through the first few terms and removing all but the first few will decrease the dimension-
ality of the problem, while hopefully only making a small impact on the actual data9.
8 Depending on the calculation method and the centering of the data, the two techniques can be completely 
equivalent or not (Wall, Rechtsteiner, and Rocha 2003).
9 Though there is no guarantee that the variable of interest will be contained in a component that is kept.
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2.5.3 The Chromowave Methodology 
The Chromowave approach applies SVD in wavelet space to determine a set of case loadings and 
associated eigenvectors, which represent regions of chromosomes that show spatially coherent 
expression. Once a meaningful set of case loadings is chosen (typically only the first would be 
used) the wavelet space eigenvectors are calculated and then denoised before being transformed 
back into real space. Denoising is performed by determining a threshold (Τ(W)) for each wavelet 
coefficient  (W) and zeroing any below the threshold. The threshold (equation  4),  is  a distance 
penalty (P(W)) multiplied by a standard wavelet denoising threshold (Donoho 1995). The distance 
penalty accounts for the non-uniform distribution of probes and is calculated via equation 5 where 
the function  G is  the  Gaussian cumulative  distribution  function  at  a  distance (d),  for  a  mean 
distance μ and standard deviation τ while σ is determined by calculating the median absolute 
deviation (MAD) of the wavelet coefficients (W) scaled to match the Gaussian distribution (as in 
equation 6).
τ (W )=P (W )σ̂ √2log(2n) (4)
P (W )=1−G (ln (d ) ,μ , τ) (5)
σ̂=MAD( W
0.6745
)  (6)
However, before applying the wavelet transform, each gene must first be mapped to the correct 
chromosomal location (using location information provided by the array manufacturer) and log2 
transformed.  Logged  data  is  used  because  the  variance  of  each  gene  is  proportional  to  the 
absolute expression, which is mathematically troublesome. By using the logarithm this dependence 
is avoided and the data transformed into a normal distribution  (Li, Suh, and Zhang 2006), as is 
common in gene expression analysis. 
 It  may  be  asked  how  Chromowave  fits  with  the  concept  of  spatial  coherence.  The 
application of the wavelet transform incorporates the spatial aspect. Each coefficient represents 
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the expression of a number of probes which are located along the chromosomes and the analysis 
therefore emphasises spatially coherent expression. 
One issue specific to spatial modelling is that neither genes, nor expression probes are 
uniformly distributed along chromosomes. Chromowave attempts to rectify this problem by adding 
an  extra  denoising  coefficient  P  (see  equation  5)  which  takes  into  account  the  non-uniform 
distribution of probes. If noise levels were lower, it would be possible to infer intermediate values 
using linear regression as an alternative to the distance penalty. 
The Chromowave program actually includes analysis methods other than the eponymous 
method. The main analysis technique is of course the Chromowave method, which can be applied 
to an individual chromosome or to a genome. When using the Chromowave method, it is normal in 
Chromowave (Turkheimer et al. 2006; Anderson et al. 2008) to look merely at the first eigenvector 
either for each chromosome or for the genome as a whole. In previous studies this has shown 
significant association with the disorders investigated and in the case of the initial publication it was 
shown that the case loadings were better calculated in wavelet space than in real space (using 
probe-SVD).  Another  method included in  the Chromowave software package is  called wavelet 
analysis of gene expression (WAGE) (Turkheimer et al. 2004) , which is a group analysis technique 
described in section 2.5.4.1 WAGE. The Chromowave software also includes implementations of 
standard analysis technques such as probe-SVD and where this is used it is this implementation 
which is used.
Since the main aims of the PhD revolve around the Chromowave methodology and at the 
beginning of this PhD this was the only existing method for investigating spatially controlled gene 
expression it  is first worth looking at the range of investigations already performed using Chro-
mowave. 
2.5.4 Chromowave before the PhD
As has been said the Chromowave methodology was developed by Dr Federico Turkheimer and 
first published in 2006 (Turkheimer et al. 2006). It was based on previous work (Turkheimer et al. 
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2004) on a methodology entitled Wavelet Analysis of Gene Expression. It is worth now discussing 
these early papers showing both the methods in more depth and the results from this program. The 
first publication was actually on the methodology WAGE, described in the next section.
2.5.4.1 WAGE
Wavelet Analysis of Gene Expression (WAGE)  (Turkheimer et al. 2004) was one of the earliest 
wavelet based method for analysing gene expression10. WAGE transforms the expression for each 
sample  into  wavelet  space,  having  first  aligned  the  chromosomes  into  spatial  order  on  each 
Chromosome.  The  difference  between  the  wavelet  profiles  is  then  taken  using  either  a 
homoscedastic model (equation 7) or a heteroscedastic mode (equation 8). 
U (l )=Ū D(l)−Ū C(l) (7)
U (l )=
Ū D(l )−Ū C (l)
s(l)
(8)
With s(l)  being the standard deviation,  WD(l)  being the average coefficient  for  location l  in  the 
disease group and WC(l) the average coefficient for location l in the control group. It was suggested 
in the paper that the homoscedastic model should be used for low degrees of freedom (below 20) 
while the heteroscedastic model was more sensitive for higher degrees of freedom. Denoising of 
these coefficients was conducted using a hard threshold equation, with the version implemented in 
Chromowave modified to include a distance penalty (see equations 4 to 6). 
The initial results that WAGE produced showed that not only could the noisy uninterpretable 
differential profile be 'cleaned up', but that regions on this new profile produced meaningful regions 
of expression (see figure 5). 
WAGE however, has been largely replaced with the Chromowave method. Chromowave is 
10 Most earlier attempts to use wavelets had focussed on errors caused by non-independence of probes in  
close proximity on the microarray chips, rather than in the gene expression itself  (Fujita et al.  2006), 
though some analysis of time-expression data had been performed (Klevecz 2000).
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unsupervised and so can analyse more complex data than WAGE as well as being more sensitive. 
However,  because of  the use of  unsupervised analysis  in  Chromowave,  it  is  less sensitive  to 
examples where only a very small region is affected. This is because if the difference between two 
groups is small, then the variance it explains will be small and hence it will not be ideal for analysis 
with SVD. Additionally it may be that none of the case loadings captures useful information, and so 
other analyses such as WAGE may still be useful.
Figure  5, demonstration of WAGE denoising of nigral tissue from 3 Parkinson's brains and one  
control.  Denoised results are easier  to interpret  than the raw signals.  Figure reproduced from  
original publication (Turkheimer et al. 2004)
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2.5.4.2 Chromowave
The  mathematics  underneath  Chromowave  have  already  been  discussed  in  section  2.5
Chromowave. So in this section we will focus on the actual results which were published before 
this PhD started. Two papers were written using Chromowave, one validating Chromowave using 
tumour samples and the other an investigation into Huntington's disease using Chromowave. The 
results in this section are a reanalysis of the results from those papers using the same data and 
methods. However, first it is useful to explain how Chromowave results can be interpreted. 
Figure  6,  case  loadings  from a  simulated  Chromowave  result.  This  image  illustrates  how  to  
interpret Chromowave results. Bars represent 4 subjects (A, B, C and D). The differences between  
subjects can be identified by looking both at these case loadings and the denoised profile (see  
figure 7). Case loadings quantify the amount of the pattern showed by each subject. The result is  
the multiplication of the case loading by the profile. Therefore if a region in the denoised profile is  
positive, then subjects B and D have lower expression of this region than subjects A and C. If a  
region in the denoised profile is negative then subjects B and D have higher expression of this  
region than subjects A and C. 
Visually Chromowave results can be seen as the combination of two graphs illustrated in 
the following simulated example. The first graph (figure 6) shows the 'case loadings'. This shows 
how each subject reflects the expression pattern. If a subject has a positive value on this plot then 
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they show more of the expression pattern than is average for the experiment, if they are negative 
values then they show less of  the expression pattern than average.  The second graph is  the 
denoised expression pattern (figure  7).  This shows the denoised gene expression pattern with 
genes plotted along their chromosomal position (each chromosome is plotted separately). 
To understand more specifically,  the right hand side (q-end) of the denoised expression 
profile in figure 7, is higher in subjects A and C than it is in subjects B and D. This is because the 
expression value is positive and so are the case loadings. The left hand side (p-end) however is 
lower in subjects A and C than B and D. This is because denoised expression pattern is negative, 
while the case loadings are positive. Measurements in experiments are only relative, however if 
subjects B and D were control subjects, while A and C were patients, the expression pattern would 
be higher in patients than in controls. Looking at the expression pattern this would mean that the p-
end of the chromosome was  expressed more in patients and the q-end less.
Figure  7, simulated denoised expression profile of chromosome 1. The profile is a step function  
with negative values on the left hand side of chromosome 1 (1p) and positive expression on the  
right hand side (1q). Combining this profile with the case loadings in figure 6, it can be seen that  
subjects A & C show higher expression of 1q than subjects B & D, and also lower expression of  
1p. Notation at the top of the diagram (e.g. chr1p36.33) is the approximate location in cytogenetic  
notation.
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2.5.4.2.1 Chromowave applied to tumour samples
Chromowave was originally validated by applying the method to expression data from a set of 27 
low  grade  and  anaplastic  diffuse  gliomas,  and  8  normal  subjects  (Turkheimer  et  al.  2006). 
Oligodendrogliomas frequently have chromosomal deletions, particularly on regions 1p and 19q 
(Reifenberger et al. 1994; Mitra, Liu, and Song 2009; Burger et al. 2001; Smith et al. 1999; Smith 
et  al.  2000).  The  link  between  copy number  and  expression  is  not  a  completely  simple  one 
(Schlesinger et al. 2009), however for most genes it  can be expected that a reduction in copy 
number results in a loss of expression. Therefore it was hypothesised whether Chromowave could 
detect  spatially  coherent  expression  changes  caused  by  copy  number  variations  in  tumour 
samples. 
Chromowave was applied to individual chromosomes and produced expression patterns for 
chromosomes 1p, 9q, 4, 13, 15, 18 and 19q.which closely matched several characteristic copy 
number profiles for those chromosomes. To identify whether the expression patterns represented 
the CNVs in the samples, Fluorescence in-situ hybridisation (FISH11) was used to determine which 
subjects had deletions in those regions. Direct measurements had not been performed at the time, 
however  these  have  now been  produced  and  are  analysed  in  section  5.2.1.3  Comparison  of
Chromowave tumour results and Wavelet denoised CGH profiles. To demonstrate the results of 
Chromowave, these chromosomes are re-analysed below using the same settings as the original 
Chromowave paper. 
The results of chr1 can be seen in figure 8. It is clear from the expression profile (right hand 
side) that there is a difference in expression between the 1p/1q parts of the chromosome, however 
it is necessary to look at the case loadings to interpret these results. From the values of the normal 
subjects, it seems clear that this represents the common 1p deletion (Smith et al. 2000), a good 
rough threshold for which subjects have the deletion is the value of 0 on the case loadings, though 
any that  are  strongly  different  from the normals  show possible  deletions.  Subjects  thought  to 
posses the deletion include AD14, O1, O10, O17 & O19, i.e.  those with positive valued case 
loadings. There is some disagreement between the identification of the monosomy via FISH and 
11 Fish  is  a  technique  that  attaches  probes  to  specific  locations  on  chromosomes.  It  can  then  be 
demonstrated whether these regions are present in the sample (Price 1993). 
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Chromowave, since AD11 and O18 show no evidence of deletion on the Chromowave analysis, 
yet were shown to have it using FISH. In the original paper it is suggested that this may be due to 
the highly localised nature of FISH, which may detect local features, rather than the large scale 
monosomies, but until this is verified using a further independent technique it is unknown where 
Chromowave or FISH provide better detection. An independent analysis is performed in section 
5.2.1.3 Comparison of Chromowave tumour results and Wavelet denoised CGH profiles, which 
helps to determine differences between these techniques.
Figure  8,  case loadings and profile  from the primary  eigenvector  for  Chromosome 1 (80% of  
variance) from a set of tumour samples. Case loadings (left) show normals (white), and tumours  
(grey and black) with the FISH deletions coloured in black. It can be seen that the profile (right)  
represents  a  1p  deletion  with  multiple  tumour  samples  shown as  having  the deletion,  mostly  
oligodendrogliomas  as  expected from the literature.  Although mostly  in  agreement,  there is  a  
difference in those identified as having the deletion through FISH and those identified through  
Chromowave. Reasons for this difference may include the highly localised nature of FISH or false  
positives because of low expression on 1p due to other causes than CNVs. 
The results for chr4 can be seen in figure 9. The chromosome shows an apparent deletion over the 
entire Chromosome for subjects O29, O3 O30 and O32 (and possibly O2 and O9 as well). The 
case loadings show agreement with the single FISH detection, which is the largest result  from 
Chromowave.  However  other  subjects  suggested by Chromowave do not  show evidence of  a 
deletion using FISH. The profile indicates that this is a chromosome wide deletion  Whether these 
other subjects also have the monosomy and the reason FISH did not detect them will be discussed 
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later in section  5.2.1.3 Comparison of Chromowave tumour results and Wavelet denoised CGH
profiles.
Figure 9, case loadings and profile for chr4 of tumour samples (grey bars) normal subjects (white  
bars) and the single FISH determined monosomy (black, patient O3). The profile represents a  
chromosome wide loss for subjects O29, O3 O30 and O32 (and possibly O2 and O9 as well). The  
single  FISH  determined  monosomy  is  identified.  Other  subjects  have  similar  Chromowave  
expression values but are not identified through FISH.
Figure 10, case loadings and profile for chr9 of tumour samples (grey bars) Normal subjects (white  
bars) and the single FISH determined monosomy. The profile appears to represent  a gain on  
subjects AA3, AD21 and O30 and possible deletions on AA6 and O20. The match with FISH is  
poor.
The results for chr9 can be seen in figure  10. The expression pattern combined with the case 
loadings suggests a 9q deletion for subjects AA6 and O20, neither detected through FISH.  In 
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general  for  this chromosome, the case loadings show little agreement with  the FISH analysis. 
Some subjects (e.g. AA3, AD21 and O30) appear to show definite 9q gains, which would not be 
detected by FISH. The values from other subjects (e.g. AA6 and O20) seem to reflect deletions 
which were not detected by FISH. It is noted in the original paper that this chromosome shows a 
poor  match  with  FISH.  This  chromosome  will  be  revisited  in  section  5.2.1.3  Comparison  of
Chromowave tumour results and Wavelet denoised CGH profiles and this may help to understand 
the results for this chromosome better. 
The results for chr13 can be seen in figure 11. These results clearly show a chromosome 
wide deletion for subjects AD13, AD14, O10, O2, O3, O30, and O7. There is a good agreement 
between  FISH and  Chromowave,  with  subjects  O10,  O2,  O3 and  O7 identified  through  both 
methods.  However  one subject  (O17)  is  identified  via FISH but  not  Chromowave while  AD13, 
AD14 and O30 show evidence of the deletion on Chromowave but not FISH. These differences will  
be used to help compare the two methods in a later section.
Figure 11, case loadings and expression profile from chromosome 13 of tumour data. This result  
indicates a deletion in subjects such as O3, we can see that those subjects with a low negative  
case loading represent chromosome wide deletions. There is a good agreement with FISH results  
(black bars) but the match is not perfect and there are several subjects identified as having the  
deletion via Chromowave but not FISH.
The  results  produced  from  chr15  are  shown  in  figure  12,  and  seem  to  represent  a 
chromosome wide change, most likely a deletion. However the FISH measurements seem to be a 
poor match with the Chromowave analysis,  with two FISH monosomic subjects (O9 and O18) 
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showing likely deletions, but the others showing either no real difference compared to controls or a 
possible gain. It seems also that some subjects may show a gain rather than a deletion of this 
chromosome, in particular subjects O32, O33 and O17 appea to show a gain. Subject  O17 is of 
special  interest  as  it  is  identified  as  having  a  deletion  via  FISH,  yet  seemingly  a  gain  in 
Chromowave, this will also be investigated more in a later section. 
Figure 12 case loadings and expression profile from chromosome 15 of a set of tumour samples  
(dark bars) and normal data (white bars). The profile combined with the case loadings suggests a  
chromosome wide monosomy or trisomy. However results appear to be a poor match with FISH  
monosomy measurements (black bars).Results may represent a mixture of both gains and losses,  
but this is unknown without other measurements of the copy number. 
 
 The results for chr19 are presented in figure 13. It can be seen that there are a number of 
tumour samples identified as containing the 19q deletion. Subjects with positive case loadings are 
likely to have the deletion. It can also be seen that there is a good agreement with FISH (black 
bars),  though  there  are  more positive  detections  through Chromowave  than  through  FISH.  In 
section 5.2.1.3 Comparison of Chromowave tumour results and Wavelet denoised CGH profiles, it 
will be investigated whether this 19q deletion can be validated using CGH measurements 
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Figure 13, case loadings and expression profile of chromosome 19 from a set of tumour (dark grey  
bars)  and  normal  samples  (white  bars).  It  can  be  seen  that  the  profile  represents  a  19q  
monosomy, which is commonly seen in oligodendrogliomas (Barbashina et al. 2005). There is a 
good match between those identified as containing the monosomy through FISH (black bars) and  
those through Chromowave, however as in previous chromosomes more are detected through  
Chromowave than FISH.
2.5.4.2.2 Chromowave applied to Huntington's disease
The original paper showed that Chromowave could detect spatially coherent profiles caused by 
CNVs.  However,  it  was  also  suggested  epigenetic  mechanisms  would  also  be  detectable. 
Consequently the second paper by Anderson et al, investigated expression changes caused by 
Huntingdon's Disease (HD) (Anderson et al. 2008). 
HD is caused by a mutation in a gene coding for the 'Huntingtin' protein with an abnormally 
high  number  of  C-A-G  repeats  (Chen-Plotkin  et  al.  2006).  The  actual  mechanism  of  the 
downstream pathological  process is unknown,  however  it  has been suggested that  the mutant 
protein is produced and then proceeds to alter the DNA conformation of regions of chromosomes, 
causing abnormal expression  (Chen-Plotkin et al. 2006; Sadri-Vakili  and Cha 2006) or that the 
mutant  Huntingtin  protein  affects  RNA  globally  by  changing  the  higher  order  chromatin 
organisation  (Benn et al. 2008). Additionally and in particular in brain, poorly soluble aggregates 
sequester  transcription  factors  and  interfere  with  histone  deacetylation.  In  all  cases  extended 
regions of spatially coherent expression changes would be expected and these were those that 
Chromowave  investigation  was  testing.  By  applying  this  it  could  also  be  determined  whether 
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Chromowave can be validated for these non-copy number based changes in gene expression 
levels. 
Chromowave showed that in both blood and post-mortem brain samples from the caudate 
that Chromowave distinguished between disease carriers and controls and that the expression 
profiles show good similarities on various chromosomes, which the paper suggests may represent 
similar disruption mechanisms in different body compartments. The results from the two different 
tissues  are  reproduced  below  using  the  same  data  and  settings  as  the  original  paper,  to 
demonstrate what was found using Chromowave.
The primary eigenvector (40% of variance) for the blood data was found to significantly 
distinguish between HD carriers and normal subjects (p = 5 x 10-9). The case loadings can be seen 
in figure 14 and It can be seen from these that the presymptomatic HD carriers are more like the 
HD patients than the controls. The primary expression pattern can be seen in figure 15, it can be 
seen that there are large scale changes of a similar magnitude to those found from copy number 
changes, which suggests (given that Chromowave was effectively validated for variations of that 
magnitude) that these too are reasonable results.   
Figure 14, case loadings from primary eigenvector (40% of variance) from a Chromowave analysis  
of  a dataset  of  blood from Huntington's  disease (HD) patients,  normal  subjects  and and pre-
symptomatic  mutation  carriers.  Case loadings  significantly  distinguish  HD patients and normal  
subjects  (p  =  5  x  10-9)  and  between  presymptomatic  mutation  carriers  and  normal  subjects  
(0.0002). It is clear that the mutation carriers are more similar to the HD patients rather than the  
normal subjects.
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Figure 15, primary expression profile (40% of variance) from an analysis of a dataset of blood from  
Huntington's disease (HD) patients, normal subjects and and pre-symptomatic mutation carriers.  
Case loadings show that controls show this pattern more than HD or presymptomatics. 
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The case loadings for the primary eigenvector (50% of variance) from the caudate samples can be 
found in figure  16, and the associated expression patterns for all chromosomes can be found in 
figure 17. The case loadings significantly distinguish controls from HD patients (p = 3 x 10 -5) and 
even correlate significantly (p = 0.017) with the Vonsattel scales for each patient. Vonsattel scores 
are a measure of the extent of striatal neuropathological involvement in the disease. Effectively a 
measurement of the quantity of neuronal loss in the striatum. From the expression profiles (figure 
17), it can be seen that several chromosomes show extremely similar expression patterns to those 
from the blood samples. In particular chromosomes  4, 5, 8, 10, 19 and 20 show the greatest 
similarities. 
Figure 16, case loadings of post-mortem brain samples from HD patients and controls showing a  
significant (p = 3 x 10-5) difference between HD patients (dark bars), and normal controls (light  
bars). In the original publication (Anderson et al. 2008), it was shown that the case loadings from 
patients correlate significantly with Vonsattel scale. The expression pattern associated with this is  
shown in figure 17, and closely matches the one shown in figure 15. 
The  conclusions  from  these  two  papers  is  that  Chromowave  can  detect  spatially  coherent 
differences in  transcription  and  that  these  can due  to  copy number  variations  and epigenetic 
reasons, such as those underlying HD. The methods underlying this work have not actually been 
discussed in detail, and this is therefore the subject of the next chapter. 
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Figure 17, primary expression profile (50% of variance) from an analysis of a dataset of caudate  
samples  from HD patients  and  normal  subjects.  Case  loadings  show that  controls  show this  
pattern more than HD or presymptomatics which closely matches the results shown in figure 15. 
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3. GENERAL MATERIALS & METHODS
This thesis is primarily a methodological one, on a disparate range of subjects, and so all novel 
methods will be discussed in the appropriate sections. However, this thesis largely relies on the 
pre-existing Chromowave method, and so the details of how to conduct such an analysis will be 
explained here. 
3.1 Data Collection 
The data for Chromowave experiments is not raw expression values as obtained from a microarray 
experiment. Instead Chromowave uses the processed expression files for the different arrays. This 
often means that background correction and the combining of probesets has already been done 
(Brazma et al. 2001).
Chromowave requires columns containing the probe names, the expression values and 
'present calls', with a single header row all ordered so that the probe names are in descending 
alphabetical  order.  Present  calls  can have three values,  'P',  'A'  or  'M'.  The first,  'P'  stands for 
present (the signal intensity from the probes is significantly higher than background12). The signal 
value 'A' (absent) means that the value is non-significantly different to the background, while the 
value 'M' refers to a probe which has borderline detection (see section 2.4.1 Traditional Microarray
Analysis). Present calls are produced by Affymetrix MAS5 software (Pepper et al. 2007), and are 
based on the differences between perfect match and mismatch probes. As not all researchers use 
these tools or arrays, they are not provided for all datasets. In the absence of present calls  (or 
detection p-values) and depending on the experiment, it  is often necessary to set all  genes to 
'present', effectively assuming that all genes have correctly hybridised with the array. Alternatively, 
an expression threshold for absent and present can be made, given a 'rule of thumb' value. This 
latter method cannot be made rigorous since it ignores variations in background between probes. 
These data can be obtained directly from the analysis software or they can frequently be 
12 Significance in this case is determined using the different intensity values from the perfect match and mis-
match probes built in to the Affymetrix arrays (see section 2.4.1 Traditional Microarray Analysis).
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obtained from online databases, such as the gene expression omnibus13 (GEO), Array Express14 or 
the Harvard Brain tissue resource center15.
At the beginning of the PhD the only arrays which Chromowave could analyse were the 
following Affymetrix arrays; Hu6800, HG-U95A, HG-U95A version 2, HG-U133A, HG-U133B (only 
when also using the complementary HG-U133A array)  and the HG-U133 plus 2 array. However, 
by the end of the project the arrays Chromowave could deal with also included, Affymetrix HG-
U133A2 , Affymetrix mouse 430 2 and Affymetrix rhesus arrays, the Illumina Human-8-beadchip, 
Agilent  custom  arrays  and  the  Infium  methylation  array.  These  further  arrays  were  added  to 
Chromowave by me as part of the PhD. Work to include these required the collection of information 
on the probe names and genomic locations of each probe. These files then had to be put into the 
correct format and the Chromowave code edited to include the new arrays. To speed this process 
up for future Affymetrix arrays, tools were written in the Perl programming language to process 
Affymetrix location files into the desired format. 
3.2 Data Analysis
3.2.1 Normalisation
Once data has been downloaded, it  must be normalised. A choice of normalisation procedures 
exists, with a wide variety available in the literature  (Gautier et al. 2004). The two normalisation 
methods built into Chromowave are median normalisation (also known as MAS5) and percentile 
normalisation (based on RMA normalisation)  (Bolstad et al. 2003). Median normalisation divides 
each probes value by the median of that probes values, for each probe with a certain number of 
present calls. RMA normalisation instead attempts to match the distribution of probe values for 
each array. It does this by splitting the data into different groups (quantiles or percentiles etc). In 
Chromowave whichever normalisation scheme is used, results are filtered before analysis on the 
basis of a minimum number of present calls for each probe. The choice of number of present calls 
13 http://www.ncbi.nlm.nih.gov/geo/
14 http://www.ebi.ac.uk/arrayexpress/
15 http://national_databank.mclean.harvard.edu/brainbank/Main
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is essentially arbitrary, however a conservative approach would require a probe to be present in 
around 50% of the samples16. 
Some data acquired from online sources is already normalised and since normalisation has 
already occurred, this step can be ignored, instead Chromowave can be used to mark the data as 
normalised, without making any changes. As well as being normalised some online data is logged. 
Since Chromowave applies the log transform to the data as the first step of wavelet analysis data 
must be unlogged before continuing. 
3.2.2 Chromowave Analysis
As has been mentioned Chromowave can be applied either to an individual chromosome or the 
entire genome. The choice depends on the hypothesis underlying the investigation. If the effects 
are expected to be localised to a single chromosome, or a small handful of known chromosomes 
the  former  should  be  used.  Consequently  only  those  which  are  expected  to  be  affected  are 
investigated. If it is expected to occur on nearly every chromosome however then a global analysis 
is the better choice, since this will allow for better characterisation of the case loadings.
Once this choice is made, the process is the same. Chromowave aligns the data to its 
chromosomal  location,  then  log  transforms  it  and  applies  the  Haar  wavelet  transform (to  the 
chromosome in question in an individual analysis, or to each chromosome sequentially in the case 
of a global analysis). Once the wavelet coefficients are calculated SVD is applied and the case 
loadings and eigenvectors are calculated (in fact they are calculated using the method from (Alter, 
Brown, and Botstein 2000)). Graphs of the case loadings are produced and shown on the screen, 
and the user chooses whether  to  save this  set  of  case loadings (and the associated singular 
values and eigenvectors). In general only the first two or three case loadings are used, though in 
theory any could be17. The saved data can be viewed using spreadsheet software and is stored as 
a text file and one image showing the expression profile. 
16 Due to the use of multiple probes in any given region in Chromowave the number of present calls filtered 
for makes relatively little difference. 
17 However, if large numbers of case loadings are investigated then it is necessary to consider multiple 
comparisons correction. 
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Eigenvectors can represent a range of features, not just disease status. Consequently it is 
possible to examine this and see whether normalisation has been successful, since it is normally 
simple  to  see  cases  of  poor  normalisation18.  The program will  display  the expression  for  the 
chromosome in question if  an individual chromosomal analysis is being conducted,  or  multiple 
chromosomes in series if a global analysis.
Statistical  analysis  is  the  next  step,  and  this  depends  on  the  actual  hypothesis  being 
investigated.  In  all  cases,  the  statistical  tests  are  applied  to  the  case  loadings  from  the 
Chromowave analysis.  Statistical methods which can be applied include techniques such as t-
tests, anovas and regression analyses. Parametric methods are generally used in the work of this 
thesis, with a few exceptions. The assumption is made that in the absence of signal, case loadings 
are normally distributed as previous work has shown (Turkheimer et al, 2006). Both the wavelet  
transform and SVD are orthogonal transform and should preserve normality. PCA (closely related 
to SVD) can be interpreted as a Gaussian latent variable model (Tipping and Bishop 1999). We 
can assume therefore that although SVD and PCA can be applied widely with good results, they 
are optimised for Gaussian distributed variables (Schein, Saul, and Ungar 2003). 
18 In cases of poor normalisation, all chromosomes will show near uniform co-regulation.
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Figure  18. A diagram of the basic processes in Chromowave analysis. Work is started by using  
microarrays to analyse transcription from a series of samples (a) which are pre-processed in the  
standard ways. Values are extracted and Chromowave aligns the probes to their chromosomal  
locations (b). Data for each chromosome to be analysed is log transformed and converted into  
wavelet space (c), where it is analysed using singular value decomposition. The case loadings are  
inspected and if they are of interest the denoised expression profile (d) is produced. Case loadings  
can be analysed using standard statistical analysis techniques.
3.2.3 Other analyses
Other similar analysis techniques which are used in this project include WAGE and probe-SVD.
The basic method for WAGE is very similar to that for Chromowave. The difference is that 
62
each subject must have a group (starting with number 1) associated with it. After that the probes 
are aligned as in Chromowave. The analysis then continues automatically converting the values for 
each chromosome into wavelet  coefficients and then applying the model chosen (described in 
section 2.5 Chromowave). Unlike Chromowave there are no case loadings or eigenvectors, since 
the process is supervised rather than unsupervised. Instead it is necessary to select which group is 
the control group and which the patient group. 
Probe-SVD was originally suggested by Alter et al  (Alter, Brown, and Botstein 2000), and 
performs a singular value decomposition on the probe data matrix, rather than in wavelet space as 
Chromowave  does.  A  number  of  case  loadings  for  each  eigenvector  are  calculated  and 
interrogated  individually  to  see  whether  they  represent  biologically  interesting  parameters  or 
artefacts  such  as  normalisation  errors.  The  code  to  perform  this  analysis  is  included  in 
Chromowave. 
3.3 Materials
A number of different datasets have been used in this thesis. Most of these are sets of expression 
data,  using  various  transcription  microarrays.  However,  other  datasets  analysed  include 
methylation arrays and SNP-arrays. Consequently the datasets listed below are split into different 
categories depending on the type of data that was analysed, within each category the datasets are 
organised by the disorder that is being investigated. Some datasets are also analysed multiple 
times, using different methods. 
Choice of  dataset  depended on the investigation.  For example,  biological investigations 
centred on determining whether variations detected by Chromowave could be linked to known 
biological mechanisms. This included epigenetic factors and chromosome X (chrX) upregulation in 
brain. To investigate epigenetic factors, datasets with known epigenetic connections were needed, 
while analyses chrX upregulation require brain tissue. Most datasets were obtained from public 
databases,  which  clearly  limits  the  available  data,  though  some were obtained from research 
collaborators. More collaborators were sought, but frequently did not respond, or were unhappy 
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with inclusion in this thesis. Another criteria for inclusion was microarray platform. Not all platforms 
have sufficient coverage to accurately analyse different Chromosomes. Some platforms (but not 
those  by  Illumina  or  Affymetrix)  do  not  include  accurate  location  information  for  the  probes. 
Because location is of high importance, arrays which did not have this information available were 
disgarded. To find data, searches were made using resources such as Pubmed19, and the inbuilt 
database searches, using keywords related to the inquiry.  
3.3.1 Gene Expression Data
3.3.1.1 Tumour Data
This  is  possibly  the  most  used  dataset,  in  this  thesis.  the  tumour  dataset  was  analysed  by 
Chromowave in  the initial  paper  (Turkheimer  et  al.  2006).  It  consists  of  a  series  of  8 normal 
subjects and 27 gliomas (4 patients with oligodendrogliomas, 5 with mixed oligoastrocytomas, 6 
with  astrocytomas,  6  with  anaplastic  oligodendrogliomas  and  4  with  anaplastic  astrocytomas). 
Clinical data for these patients is available in the original Chromowave paper.
Tumours were normalised by using MAS 5.0 normalisation as in the original paper. Data is 
available from the GEO database (GSE2817 record: platform: Affymetrix HG-U133_Plus_2  array).
A subset of patients were also analysed using Comparative Genomic Hybridisation (CGH) 
analysis. Data for this subset was analysed with the methods described in section 5.2.1 Application
to SNP arrays. This sort of data allows for the direct identification of chromosomal deletions and 
gains and can therefore be used to re-investigate the link between spatially coherent expression 
profiles and copy number variations.  
The first dataset analysed was a tumour data with known deletions, previously investigated 
by Chromowave and used to validate the technique. Clinical data is available in the original paper 
and CGH analysis has since been conducted allowing for unambiguous identification of deletions 
and gains. Consequently for chromosome 1, 16 patients with the 1p deletion were chosen (13 
Oligodendrogliomas grades II, III & IV, 2 Astrocytomas grades II and IV and 1  OligoAstrocytoma 
19 http://www.ncbi.nlm.nih.gov/pubmed/
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grade  II).  A  total  of  16  subjects  without  deletions  were  also  chosen  (8  normal  subjects,  7 
Astrocytomas grades II  & III  and One oligoastrocytoma grade II).  For Chromosome 19,  fifteen 
subjects with confirmed 19q deletions (13 Oligodendrogliomas grades II & III, 1 oligoastrocytoma 
grade II and one astrocytoma grade II) and 18 cases confirmed not to have deletions (8 normal 
subjects, 7 astrocytomas groups II-IV and 3 Oligodendroglioma grades II and IV) were selected. 
3.3.1.2 Huntington's Data
Huntington's disease (HD) data was originally analysed in Chromowave in a paper  from 2008 
(Anderson et al. 2008). Two different datasets were used and both are publicly available.
The first HD dataset consists of a set of 31 blood samples from 12 HD patients, 14 control 
subjects  and 5 presymptomatic mutation carriers. The data is available from the GEO database 
(GEO  series  accession  GSE1751,  platform  Affymetrix GeneChip  HG-U133A).  The  data  was 
normalised using MAS 5.0 normalisation routine to match by the original authors. 
The second HD dataset, consisted of samples from the caudate nucleus of 15 confirmed 
HD patients and 14 age-and sex-matched normal subjects. The dataset is available from the Array 
Express Repository (Experiment E-AFMX-6, platform Affymetrix GeneChip HG-U133A and HG-
U133B).  Information  is  available  in  the  original  paper.  The  data  was  normalised  using  the 
Affymetrix MAS 5.0 normalisation method by the original authors.
3.3.1.3 Demethylated Lung Tissue
Data from an unpublished study into lung cancer cell  lines was obtained from the GEO (GEO 
series accession GSE14315, platform Affymetrix GeneChip HG-U133 Plus 2). 
This dataset was made up of a series of 10 different cell lines (Calu 1, Hotz, U1752, Calu 6, 
ZL25, Calu 3, SW2, A549, H125, and H460) with six samples of each cell line (three treated, three 
untreated). Treated samples were treated with a mixture of 5-aza-2’deoxycitidine and trychostatin A 
(5AzaC/TSA) a well known de-methylation and deacetylation protocols. Available details can be 
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found on the GEO page for these data. Data was normalised using the percentile RMA method20.
3.3.1.4 Human Hepatoma Cell line
This  is  a publicly  available  dataset  from the GEO  (GEO series  accession GSE5230,  platform 
Affymetrix GeneChip HG-U133 Plus 2) analyses the response to inhibition of DNA methylation and 
histone deacetylation in Human hepatoma cell lines. Both 5AzaC and TSA, were applied to a set of 
hepatoma cell lines. These were applied both separately and together, so that the effects from 
each  process  could  be  determined  as  could  their  combined  response.  The  experiment  was 
conducted using HGU133 plus 2 arrays and normalised using percentile normalisation20.
3.3.1.5 Parkinson's Disease data
Parkinson's disease data was acquired from a mixture of publicly available sources and acquired 
from collaborators. 
The first  PD dataset was made up of gene expression in samples from the medial and 
lateral  nigra of  PD  patients  and  aged-matched  normal  controls  (Moran  et  al.  2006) Gene 
Expression Omnibus, NCIB, Bethesda, MD, USA, series accession GSE8397, platform Affymetrix 
GeneChip HG-U133A and HG-U133B). The lateral nigral subset includes 5 control subjects and 8 
PD patients. The medial nigra subset included 6 control subjects and 13 PD patients. The patients 
in the lateral nigra dataset represent a subset of those who had nigral samples. Clinical data for 
these subjects is available from the original reference.  
The second PD dataset was made up of gene expression from the substantia nigra, without 
further  specification  of  site  (Papapetropoulos  et  al.  2006) (GEO  series  accession  GSE7621, 
platform Affymetrix GeneChip HGU133 Plus 2.0 Array). This dataset consists of 9 controls and 16 
PD cases. Clinical data for this dataset can be found in the original paper. 
The third PD dataset consists of data from the SN of 7 controls, with one control duplicated 
for  statistical  purposes,  and  12  neuropathologically  confirmed  sporadic  PD  cases  (6  males). 
20 This method is the preferred method in the literature and does not require arbitrary choice of present call  
thresholds, so was used as the default normalization method.
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Samples were provided by the U.K. Parkinson’s disease Society tissue Bank at Imperial College 
London and processed by Pascal  F.  Durrenberger21.  Firstly the RNA was extracted from snap 
frozen tissues using the Illumina whole genome HumanRef8 v2 Beadchip (Illumina, London UK). 
RNA  samples  were  prepared  for  analysis  using  using  the  Illumina  TotalPrepTM -  96  RNA 
Amplification kit (Ambion/Applied Biosystems, Warrington, UK). First and second strand cDNA was 
synthesised from 0.5µg of total RNA and labeled with biotin. The biotin-labelled cRNA were applied 
to the arrays using the whole-genome gene expression direct hybridization assay system. The 
beadchips  were  scanned  using  the  Illumina  beadarray  reader  with  the  data  extracted  using 
BeadStudio 3.2 (Illumina).
The final PD dataset was obtained from the GEO public database (GEO series accession 
GSE6613, platform Affymetrix GeneChip HGU133A Array) and consisted of blood samples from 50 
PD patients and 21 control subjects  (Scherzer et al. 2007).  Neurological controls from the same 
study were not used, since their specific disease state was unknown. 
3.3.1.6 Alzheimer's Disease data
Alzheimer's  Disease  data  analysed  was  of  a  publicly  available  dataset  obtained  investigating 
hippocampal samples from brains with AD (Blalock et al. 2004), (GEO series accession, platform 
Affymetrix GeneChip HGU133A Array). The dataset is made from 8 controls, 6 patients suffering 
minor AD, 6  moderate AD and 6 severe AD. 
3.3.1.7 Bipolar Data
Three different bipolar disorder datasets were used in this thesis. All of them were obtained from 
the GEO online database. 
The first dataset was made up of post-mortem tissue from the dorsolateral prefrontal cortex 
of 30 adults with bipolar disorder and 31 age matched normal controls (GEO series accession 
21 Wolfson Neuroscience Laboratories and Division of Experimental Medicine, Faculty of Medicine, Imperial  
College London, UK. Working under Dr Richard Reynolds and Dr David T. Dexter. 
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GSE5388,  platform Affymetrix  GeneChip  HGU133A  Array).  Clinical  data is  available from the 
original publication (Ryan et al. 2006) and from the GEO pages. 
The second bipolar dataset originates from the same publication but refers to a different 
cohort  of  patients  and  normals.  This  dataset  was  made  up  of  post-mortem  tissue  from  the 
orbitofrontal cortex of 10 adults with bipolar disorder and 11 age matched controls (GEO series 
accession GSE5388, platform Affymetrix GeneChip HGU133A  Array). 
The third bipolar dataset is from an investigation into bipolar disorder and schizophrenia 
(Iwamoto, Bundo, and Kato 2005). This subset was composed of 33 Adult bipolar cases and 34 
age matched control subjects (GEO series accession GSE12649, platform Affymetrix GeneChip 
HGU133A  Array).
3.3.1.8 Down's Syndrome
Down's syndrome data used in this thesis originates in a set of postmortem brain samples from 7 
Down Syndrome patients and 8 matched controls (Lockstone et al. 2007) (GEO series  accession 
GSE5390, platform Affymetrix GeneChip HG-U133A). Brain regions for the samples are not given. 
Of these subjects  12 had available information on the length of  postmortem interval  (PMI)  (6 
patients, 6 controls) making them suitable for analysing PMI. It  is unknown why the remaining 
subjects did not have PMI information.
3.3.1.9 Progeria data-set:
The progeria dataset is made up of fibroblast data from cell lines derived from Hutchinson-Gilford 
progeria syndrome patients and controls  (Csoka et al. 2004) Data was obtained from an public 
database  (GEO  series  accession  GSE3860,  platforms  Affymetrix  GeneChip  HG-U133A and 
Affymetrix  GeneChip HG-U133B).  The samples include three fibroblast  cell  lines taken from 3 
patients (2 male, 1 female) and 3 age matched controls (2 male, 1 female).
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3.3.2 CGH data
As well as transcription data, this thesis includes analysis of Comparative Genomic Hybridisation 
(CGH) data. These data were analysed using a variety of different techniques by different people. 
Christophe Poulet22 analysed the data using standard technique of Circular Binary Segmentation 
(Olshen et al. 2004). Whereas they were re-analysed by myself using novel methods in sections 
5.2.1 Application to SNP arrays and 5.2.2 Measurements of Loss of Heterozygousity (LOH).  
3.3.2.1 Tumour 
The samples making up the tumour dataset discussed above, were also analysed using 250K 
Affymetrix SNP arrays (by Christophe Poulet). Only a subset were available, since some samples 
had too few cells to analyse using CGH arrays. Values used are the ratio of values from each 
probe to the values from the Hapmap 270 reference set  (Thorisson et al. 2005). This effectively 
normalises the samples. Normalisation and allelic crosstalk calibration were performed with the R-
cran  package  aroma.a ymetrix  ﬀ (Team  2009;  Bengtsson  et  al.  2008),  by  Christophe  Poulet.  
3.3.2.2 Leukaemia,
This  dataset  is  made  up  of  10  chronic  lymphocytic  leukemia  (CLL)  samples,  (GEO  series 
accession GSE3860, platform 250K Affymetrix SNP array). Only the data from the 250K Affymetrix 
SNP arrays was used, for direct comparison with other arrays. Values used are the ratio of values 
from each probe to the values from the Hapmap 270 reference set (Thorisson et al. 2005) which 
effectively normalises the samples. Normalisation and allelic crosstalk calibration were performed 
with the R-cran package aroma.a ymetrix  ﬀ (Team 2009;  Bengtsson et  al.  2008), by Christophe 
Poulet. 
22 Human Genetics Department, GIGA research, University of Liege, Belgium. Working under Dr Vincent 
Bours and Dr Manuel Deprez.
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3.3.2.3 Small cell lung cancer
This dataset was made of SNP array data from 43 non-small cell lung cancer samples  (GEO 
series accession GSE13557, platform 250K Affymetrix SNP array). Values used are the ratio of 
each  probe  to  the  Hapmap  270  reference  set.  This  effectively  normalises  the  samples. 
Normalisation  and  allelic  crosstalk  calibration  were  performed  with  the  R-cran  package 
aroma.a ymetrix ﬀ (Team 2009; Bengtsson et al. 2008), by Christophe Poulet.
3.3.3 Methylation Data
2.4.3.1 MethySeq
Methyl-seq data originated in the original methodological publication on methyl-seq (Brunner et al. 
2009). Data is available from their  website23 along with details  on how the DNA strands were 
purified. The data used was in binarised format, with those methylated having a value of 1 and 
those lowly methylated (or  unmethylated) 0.  Normalisation and other pre-processing steps are 
described in the original paper and on the related website. Alignment data was acquired from the 
same website.
3.3.3.2 Colorectal Cancer Data
This dataset is made up of data of 44 samples from colorectal cancer patients, with 22 of them 
being sampled from the tumours and 22 sampled from adjacent  normal  mucosa in  the same 
subjects  (Kim et al.  2011). Dataset  is publicly  available from the GEO (GEO series accession 
GSE17648, platform Illumina HumanMethylation27 BeadChip). Missing values were included by 
setting them to 0 and giving them an absent call  (all  other probes were given present calls)24. 
Values  had  previously  been  normalised  using  average  normalisation  (Methylation,  3.1.0, 
BeadStudio  Methylation  Analysis  Module),  methylation  values  provided  represent  the  fraction 
methylated for each CpG site. Results were not log transformed by Chromowave since results 
23 http://myers.hudsonalpha.org/content/protocols.html
24 Only  a  relatively  small  number  of  values  were  missing,  and  these  were  distributed  throughout  the 
genome. Consequently their absence is unlikely to be a major issue. Indeed they are simply viewed as 
extra absent probes.
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were in percentage form. Only probes present  in all  samples were included to avoid including 
missing values.
3.3.3.3 Cerebellum data
This dataset was made up of 16 normal subjects from an investigation of methylation patterns from 
different  tissues  in  the  brain  (Gibbs  et  al.  2010) (GEO series  accession  GSE15745,  platform 
Infinium HumanMethylation27 BeadChip). Subjects were selected from their extensive set to match 
for both age and post-mortem interval (PMI), for each gender and to balance numbers of each 
gender. The subjects chosen for inclusion and the available details on them are listed in table 1. 
Those with detection p-values above 0.05 were given absent calls, all others were given present-
calls. Missing values were replaced with a value of 0 and given an absent call irrespective of their  
detection p-value. Only those probes with all present calls were normalisation and preprocessing 
settings  were  those  used  in  the  original  paper.  Values  were  not  log2  transformed  during 
Chromowave analysis, since values are based on the percentage of probes that were methylated.
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Table 1. List of cerebellum methylation samples chosen from dataset  GSE15745. Data includes 
post-mortem interval (PMI), age and gender. Samples were chosen to match the different genders 
in number, age and PMI.
Reference Gender Age PMI
GSM401545 Female 47 20
GSM401546 Female 25 11
GSM401550 Female 33 19
GSM401554 Female 16 16
GSM401557 Female 45 20
GSM401561 Female 39 17
GSM401564 Female 49 14
GSM401566 Female 39 15
GSM401548 male 48 19
GSM401560 male 24 20
GSM401558 male 31 10
GSM401543 male 16 15
GSM401559 male 48 15
GSM401565 male 43 20
GSM401540 male 68 14
GSM401549 male 48 14
  
3.3.4 LAD data
Lamina  associated domains  maps (LADs)  originate  from a  paper  by  Guelen  et  al  which  first 
identified these  (Guelen et al. 2008). A program was written to use this data and the alignment 
information for each array, to determine which probes were entirely within a LAD region and the 
percentage  of  that  LAD associated  which  is  actually  attached.  These  were  then  selected  for 
analysis work. 
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4. RESULTS 1: Investigations with Chromowave
4.1 Introduction
This chapter aims to investigate specific causes of spatially coherent changes in transcription using 
the Chromowave methodology. This is intended to help gain insight into the biology underlying the 
variability in mRNA transcription; effectively looking for biological causes for Chromowave results. 
Most of  this chapter relies on the techniques described in detail  in section  3.2.2 Chromowave
Analysis and where other methods are used, they are described in the relevant subsections. 
In section  2.2 Controlling the rate of transcription some of the different variables that can 
affect expression were mentioned. Chromowave has been validated for the detection of CNVs (see 
2.5.4  Chromowave  before  the  PhD),  however  other  mechanisms are  also  expected  to  cause 
spatially coherent changes in transcription. Epigenetic mechanisms which interact with chromatin 
are expected to operate in a spatially coherent way. However, while the analysis of HD suggests 
that Chromowave can detect epigenetic changes, the mechanisms underlying expression changes 
in HD is not clear. Consequently to truly understand the response of Chromowave to epigenetic 
changes it  is  necessary to investigate expression variability in  datasets with known epigenetic 
modifications.
Another area of investigation is into the regulation of lamina associated domains (LADs). 
Nuclear  domains  associated  with  the lamina  show lower  transcription  than other  regions  and 
diseases such as Hutchinson-Gilford progeria, are associated with disruption of the lamina. Given 
that  the  lamina  causes  the  low  expression  we  hypothesised  that  laminopathies  would  be 
associated  with  spatially  coherent  changes  in  expression.  We  also  sought  to  verify  the 
relationships between expression and lamina association both as validation of the probes selected. 
The quest for biological explanations for Chromowave signals should not distract from the 
fact  that  transcription  levels  measured  by  microarrays  are  affected  by  a  number  of  nuisance 
variables. These nuisance variables are particularly problematic when dealing with post-mortem 
tissue. Factors such as post-mortem interval (PMI) (Ferrer et al. 2008), pH (Vawter et al. 2006) or 
varying ratios of cell types (Clarke, Seo, and Clarke 2010) have all been implicated in variations in 
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transcription  levels. Some of  these  (pH and  PMI)  are  known  to  degrade  the  mRNA which  is 
investigated using microarrays (Tomita et al. 2004) and it is routine to record and report the pH of a 
sample (and to a lesser extent the same is true of PMI). In particular if the pH is below 6, RNA 
tends to be either fragmented or absent and in brain, increased PMI is associated with decreased 
pH (Tomita et al. 2004). Early criticisms of Chromowave included the suggestion that factors like 
these  could  be  the  driving  factors  behind  Chromowave  results.  Consequently  datasets  which 
included information on these variables were sought out both from public databases and through 
published authors. The scope of this chapter was therefore extended to include both biological and 
non-biological  variation  with  both  PMI and neuronal  ratio  being found to make up part  of  the 
spatially coherent variation.
4.2 Results 1
4.2.1 Transcriptional effects of epigenetic changes
The obvious way of determining whether Chromowave can detect changes to DNA methylation 
and histone acetylation,  is to make use of  experiments which directly affect  epigenetic marks. 
Several suitable experiments exist, and some of these are analysed below to determine whether 
Chromowave  responds  to  epigenetic  changes.  However,  it  is  not  enough  just  to  demonstrate 
whether  Chromowave detects  changes  associated with  epigenetic  modifications.  To determine 
whether epigenetic changes are really associated with spatially coherent expression changes it is 
also  necessary to  compare the Chromowave results  with  those from a comparable  traditional 
technique working on individual probes. The technique we use is probe-SVD, which applies SVD 
directly to the probes rather than the wavelet space representation as Chromowave does. This 
comparison helps to evaluate the claim from the original Chromowave paper that  SVD spatial 
modelling in wavelet space provides better identification of groupings and biological effects.
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4.2.1.1 Demethylated Lung Tissue
The first dataset was made from samples of multiple lung tissue cell lines. Two of these (A549 and 
H460) were analysed. All chromosomes were analysed together, firstly using a Chromowave global 
analysis  and  secondly  applying  probe-SVD  to  all  probes.  Cell  lines  vary  extensively  in  both 
genetics and epigenetics. Consequently each cell line was investigated separately since analysis 
of the combined datasets show large differences between the cell lines rather than between the 
conditions. 
4.2.1.1.1 A549 Cell line
This experiment was analysed using Chromowave global analysis. The first eigenvector (91% of 
the variance), was found to significantly distinguish between the two groups (p = 3 x 10-7) using a 
2-tailed Student's t-test. The case loadings for this are found in figure 19. The expression profiles 
associated with these case loadings are included in figure  20. It can be seen that although the 
results  show  both  increases  and  decreases  in  expression,  the  highest  results  are  primarily 
increases in those treated samples. This fits with the current understanding of methylation, as 
causing reduced expression of genes and of 5AzaC and TSA as demethylation agents.
The probe-SVD analysis, was quite different. The first component (77% of the variance) 
seems unrelated to the experimental protocol (p = 0.79, figure 21). To properly investigate whether 
probe SVD can model the epigenetic effects further components were investigated25. The second 
component (8% of variance) distinguishes between the two classes, though not as well  as the 
Chromowave method did (p = 0.01, figure 22). 
25 Multiple comparisons is an issue here. Further components were looked at merely to demonstration that  
Chromowave analysis was better. Consequently multiple comparisons was ignored. 
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Figure  19.  This  experiment  used  a  mixture  of  5AzaC  and  TSA to  reactivate  genes  silenced  
through  DNA methylation  in  samples  of  A549  lung  cancer  cell  lines.  The  first  Chromowave  
eigenvector (91% of the variance) clearly distinguish between treated (dark grey) and untreated  
(light grey) samples  (p = 3 x 10-7).
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Figure  20, expression profile  (91% of the variance)  from a global analysis into  samples of A549 
cell line treated with 5AzaC and TSA to activate genes silenced by DNA methylation. Most genetic  
regions appear to show increased expression upon treatment.
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Figure 21, the primary eigenvector (77% of the variance) from a probe-SVD analysis of A549 cell  
line samples treated with 5AzaC and TSA. This data was analysed using Chromowave in figure 19 
but is analysed using probe-SVD here. This eigenvector does not vary between conditions (p =  
0.8) unlike that from the Chromowave analysis. 
Figure  22. The third probe-SVD eigenvector (6% of the variance) from the A549 TSA + 5AzaC 
cell line significantly distinguishes (p = 0.01) between treated and untreated samples. However this  
ignores the multiple comparisons issue.
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4.2.1.1.2 H460 Cell line
As in the previous cell line, the first global analysis eigenvector (76% of the variance), was found to 
significantly distinguish between the two groups (p = 0.0017). The case loadings for this are found 
in figure 23 and the associated expression pattern is found in figure 24. The cell lines are likely to 
differ both genetically and epigenetically and as expected the expression pattern shows no real 
similarities with that from the A549 cell line (compare figure 24 with figure 20).
By contrast when the probe-SVD technique was applied, neither the first nor the second 
eigenvectors were found to be associated with the experimental design (p = 0.32 and  p = 0.7 
respectively).  The third  component  (see  figure  25)  was  the  most  associated  with  the  design, 
however this was not significant (p = 0.08). That the third component of probe-SVD must be used 
to obtain even this result is a further criticism of the method compared with Chromowave, because 
of the multiple-comparisons issue that this involves. 
Figure  23.  Chromowave analysis of  an experiment that  used a mixture of  5AzaC and TSA to 
reactivate genes silenced  through DNA methylation in samples of H460 lung cancer cell line. The  
first  Chromowave eigenvector  (76% of  the  variance)  clearly  distinguish  between treated (dark  
grey)  and untreated (light grey) samples  (p = 0.0017).
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Figure 24, expression profile (76% of the variance) from a global analysis into H460 lung cancer  
cell line samples treated with 5AzaC and TSA to re-activate silenced genes silenced. The most  
differentially expressed regions show increased expression upon treatment, as expected.
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Figure  25. Third probe-SVD eigenvector (8% of the variance) from an experiment into using a  
mixture of  5AzaC and TSA to reactivate genes silenced through DNA methylation in samples of  
H460 lung cancer cell line. The eigenvector shows a non-significant difference between treated  
(dark grey)  and untreated (light grey) samples  (p = 0.08).
Each cell  line gives similar results.  In both cases  Chromowave detects a significant  difference 
between the treated and untreated data, while probe-SVD either detects no significant difference or 
has a higher p-value. There are also limited similarities in the expression patterns. The above 
confirms the additional power conferred to Chromowave by projecting the data into a space (e.g. 
wavelet space) where spatially coherent features are amplified.
4.2.1.2 Human Hepatoma Cell line
This  experiment  investigated  the  response  to  inhibition  of  DNA  methylation  and  histone 
deacetylation in human hepatoma cell lines. In this experiment, the samples were  treated with 
both 5AzaC and TSA that were applied both separately (groups a and b) and together (group c), to 
verify independent effects and their interaction. In the original paper the authors concluded that 
both treatments had an effect, though DNA demethylation was more important.
The case loadings of  the first  eigenvector  (figure  26),  show that  when  Chromowave is 
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applied, the main variation (36% of variance) is associated with the methylation inhibitor 5AzaC. In 
this case it is seen that those treated with just the histone deacetylation chemical show similar 
values to normals, while those treated with both chemicals show similar case loadings to those 
treated with just the methylation inhibitor. There is a significant (p =  6.5 x 10-14) difference between 
those treated with 5AzaC and those not. The expression pattern (figure 27) associated with this set 
of  case  loadings  primarily  shows  increased  expression,  due  to  silenced  genes  becoming 
reactivated.
The second set of case loadings (figure 28) show a good distinction between those which 
were  treated  with  TSA and  those  which  were  not  (p =  0.02).  However  these  case  loadings 
represent a lower percentage of the variance (27%). This result fits with the original paper which 
found that methylation had a bigger impact than acetylation. Most chromosomes (see figure  29) 
show lower  expression when given TSA (with some exceptions such as chr19),  whereas TSA 
should activate silenced genes. This result suggests that either the process is poorly understood, 
or that this eigenvector represents a confounding factor and not the results of TSA.
Figure 26, primary case loadings for a series of replicates, both of controls and treated samples.  
Treated samples can be broken down into groups  a (treated with 5-aza-2'-deoxycytidine {5-aza-
dc},  a DNA methylation inhibitor),  b (treated with Trichostatin A {TSA}, a histone deacetylation  
inhibitor) and c (treated with both). 
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Figure  27, primary eigenvectors for a series of replicates, variously treated as controls, or with  
TSA,  5-aza-dc or both. From the case loadings (figure 26), this clearly represents the effects of  
the demethylating agent  5-aza-dc. Most results are positive as expected due to de-methylation.
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Figure  28, second case loadings for Chromowave analysis of a series of replicates, treated and  
untreated. Subjects can be broken down into group a (treated with 5-aza-2'-deoxycytidine {5-aza-
dc},  a DNA methylation inhibitor),  b (treated with Trichostatin A {TSA}, a histone deacetylation  
inhibitor) and c (treated with both). Case loadings distinguish between subjects treated with TSA 
and subjects not treated with TSA (p = 0.02)
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Figure  29, second expression profile for a series of replicates, treated as controls, treated with  
TSA,  5-aza-dc or both. The case loadings (figure 28), suggest this represents the effects of the  
histone deacetylation inhibitor TSA. However the expression profile is not consistent with this.
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When probe-SVD was applied, none of the 16 eigenvectors represented the effects of 5-aza-dc, 
while  the  third  eigenvector  (8% of  the  variance)  did  show a significant  difference (p =  0.01), 
between  those  treated with  TSA and  those  who  were  not  (see  figure  30).  However  this  was 
associated with genes both increasing and decreasing in expression and so it is unknown if it is 
truly associated with the biological effects of TSA.
Figure 30, Illustration of the third set of case loadings (8% of variance) for a series of replicates.  
Subjects can be broken down into controls who have not been treated, group  a (treated with 5-
aza-dc, a DNA methylation inhibitor), b (treated with TSA, a histone deacetylation inhibitor) and c 
(treated with both 5-aza-dc, and TSA). Case loadings show a significant difference between those  
not treated with TSA (controls and group a) and those treated with TSA (groups b and c).
4.2.2 Effect of LADs and Progeria on Chromowave
Another  spatially  coherent  variation  in  expression  is  that  associated  with  lamina  associated 
domains (LADs). LADs are known to show low expression (Guelen et al. 2008) and to extend over 
a  finite  distance.  Changes  in  these  should  represent  an  almost  ideal  case  for  Chromowave 
analysis. LADs are a recent discovery and so there are no example cases to demonstrate changes 
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in these domains. However, it is known that laminopathies such as Progeria involve large scale 
disruptions to the nuclear lamina (in the case of  Hutchinson-Gilford progeria syndrome it is caused 
by a mutation in the gene that codes for lamin-a). Consequently, a set of data from an investigation 
into Progeria was chosen as an ideal example data set to test this.
4.2.2.1 Chromowave distinguishes between cell lines with Hutchinson-
Gilford progeria syndrome and those without
Initially Chromowave was applied to the Progeria dataset, using a global analysis, to see whether it 
could  detect  consistent  changes  related  to  the  pathology.  The  first  eigenvector  (41%  of  the 
variance) was extracted from all chromosomes. The case loadings (see figure 31) were found to 
significantly (p = 3.1 x 10-6) distinguish between the two groups. The expression pattern for this can 
be seen in figure  32. It  can be seen that there are many changes associated with the disease 
status. Some chromosomes show near chromosome-wide higher transcription in Progeria subjects 
(e.g. chr 3, 4, 5 and 19) or even chromosome wide lower transcription (chr 19 and 22) suggesting 
that large scale chromatin organisation may be involved. In other cases (e.g. chr 14q24 19q13) 
there are small regions of extremely differential expression reflecting more local changes, which 
may represent the various methylation and other epigenetic modifications known to occur.
Figure 31, Case loadings of the primary global eigenvector (41% of variance), for an investigation  
into  progeria  using  Chromowave.  Case  loadings  clearly  distinguish  (p  =  3.1  x  10-6)  between 
controls and Progeria cell lines. 
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 Figure 32, expression profiles from Chromowave analysis of Hutchinson-Gilford progeria dataset  
for all chromosomes. Associated case loadings (41% of variance), are significantly (p = 3.1 x 10-6)  
different between groups. 
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4.2.2.2 Lamina associated domains show lower expression than non-
lamina associated regions
To validate the identification of LAD probes, it was sought to replicate the low expression result 
using the control subjects for the Progeria dataset investigated in the previous section. 
The values for all probes marked as present in more than 4 of the samples were extracted, 
and separated into those within LADs (~1500 probes) and those not within LADs (~4000 probes). 
The values for each probe were log2 transformed and averaged across all control samples. These 
averages were then analysed using a simple t-test, and found to show a clear difference between 
the groups (see figure 33). Because of the massive number of genes, the p-value of the difference 
could not be calculated (it was too low), however this clearly marks it as significant. The overlap 
between  the  two  groups  is  expected  both  because  many  genes  are  inactivated  when  not 
associated with the lamina, and also that not all LAD genes are inactive. It is also likely that since 
the data used were only filtered to have more than 4 present calls, rather than be entirely present, 
absent probes are masking some of the difference between the groups. This filtering may also bias 
the values for the LAD genes, since many of these may be absent in a normal sample, however 
this was deemed to be a good compromise between the two potential sources of bias. The large 
difference in mean expression value between the two groups helps to justify that the correct probes 
were identified.
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Figure  33, box-plot of probes not within LADs and those within LADs. There is a large range of  
variation for both samples, however, the mean is significantly (p < 1 x 10-10) higher in the probes 
not associated with the lamina. Since not all probes would be present in the datasets, it is likely  
that a number of absent probes helps to mask a bigger difference between the two groups.
4.2.2.3  Chromowave  analysis  of  Progeria  does  not  show  abnormal 
expression increases in LADs 
The hypothesis for this section is that since genes within LADs show low expression, and since 
when a gene is moved to the lamina its expression reduces (Finlan et al. 2008; Reddy et al. 2008), 
any  disruption  to  the lamina  should  increase  its  average  expression.  Progeria  can  be  clearly 
identified using Chromowave and that the expression pattern shows both increases and decreases 
(see  4.2.2.1  Chromowave  distinguishes  between  cell  lines  with  Hutchinson-Gilford  progeria
syndrome and those without). To test whether the profile shows a bias for increased expression 
amongst  those  probes  in  LADs,  the  projected  Chromowave  values  were  collected  and  split 
between LAD probes and non-LAD probes. Distributions were individually examined and seen to 
be approximately Gaussian, and so were analysed in a t-test (see figure  34). Despite the high 
degrees of freedom, the difference between the two sets was non-significant (p = 0.28). Although it 
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is impossible to prove a negative, it is clear that the hypothesis has not been supported and that 
any difference is small. It can also be seen that both distributions average at approximately zero 
suggesting no bias towards increased expression in either group.
 Figure 34 showing the difference in values between the Chromowave projected expression from  
lamina associated probes and probes not associated with the lamina. There was no significant  
difference  (p  =  0.28)  between  the  two  datasets,  not  supporting  the  hypothesis  that  genes  
associated with the lamina would show increased expression due to its disruption. Both groups  
have  an  average  value  of  approximately  0,  suggesting  little  bias  towards  either  increased  or  
decreased expression changes in either group. 
4.2.2.4  LADs do not  show abnormally  high  differential  expression in 
Progeria
As  the  previous  hypothesis  was  not  supported,  it  was  hypothesised  that,  in  progeria,  genes 
associated with the lamina would show differential  expression at  higher levels  than genes not 
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associated with the lamina. 
To test whether probes attached to the lamina were more associated with the changes that 
occur in Progeria, each probe was correlated with a simple two class model and the absolute value 
of each correlation was chosen. The two datasets were then compared using a Mann–Whitney U 
test applied to determine whether the two distributions were the same.  The results are shown in 
figure 35. As can be seen there is little difference between the values, however the high sample 
size means that even small differences can be significant. In this case there is a highly significant 
difference (p = 1.2 x 10-11), however the direction is in fact the opposite to hypothesised. Genes not 
associated with the lamina are more likely to be differentially expressed between the two cases,  
though the actual difference is small. LAD values are generally lower than non-LADs and so it may 
be that there are a higher number of absent genes in the LAD distribution which could explain this 
finding. However it seems clear that there is no large difference between the two sets, contrary to 
the hypothesis.  It  is  also possible that  in  some way the genes associated with  the LADs are 
protected more than the other genes, though this is highly speculative and not investigated here 
further.
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Figure  35, box-plot of the association (absolute Pearson correlation) of each probes expression  
with  the  grouping  classification  (progeria  and  control).  There  is  a  slight  but  significant  higher  
association amongst those probes not associated with the lamina, which is the opposite of what  
was hypothesised. Reasons for this difference may be that lamina genes do not change much  
between the conditions, that only a small number of LAD genes are affected or that the noise  
levels are higher than for other genes and mask the differences between the two states. Probes  
were not filtered for present call, which may also help to mask this difference.
4.2.3 Effects of Confounding factors on Chromowave
Chromowave analysis was applied to two of the most common potential confounding factors, which 
are  differences  in  the  cell  type  ratios  and  differences  in  post-mortem  interval  (PMI).  Multiple 
datasets were used to investigate each factor, to test whether findings were reproducible.
 
4.2.3.1  Low  X-expression  is  associated  with  low  concentrations  of 
neurons
As described in the introduction, the brain has higher rate of transcription for chromosome X than 
93
other tissues  (Nguyen and Disteche 2006) and ChrX is particularly rich in brain related genes 
(Laumonnier, Cuthbert, and Grant 2007). Consequently it was hypothesised that changes could be 
observed in chromosome X profiles associated with changes in the concentration of neuronal cells 
in Human post-mortem brain samples. Many neurological diseases are associated with a reduction 
in the number of neurons (e.g. Alzheimer's disease (Gómez-Isla et al. 1997), Huntington's disease 
(Hedreen and Folstein 1995), Multiple Sclerosis  (Wegner et al.  2006) and Parkinson's disease 
(Bossers  et  al.  2009)). Post-mortem data  from subjects  with  some of  these pathologies  were 
selected. Blood samples from subjects with these diseases were used as tissue control data. 
To determine the concentration of neurons in the samples, a set of reporter genes26 were 
identified  by  Dr  Pascal  Durrenburger27.  These  genes  were  chosen  as  they  are  known  to  be 
expressed highly and specifically in neurons. Expression patterns for these genes were calculated 
by applying SVD to the set and using the primary eigenvector as a summary of the expression 
behaviour of multiple genes. The case loadings for this eigenvector were then correlated with the 
case loadings from chromosome X. This was backed up by using the median expression for each 
subject to determine the direction of association, median expression wasn't used to determine the 
significance of association since it is more prone to noise. 
4.2.3.1.1 Association of Low X-expression with Neuronal loss in Parkinson's
All  the  Parkinson's  datasets  from post-mortem brain  tissue,  demonstrated similar,  near 
chromosome wide, patterns of ChrX expression (see figure 36). This expression pattern shows a 
reduction in ChrX expression for the entire chromosome, with the exception of the telomeric p-end 
of the chromosome. 
In the dataset  from PD medial  nigra tissue,  there was a significant  correlation (64% of 
variance, r = 0.7, p = 0.001) between the reduction in expression of neuron reporter genes and the 
pattern of reduced expression on ChrX (see figure 36, top left). While in the related dataset from 
the lateral nigra in PD subjects and controls, there was also significant (50% variance, r = 0.7, p = 
26 The list of genes can be found in appendix 1. 
27 Wolfson Neuroscience Laboratories and Division of Experimental Medicine, Faculty of Medicine, Imperial 
College London, UK. Working under Dr Richard Reynolds and Dr David T. Dexter. 
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0.01)  correlation  between the neuron reporter  gene pattern  and the ChrX case loadings.  The 
pattern of expression was extremely similar to that produced by the medial nigra from the same 
patients,  demonstrating the reproducibility of the results.  These results could also be taken as 
being significantly different between male patients and controls (p =  0.0004 for the medial nigra 
and p = 0.05 for the lateral nigra). The gender specificity makes sense given that women have a 
higher age at  onset and a more benign phenotype with milder motor deterioration and striatal 
degeneration (Haaxma et al. 2007). 
In the PD whole nigra measured using Affymetrix arrays, there was a significant (75% of 
variance, r = 0.8, with  p = 3x10-6) correlation between the neuron reporter genes and the ChrX 
pattern, which was again visually similar to the previous patterns (see figure  36, top right). This 
result  again be taken as significant  in  male subjects  (p =  0.007),  though not  significant  when 
female subjects are included. 
In  the  whole  nigra  PD dataset  measured using Illumina beadchips,  there  was  again  a 
significant correlation (66% of variance, r = -0.85 p = 5 x 10-6) between the expression pattern of 
the neuron reporter genes and that for the ChrX reduction in expression. The pattern (see figure 
36, bottom right) is similar to those found in the other datasets, being a reduction over the whole of 
ChrX, with the exception of the telomeric p-end. This is despite the array being made by a different 
manufacturer, and the normalisation method being quite different from any of the other datasets.  
As in previous datasets, this result can also be interpreted as a significant difference between male 
PD subjects and male controls (p = 0.002).
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Figure 36, Expression profiles from ChrX in four different datasets. Datasets are the medial nigra  
(top left), the lateral nigra (top right), and the whole nigra measured using Affymetrix chips (bottom  
left) and Illumina chips (bottom right). The lateral nigral data originates from a subsample of the  
subject for the medial nigra, while the whole nigra datasets are independent of all other samples.  
Case loadings associated with each eigenvector correlate significantly with case loadings derived  
from neuron reporter genes. Each expression pattern shows a general reduction associated with  
loss of neurons, with the exception of the telomeric p-end of the chromosomes (Xp22-Xp21).
In the PD blood dataset, there was no significant correlation (r = 0.02, p = 0.8) between neuronal 
reporter gene expression and ChrX expression. The expression pattern obtained was also quite 
different to those obtained from brain (see figure 37). There was also no association with disease 
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status in males, females or both combined, despite it being a much larger cohort.
Figure  37.  Expression pattern  from PD blood and controls.  The expression pattern  is  similar,  
though with definite differences, to those from brain tissue. The correlation with the neuron reporter  
genes is  low (r  = 0.02 p = 0.8),  as expected,  but  the similarities between this  and the other  
expression patterns may suggest the expression pattern from the brain datasets are not unique.
3.2.3.1.2 Association of Low X-expression with Neuronal loss in Alzheimer's disease
In the set of AD hippocampus data a significant correlation (r = 0.65,  p = 6 x 10-4) was found 
between the expression pattern of the neuron reporter genes and that for the ChrX reduction in 
expression. Notably  there  was  no  association  of  this  pattern  with  disease  supporting  the  link 
between neuronal concentration and these results (irrespective of disease). The pattern produced 
by this analysis is again very similar to those from the PD results, supporting the idea that this is a 
general result rather than a disease specific one.
In the AD blood data, neither the first nor the second eigenvector look very similar to those 
from the brain datasets. The primary expression pattern was not significantly associated with the 
neuronal reporter genes (r = 0.6,  p = 0.3), though the small sample size (3 patients, 3 controls) 
may hinder this.  However  more importantly the first  eigenvector (see figure  38) appears to be 
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related to gender (given the extreme peak which is centred on the Xist gene, which is only active 
on the silenced  ChrX and hence in  female  subjects).  This  suggests  that  perhaps the second 
eigenvector should also be analysed,  since the results may have been forced into the second 
component. 
The second expression pattern (figure 39) looks even less like that from the brain datasets, 
with  a  pattern  showing  changes  in  two  smaller  regions,  rather  than  the  whole  chromosome. 
Similarly to the previous results in blood there is no significant association with the reporter genes 
(r = 0.05, p = 0.9). 
Figure  38. Expression pattern from the hippocampus of a set of AD patients and controls. The  
expression pattern is similar, to the results from PD brain samples (see figure 36). There is also a  
significant correlation with the neuron reporter genes (r = 0.65, p = 6 x 10 -4), again suggesting 
there is a near chromosome wide reduction in ChrX (except for Xp22-Xp21) associated with loss of  
neuronal expression, similarly to the PD results. Similar results were not found on the autosomes.
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Figure 39. Expression pattern from primary eigenvector from chromowave analysis of 3 AD blood  
and 3 controls. The expression pattern shows limited similarities with those from brain tissue. The  
correlation with the neuron reporter genes is non-significant (r = 0.6 p = 0.3), as expected, though  
this may be due to low sample sizes. The most likely cause for this eigenvector is gender (due to  
extensive activation of Xist gene), consequently the next eigenvector was also investigated.
Figure  40. Expression pattern from 3 AD blood and 3 controls. The expression pattern is very  
different to those from brain tissue. The correlation with the neuron reporter genes is low (r = 0.05,  
p = 0.9), as expected.
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4.2.3.1.3 Association of Low X-expression with Neuronal loss in Huntington's disease
In the HD blood samples, the expression pattern obtained (see figure  41) was very different to 
those produced from brain and also that from dataset D1. No significant correlation (r = 0.3,  p = 
0.14) was found. This is as expected and in line with the results from other blood samples. 
In the HD caudate samples however, a significant correlation (r = 0.91, p = 1 x 10-11) was 
found.  The expression pattern,  was similar  to  those from other  datasets,  though with  a slight 
increase in expression for the 1p telomeric region, whereas previous patterns showed either a 
small reduction or no expression changes for this region.
Figure 41. Expression pattern from HD blood dataset. The expression pattern is very different to  
those from brain datasets, though it shows some similarities to those from AD blood (see figure  
40). The case loadings show no significant correlation with the neuron reporter genes (r = 0.3, p =  
0.14). 
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Figure 42. Expression pattern from caudate samples from a set of HD patients and controls. This  
expression pattern is significantly associated with the loss of neuronal expression (r = 0.91, p = 1 x  
10-11). Similar to previous results (see figures  36 and  38) there is a loss of expression over the  
majority of the ChrX, (except Xp22). Unlike the other results, there is increased expression at the  
telomeric p-end. This may be a HD specific change, since it was not present in the other results.
These similar  expression  patterns  in  brain  subjects  occurred  despite  the  use  of  a  mixture  of 
microarray platforms and protocols,  as well  as different  normalisation schemes. This seems to 
support the generality of the finding. All case loadings associated with these patterns correlated 
well with the patterns of expression extracted from the genes representing neuronal concentration 
in the samples while those from blood samples showed both no connection and a generally quite 
different expression pattern. 
4.2.3.2 Statistical robustness of chromosome expression patterns
Because the association of  mean X expression and neuronal  concentration is  one of  the first 
suggested links between chromosome wide transcription levels and a cell  type, it  was thought 
necessary  to  further  verify  the  Chromowave  analysis.  To  do  this,  the  normalised  and  log2 
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transformed intensity values of the X-linked probes were averaged for each subject. These were 
then correlated with the previously calculated neuronal expression values. Results from these are 
seen in figures 43-48 and they agreed with those from the Chromowave analysis, demonstrating 
that the results of Chromowave are not the result of poor modelling.
Figure 43. Scatter plot (with linear fit) of mean X-linked expression against the case loadings from  
neuronal genes, from the medial nigra, supporting the Chromowave analysis.
Figure 44. Scatter plot (with linear fit) of mean X-linked expression against the case loadings from  
neuronal  genes,  from  the  lateral  nigra,  dataset  showing  a  straight  line  fit,  supporting  the  
Chromowave analysis.
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Figure  45. Scatter plot (with linear fit) of mean X-linked expression against the neuronal genes  
case loadings from the Affymetrix whole nigra dataset. Graph shows a straight line fit, supporting  
the Chromowave analysis.
Figure 46. Scatter plot (with linear fit) of mean X-linked expression against the case loadings from  
neuronal genes, from the whole nigra from Illumina beadchips dataset, showing a straight line fit,  
supporting the Chromowave analysis.
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Figure 47. Scatter plot (with linear fit) of mean X-linked expression against the case loadings from  
neuronal genes, from the AD brain dataset, showing a straight line fit, supporting the Chromowave  
analysis.
Figure 48. Scatter plot (with linear fit) of mean X-linked expression against the case loadings from  
neuronal  genes,  from  the  HD  caudate  samples,  showing  a  straight  line  fit,  supporting  the  
Chromowave analysis.
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4.2.3.3  Correlation  of  Expression  patterns  with  post-mortem  Interval  
(PMI)
4.2.3.3.1 PMI associated expression pattern in bipolar disorder datasets
Analysis of the supplementary information that came with the orbitofrontal and dorsolateral bipolar 
datasets (age, gender, duration of illness, pH, PMI, drug abuse, drug status and alcohol abuse), 
showed that both of these datasets were significantly associated with post-mortem interval (PMI, 
also known as post mortem delay) but no other features. Consequently all the other datasets which 
included PMI were acquired and investigated. 
In  the  dataset  of  orbitofrontal  cortex  from  bipolar  subjects  and  controls,  there  was  a 
significant correlation (r = 0.7,  p = 5x10-4) between the first global pattern of expression (59% of 
variance) and the PMI. No significant correlation was found with any other feature given in the 
supplementary information. The expression pattern associated with this result can be seen in figure 
49. This result can also be taken as significantly different between bipolars and controls (p = 0.02), 
which potentially shows the risk of PMI as a confounding factor. 
In the dataset of dorsolateral prefrontal cortex there was a significant correlation (r = 0.3 p = 
0.02) between the case loadings of the first global eigenvector (see figure 50) and the PMI. The 
expression patterns look very similar to those obtained from the previous dataset, which was from 
the same publication, but a different cohort of patients and subjects. This result can also be taken 
as significantly different between bipolar subjects and controls (p = 0.04), similarly to the previous 
result.
Treating PMI as a confound and attempting to see if there is significant difference between 
bipolars and controls in these datasets indicates that there were no significant results. Additionally, 
the non-significant association which remained was opposite in direction between the datasets, 
further suggesting that there was no difference. The differences in PMI between the two groups 
likely reflects difficulties in collection of suitable brain samples.
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Figure  49, primary global expression profile from a Chromowave analysis of  orbitofrontal cortex 
from 10 bipolar  subjects and 11 controls.  Case loadings associated with this pattern correlate  
significantly (r = 0.69 p = 5x10-4) with post-mortem interval. 
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Figure  50,  primary global  expression profile  from a Chromowave analysis  of  dorsolateral  pre-
frontal cortex from 30 bipolar subjects and 31 controls. Case loadings correlate significantly (r =  
0.31 p = 0.02) with PMI. Profile very similar to that from the obitofrontal cortex, for autosomes.
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4.2.3.3.2 PMI association in a Down's syndrome dataset
The only other dataset available that had PMI associated with the patients is a set of data from 
Down syndrome subjects and controls (7 patients 8 controls), 12 of whom had PMI information 
available. In this dataset, there was a non-significant correlation (63% of variance, r = 0.5,  p = 
0.09) between the first global case loading (see figure 51) and the PMI. This follows the trend given 
in  the  other  datasets,  and  significantly  distinguishes  between  Down  syndrome  patients  and 
controls (p = 0.0002). The prime difference between the Down syndrome sufferers and normals, is 
the trisomy of chromosome 21 (which occurs in the vast majority of Down Syndrome subjects). 
This  trisomy can be clearly  seen through the much higher  absolute values of  the expression 
pattern  on  that  chromosome.  This  trisomy however  is  not  the  only  feature  and  an  individual 
analysis  of  the  other  chromosomes  still  shows  a  significant  difference  in  case  loadings.  The 
variation for other chromosomes is extremely small, and under normal Chromowave settings would 
not  be visible.  However,  by plotting the values for  each chromosome individually with a more 
appropriate scaling than Chromowave provided, it can be seen that there is a very high level of  
similarity between the profiles from the bipolar  datasets and the expression patterns from this 
dataset.  Even the profile for chr21 shows a similar pattern. However due to the bias from the 
trisomy, the pattern is shown as all negative rather than the partially positive it was in the previous 
results (negative in this case representing higher expression in Down's patients). 
The reason for  the non-significance of the association in this dataset  may be due to a 
biasing of the case loadings due to the trisomy 21 or more likely the small sample size of this 
dataset coupled with the relatively high levels of noise due to the small scale of this variation. Or 
alternatively it may be that these results are not correlating directly with PMI but an unknown factor 
which also correlates with PMI.
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Figure 51, case loadings for a Chromowave global investigation into Down's syndrome (7 patients 
8 controls). Case loadings significantly distinguish between subjects and controls (p = 0.0002), and  
also correlate in a non-significant way with their associated post-mortem interval (PMI), (r = 0.5, p  
= 0.09). Expression patterns for this profile are below visible on a Chromowave readout, however  
when expanded these show a definite similarity to expression patterns associated with PMI.  
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Figure 52, Expression pattern from Down syndrome subjects and controls. Expression pattern is  
significantly associated with Down syndrome  (p = 0.0002), but resembles the profile associated  
with PMI (see figures 49 & 50) which it is non-significantly associated with (r = 0.5, p = 0.09). The  
profiles had too small a variation to be distinguishable on a normal Chromowave profile (except  
chr21, which carries a chromosomal duplication and hence has much larger absolute values), and  
so instead these are all  projected onto more suitable individual  scales.  Because the plot  was  
produced  outside  of  Chromowave,  chromosomal  locations  are  given  in  bp  not  in  cytogenic  
notation.
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4.3 Discussion 
This  section  supports  the  conclusion that  Chromowave produces reproducible  and meaningful 
results and that it detects epigenetic markers.  The most direct analyses were investigations into 
Human cell  lines treated with TSA and  5AzaC, chemicals  which are known to activate genes 
silenced  epigenetically.  The  analysis  of  data  treated  with  5AzaC (demethylation  agent) 
demonstrated  that  Chromowave  can  detect  transcriptional  changes  due  to  epigenetic 
modifications. Further it can be seen that the use of the wavelet transform separates the groups 
more efficiently than probe-SVD.  Consequently it  seems that  the spatially organised approach 
used  by Chromowave is  better  at  modelling  the differences  in  transcription  due to  epigenetic 
changes than alternative non-spatial approaches.  It is possible that this advantage is due to the 
sparsity  of  results  in  wavelet  space  rather  than  the  advantages  of  focussing  on  the  spatially 
coherent component. However, if there was no spatial component then the wavelet representation 
would not be sparse. A further reason to think the modelling is working, is that the unsilenced 
genes  showed  more  cases  of  increased  expression  than  decreased  (in  Chromowave),  while 
modelling with probe-SVD showed a symmetric distribution (data not shown). As this fits with the 
hypothesis of the experiment and the understanding of the treatment this gives a biological reason 
to prefer the results of Chromowave and hence the modelling. The results of treatment with just 
TSA are less easily interpretable. Although there is a significant association with the Chromowave 
analysis  (and  not  when  using  probe-SVD)  the  direction  of  association  is  the  opposite  of 
expectations.  This could reflect  a misunderstanding of  the function of  TSA, a false positive or 
perhaps a confounding factor. Repetition of this treatment would be useful to detect false positives, 
while application to other cell lines, or Human cells would usefully see whether it is a cell specific 
effect. It may also be related to other effects which TSA has, for example HDACs affect a range of 
non-histone  targets  and  also  interact  with  signal  pathways  which  can  have  further  effects 
(Ganesan et  al.  2009). These alternative interactions complicate the simple picture of  TSA as 
simply  reactivating  genes  silenced  by  histone  deacetylation28.  The  small  sample  size  in  this 
28 Similar problems presumably also exist for demethylation agents, but this appears to have received less 
attention in the literature.
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analysis is a problem here, since it does not allow any real judgement of reproducibility,  which 
would help rule out some of these possibilities. However, the work on 5AzaC (demethylation agent) 
combined  with  work  previously  performed on Huntington's  disease gives  strong evidence  that 
Chromowave  can  be  applied  to  transcriptional  changes  due  to  epigenetics  and  not  just  copy 
number variations. 
The hypothesis that lamina associated genes would be differentially expressed more often 
in laminopathies such as progeria, appears to be incorrect, since a lesser association was found. 
This may be a result of the low activation levels of the LAD genes increasing noise levels, or it may 
indicate that in fact the lamina genes are somehow protected from the changes occurring in the 
genome.  It  is  also possible that  since the mutation is in  lamina A and the lamina maps were 
produced using the lamin-B1 protein, that this may not be the appropriate map. However, since the 
lamina shows widespread disruption, this seems an unimportant difference. It is also possible that 
it is the usage of cell lines which is causing this surprising result. If differences were found between 
the behaviour of patient cells and cell lines, this would be a strong argument against their usage. 
Indeed many differences between individual cell lines and Human cells are known. However, no 
data from Human progeria patients is available, so explanations for this result are impossible. 
It is also clear that there are confounding factors, such as differences in cell types, which 
can be mistaken for changes caused by disease states. Many of the results attributed here to 
either neuronal concentration of PMI can equally be interpreted as differences due to disease. We 
discount  this  interpretation however,  as while it  is  easy to see that  the difficulties in collecting 
pathological material might mean that normals and patients differ in PMI or neuronal concentration, 
it is harder to explain why many diseases would produce such similar results. This does not mean 
that the diseases do not have some effect on the results though. However attempts to treat these 
factors as confounds, and detect disease related signal failed to reach significance in any dataset. 
No disease related effects were distinguishable using Chromowave on the X-chromosome. No 
autosomal patterns were replicable and so were assumed to be false positives. This highlights the 
care which must be taken when validating any result whether using Chromowave or not and these 
findings provide two possible explanations for results found.
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The bipolar  data appears to show differential  expression between controls and patients 
and if it was not for the inclusion of the PMI in the data, it might be assumed that the result was  
due to the disease. Fortunately though it appears that post-mortem interval has a characteristic 
expression pattern. The effect also appears to be fairly small, and the results here are not strongly 
significant. However as it occurs in a range of datasets it looks likely that it is a real effect and  
wide-spread across different data-sets and platforms. An important point to note is that all available 
data with individual PMI measurements was used, coming from a range of different tissues. Yet 
similar patterns were found for all sets. This suggests that this finding is not tissue specific, which 
is in itself of interest, given that expression patterns are often thought of as tissue specific. These 
changes are likely related to a basic gene expression pattern, perhaps related to essential genes. 
It  is  possible  that  the  result  does  not  represent  PMI  directly  but  the  results  of  some  event 
associated with PMI, which would explain the low association. However, it is not associated with 
pH, one major feature linked with PMI (since in brain the pH decreases as PMI increases (Tomita 
et al. 2004)). The identified pattern means that transcription profiles from disease states can be 
examined, and discounted if they match this pattern. This provides an extra approach in addition to 
the standard statistical methods for dealing with confounding factors. It is a clear criticism of the 
original studies that despite recording PMI they ignored the significant differences between controls 
and patients. It is obviously difficult obtaining suitable post-mortem tissue, however this does not 
excuse poor scientific practice. However it is important to note that the profiles investigated here 
are fundamentally different from the single gene approaches taken by these studies. While it is 
shown (see section 6.2.3 Anti-Chromowave) that spatial components bias the results of probe by 
probe methods, it is possible that treating PMI as a confound allowed the detection of significant 
differences between groups. 
The  changes  on  ChrX are  almost  certainly  due  to  the  varying  neuronal  concentration, 
though in several datasets they are significantly different between subjects and patients. Whether 
there will also be spatially coherent differences due to varying concentrations of other cell types is 
unknown,  but  if  so  these  are  not  expected  to  be  chromosome wide.  The  discovery  that  the 
concentration of neurons is associated with the near chromosome wide expression of  ChrX is 
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unexpected, and is the first  time a cell  type (with the exception of embryonic stem cells  (Ben-
Yehudah et al. 2010)) has been associated with chromosome wide expression. The most likely 
explanation is that chrX is higher expressed in neurons than in other brain cells. As the brain itself 
shows higher expression of ChrX than other tissues  (Nguyen and Disteche 2006), these results 
suggest  it  is primarily the neurons which exhibit  this high expression. This discovery should in 
future be examined using more direct methods, (e.g. laser microscope dissection (Lu et al. 2005)). 
Unlike PMI, this represents an uncontrollable experimental variable. Since results in most datasets 
could have been viewed as significant it does highlight the importance of considering the effects of 
a  disease  in  its  analysis.  Attempts  to  treat  neuronal  concentration  as  a  confound  were  not 
significant. The pattern of  expression found to be associated with the neurons resembles that 
described for ChrX silencing  (Brown and Greally 2003). If this is substantiated it may suggest a 
common  mechanism  linking  the  phenomena,  a  suggestion  discussed  more  in  section  5.3
Discussion.
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5. RESULTS 2: Application of Spatial modelling to non-
transcriptional data
5.1 Introduction 
The previous chapters demonstrate that spatial coherence is a common feature in transcription 
data. To properly investigate spatial coherence in gene expression however, it is also necessary to 
take a look into the mechanisms causing this coherence. In this chapter the tools to investigate 
spatial coherence are applied to data on these mechanisms to investigate the potential existence 
of  spatial  coherence  in  these.  Features  such  as  copy number  variations  (CNVs)  and  loss  of 
heterozygosity (LOH) are already analysed spatially.  Techniques used to analyse these include 
windowing functions and hidden Markov models (HMM – see section 5.2.2 Measurements of Loss
of Heterozygousity (LOH)) or other methods which take the spatial organisation into account such 
as Circular Binary Segmentation (CBS) (Olshen et al. 2004). 
It was shown using Chromowave that the spatial coherence inherrent in CNVs manifests 
itself  in  transcriptional  data,  however  this  used  indirect  evidence  only  (section  2.5.4.2.1
Chromowave applied  to tumour  samples).  Consequently  the first  aim for  this  section  is  to  re-
evaluate the effect of DNA copy number on expression. Zygosity is a measure which like CNVs is 
measured using CGH. Zygosity has been implicated in cancer development  (Green et al. 2010) 
and may affect the levels of transcription especially given dosage control mechanisms. Unlike CNV 
analysis  there  have  apparently  been  no  attempts  to  use  wavelets  to  analyse  LOH.  Software 
packages currently available require the user to make a series of choices of thresholds and other 
variables which can make for  a confusing and hard to replicate experience29.  Consequently a 
Chromowave technique is applied to tumour data and tested for the detection of zygosity.
It  is  becoming  more  common  in  research  to  measure  epigenetic  markers  such  as 
methylation and acetylation. All such markers affect transcription rates in a spatial way, but it is 
29 Discussion with Christophe Poulet (Human Genetics Department, GIGA research, University of Liege, 
Belgium. Working under Dr Vincent Bours and Dr Manuel Deprez).
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unknown whether they are organised spatially themselves. If spatial organisation can be verified 
then  this  would  represent  another  area  for  spatial  modelling.  Chromowave  works  because 
expression is organised in a spatial way along chromosomes  (Jaenisch and Bird 2003; Sproul, 
Gilbert, and Bickmore 2005; Fernandez-Ricaud et al. 2009) to apply spatial modelling to other data 
their spatial organisation must be demonstrated.
Several techniques have been developed to test whether expression is spatially organised 
(Fernandez-Ricaud et al. 2009). For our purposes we developed a new method based on the Hurst 
exponent,  a  mathematical  index  of  persistence  (Jones,  Lonergan,  and  Mainwaring  1996; 
McCauley, Gunaratne, and Bassler 2007; Hurst 1956). A persistent signal is one in which there are 
a higher number of large scale (low frequency) components than would be expected from random 
noise,  whereas  an  anti-persistent  signal  has  a  higher  ratio  of  high  frequency variation.  Hurst 
exponents greater than 0.5 refer to signals showing spatial persistence while those under 0.5 show 
anti-persistence. 
Hurst  analysis  can  test  whether  the  data  is  spatially  coherent,  if  the  data  is  not  then 
application of wavelets will be inefficient. Hurst analysis can also detect whether the variations are 
spatially coherent. This latter is performed by applying Hurst analysis to a SVD eigenvector from 
the data. Probe-SVD was chosen here due to its simplicity and similarities with Chromowave. The 
Hurst method will be discussed in more detail in section 5.2.3 Application of Spatial modelling to
Epigenetic data .
This chapter discusses a range of different points using different data, however the main 
sections are firstly the application of spatial modelling to SNP arrays and secondly the application 
of spatial modelling to epigenetic markers. The main results for the first section are the formula to 
anlayse the percentage of normal tissue in a CN1 deletion and the re-evaluation of the detection of 
CNVs using Chromowave. The second section demonstrates a new method for detecting spatial 
coherence in microarray datasets, and its application to epigenetic data (methylation and histone 
H4  acetylation).  This  section  also  demonstrates  that  Chromowave  can  be  used  to  analyse 
methylation datasets.
The data and datatypes used in this chapter can be split into different categories, these are
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1. CGH data 
1. CGH tumour data from Gorranson et al and Gunnarson et al  used to compare tumour 
percentage formulae  
2. CGH tumour data from the same subjects as Turkheimer et al, the original Chromowave 
publication. Used here to further evaluate the Chromowave identification of CNVs. And 
to demonstrate the application of wavelet denoising to LOH detection.
2. Methylation data
1. Binarised methyl-seq data from Brunner et al, which was used to determine whether 
methylation data is spatially coherent.
2. Methylation data from tumours and adjacent normal mucosa from Kim et al, used to 
demonstrate Chromowave modelling of methylation on medically relevant data
3. Methylation data from the temporal cortex and cerebellum, demonstrating Chromowave 
modelling of the differences between brain regions.
3. Histone-H4 acetylation data 
1. Histone-H4 acetylation data, used to investigate spatial coherence in acetylation data
4. Expression data
1. The Tumour expression data discussed in section  2.5.4.2.1 Chromowave applied to
tumour samples is reused in this chapter partly to compare it with the CGH profiles of 
the same subjects, but also to test the Hurst method for detecting spatial coherence.
5.2 Results
5.2.1 Application to SNP arrays
Wavelet  methods  have  been  applied  to  SNP arrays  to  denoise  CGH data  (Hsu  et  al.  2005) 
previously and consequently it  was decided here to attempt to apply WAGE to the analysis of 
CGH, to see if the analysis could be improved using a Chromowave implementation. It was later 
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decided to also apply the methods to LOH analysis using the same CGH chips. Both of these tasks 
were performed with the collaboration of Christophe Poulet30, who provided the preprocessed data, 
discussed results and thoughts and applied various software packages. 
 
5.2.1.1 Comparison of wavelet denoising  and a leading denoising scheme
Data was provided and segmented using circular binary segmentation (CBS), by Christophe Poulet 
(see sections  3.3.2.1 Tumour  ,  3.3.2.2 Leukaemia, and  3.3.2.3 Small cell lung cancer for more 
information on the data).  Data analysed was the  ratio of the experimental  values to those of 
normal subjects from the Hapmap 27031. A simple wavelet filtering method was developed using 
the wavelet transforms and denoising schemes from Chromowave  (Turkheimer et al. 2006) and 
was applied to the CGH ratio data. 
As can be seen in figure 53 the wavelet denoising system provides a similar picture to that 
from the CBS method as performed by Christophe Poulet and compares well with other  denoising 
systems previously  used  on  CGH data.  The  CBS algorithm  seems  to  detect  very  small,  but 
extremely  reduced  micro-deletions  more  often  than  the  wavelet  method,  which  detects  larger 
slightly reduced areas better. In both cases these detections may be due to noise fluctuations. 
However,  it  is  shown  in  the  next  section  that  the  large  but  only  slightly  reduced  areas  may 
represent real deletions.
30 Human Genetics Department, GIGA research, University of Liege, Belgium. Working under Dr Vincent 
Bours and Dr Manuel Deprez.
31 http://hapmap.ncbi.nlm.nih.gov/
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Figure  53,  Illustration  of  the  raw  logged  CGH signal  from  a  250K  Affymetrix  SNP array,  for 
chromosome 8, overlayed with segmented image from circular binary segmentation (CBS) (red  
line, top) and wavelet denoised signal (blue line middle). Direct comparison of the two (bottom,  
wavelet method in black, CBS in red) shows the good agreement found between the two methods.  
Visually the CBS algorithm seems to detect very small,  but extremely reduced micro-deletions  
more than the wavelet method, which detects larger slightly reduced areas better. However both of  
these detections may represent noise. 
5.2.1.2 Variations in denoised values represent tumour percentages
When analysing CGH signals, it was noticed that the denoised values for deletions such as CN1 
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came in a range of different values, depending on the subject. Naively it would be expected that all 
values for a given copy number should be the same; that of a CN1 in normal tissue. This was not 
the  case  and  it  was  additionally  noticed  that  the  values  tended  to  more  similar  for  different 
chromosomes  of  the  same  subject  than  the  same  chromosome for  different  subjects.  It  was 
hypothesised that these differences may be due to there being different ratios of CN1 and normal 
tissue (and potentially other copy numbers) in a deletion. 
Assuming that  the total  value (t)  of  a  point  on a  CGH array can be calculated by the 
summation of the copy numbers in the sample (for that region) and remembering that the values 
analysed represent the log2 transform of the CGH ratios32, it is possible to simply derive a formula 
to provide the value (t). Taking the example of a heterozygous (value CN1) deletion and assuming 
that the sample investigated is contaminated with normal tissue (value CN2), and that the amount 
of each of these two tissue types are in ratio α:β we obtain equation 9. The value t of the sample is 
seen to be a combination of the logged ratios of copy-number 1 to normal (CN1), and copy-number 
2 to normal (CN2).
t=α 2CN1+β2CN2  (9)
If these are the only copy numbers in the specific location, then this equation is subject to the 
constraint that the coefficients α and β sum to 1. 
α+β=1  (10)
Combining equations 9 & 10, we obtain equation 11. 
t=2CN11−2CN2  (11)
32 A potential criticism of this is that the analysed value (log2) is not the sum of the log transformed values 
for each copy-number. However the transform was only used to make the denoising effective and the 
mean value for the region is unchanged by denoising. In fact the values used here are effectively the non-
transformed values.
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Which when rearranged to find α becomes equation 12. 
= t−2
CN1
2CN1−2CN2
 
(12)
This  brief  analysis  justifies the initial  hypothesis  that  mixtures of  copy numbers can affect  the 
results.  Producing  differing  values,  rather  than  the  specific  and  easily  thresholded  numbers 
normally assumed. The reason for restricting this derivation to copy numbers 1 and 2 is now also 
clear. If we take the example of chromosome X, women are known to have 2 copies of this, while 
men have one. This means that normal results can provide defined numbers for both of these 
values, simply by applying wavelet denoising to chromosome X. Mean values for a range of normal 
subjects can be found in table 2. By examining the normal data it was further found, that the CN2 
and CN1 values were correlated. This was unexpected, and led to redefining t slightly in equation 
19 instead using equation 20 as the definition. Essentially this was a simple subtraction of the copy 
number 2 value observed in normals (CN2normal) from the observed CN2 in the sample (CN2obs) 
t=CN2obs−CN2normal  
(13)
It  was  decided  to  use  sets  of  biologically  validated  tumour  concentrations  to  test  the 
hypothesis that the variation in values for deletions is caused  by different mixtures of normal and 
cancerous  tissue.  Two studies  were  used,  one of  which tested  a  method  for  determining the 
'normal' fraction of cells in a lung cancer dataset validated using cell counting  (Göransson et al. 
2009), the other used flow cytometry to determine the percentage of cells containing a specific 
deletion (Gunnarsson et al. 2008). 
Table 2. Values of Chromosome X from 50K Affymetrix SNP arrays sourced from the Hapmap 270 
reference set.
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Male Subjects ChrX value Female Subjects33 ChrX value
NA10851  -0.595 NA10855 0.0161 
NA11831 -0.5753 NA10863 -0.0176 
NA12056 -0.6004 NA11832 0.0067 
NA12264 -0.5964 NA12057 -0.0058 
NA12707 -0.5558 NA12234 0.0174 
NA12716 -0.5846  NA12717 0.0103 
NA12801 -0.5852 NA12813 -0.0014 
NA12812 -0.5788 NA18505 0.0088 
NA18503 -0.6135 NA18508 -0.0029 
NA18504 -0.6223 NA18517 -0.0024 
NA18506 -0.6211 NA18532 0.0077 
NA18507 -0.5978 NA18545 0.0004 
NA18515 -0.5563 NA18969 0.0133 
NA18516 -0.591 NA18997 0.0131 
NA18558 -0.5652 NA19137 0.017 
NA18605 -0.6028 
NA18612 -0.5752 
NA18959 -0.5861 
NA18967 -0.5794 
NA19138 -0.6067 
NA19139 -0.5908 
NA19153 -0.5595 
NA19154 -0.5955 
Average -0.58847 Average 0.00538 
33 ChrX has a single copy in men but two copies in women hence the different values.
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However  to apply  this  to  biological  samples,  we need to be able to identify pure CN1 
examples. This is made easier by use of a method developed primarily by Christophe Poulet, with 
application of wavelet denoising by myself. This method utilises the fact that each chromosome 
can be arbitrarily separated into two alleles with different values. By defining one as the maximum 
allele and one as the minimum allele, it is possible to use wavelet denoising to obtain a set of 
filtered minimum and maximum values. Since in a single deletion only one variant will (normally) be 
deleted, while in a double deletion both alleles are deleted, it is possible to distinguish between 
these two cases by measuring the value of the maximum allele. While In the case of a double 
deletion this will be apparent as a deletion, and hence have negative values, for a single deletion 
the values will be positive.
Results for the two data sets can be seen in table 3. These demonstrate that the equations 
are a reliable and accurate ways of estimating the fraction of CN1 in a sample, comparing well with 
more complex methods. Sample IDs 4-10 come from Gunnarsson et al (Gunnarsson et al. 2008) 
while the other samples come from Göransson et al (Göransson et al. 2009). 
Table 3, Application of tumour percentage formula to results from Gorranson and Gunnarson.
Sample ID Cytoband Gorranson algorithm Tumour calculated Validated 
Percentage 
4 13q14 --- 60% 62%
5 13q14 --- 93% 89.6%
6 13q14 44% 41% 40%
7 13q14 --- 16% 11%
8 17p13.3-p11.1 --- 57% 73%
9 11q22.1-q23.3 --- 53% 56%
10 17p13.3-p11.2 --- 73% 90%
367A 23% 35% 29%
347A 58% 55% 50%
319A 23% 45% 23%
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234A 17% 21% 20%
189A 45% 51% 48%
165C 42% 40% 38%
39A 52% 56% 55%
5.2.1.3 Comparison of Chromowave tumour results and Wavelet denoised CGH 
profiles
Since we can now verify the existence of CNVs in tumour samples, it is worth revisiting the original  
result from Chromowave and its application to a set of tumour samples (Turkheimer et al. 2006). To 
simplify analysis, we will only investigate those which were used as part of the validation process, 
chromosomes 1, 4, 9, 13, 18 and 19.
On chromosome 1 there was a detection of a 1p deletion for 16 cancer subjects and no 
deletion for 15 cancer subjects (as well  as normals).  Of these cancer patients, 2  predicted as 
having the deletion did not have CGH analysis performed (due to samples being unsuitable). All of 
the patients without  the deletion had CGH analysis performed. All  of  the patients identified as 
having a 1p deletion using Chromowave also had confirmed deletion using CGH arrays. FISH 
identified two subjects (O18 and AD11) as containing a 1p deletion, which neither Chromowave nor 
CGH validated, though both had small  deletions which may have confused the localised FISH 
results. Of those not identified as having the deletion only one subject (AA5, see figure 55) showed 
evidence of a 1p deletion, and this did not show any evidence of this using software such as CBS 
or CNAG. However, assuming this is indeed a 1p deletion (it could also be interpreted as a 1q gain 
or  as  noise)  it  suggests  a  deletion  in  around  50% of  the  sample,  using  the  tumour  formula 
(equation 12). This is also supported by the evidence from expression analysis. When the output 
for subject AA5 is produced relative to those known not to have deletions on Chromosome 1, there 
is a clear 1p/1q distinction, which again suggests a diluted 1p deletion (see figure 56). 
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Figure 54, Illustration of typical denoised deletion pattern (taken from subject O19) from a wavelet  
analysis of arrayCGH. It is clear that as expected, the deletion occupies the 1p region and there is  
virtually no change on the 1q region. Results of a pure deletion would have a value of ~ -0.59  
which shows that  even in  good samples,  there is  a substantial  amount of  cells  which do not  
contain the deletion. 
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Figure  55 Illustration of  denoised CGH pattern for  chromosome 1 in  subject  AA5. Profile  was  
produced by taking this single case and comparing it to all of the subjects known to not possess  
the 1p deletion. The differential profile (in wavelet space) was then denoised and transformed back  
into real space using normal Chromowave methods. This is an application of the single cases  
method built into Chromowave, based on the WAGE technique. The pattern suggests a very dilute  
1p deletion or a possible 1q gain. However, given the common nature of 1p deletion it is assumed  
this is what has occurred and that the subject is likely misclassified. 
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Figure  56, Expression analysis of chromosome 1 for subject AA5 relative to those subjects not  
carrying the deletion. It can be seen there is evidence of a difference between the 1p and 1q ends  
which suggests a 1p deletion. In this case it looks more like a gain on 1q however, this is likely an  
example of poor normalisation (perhaps due to the diluted nature of this sample) and it is more  
likely an example of the common 1p deletion.
For chromosome 4,  the Chromowave analysis  suggested that  there was a clear deletion on 5 
subjects (O32, O30, O3, O29, O2). CGH analysis was not performed on subject O32  however in 
the other 4 subjects there were clear chromosome wide deletions, which confirms the accuracy of 
Chromowave and its superiority in detecting deletions compared with FISH which only identified 
one subject as having the deletion (O3). O9 which was identified as possibly having the deletion 
shows no evidence of any CNV. Subject AA5 shows negative case loadings, suggesting a possible 
gain,  and  on  the  CGH  analysis  there  is  clear  evidence  of  a  gain  occupying  most  of  the 
chromosome.  All  other  subjects,  negative  on Chromowave,  showed no evidence of  any  large 
CNVs.
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For  chromosome  9  subjects  AA3,  AD21  and  O30  showed  evidence  of  gains  on  the 
Chromowave analysis, Each of these subjects did show evidence of gains on 9q, however the 
pattern was complex. Subject AA3 for example shows gains on 9q and two 9p deletions (one of 
which is a double deletion). Subject AD21 shows only a partial 9q gain and subject O30 shows a 
dilute gain over the entire chromosome. Some subjects also showed apparent loss on 9q, these 
are subjects AA6 and O20. AA6 shows evidence of a chromosome wide deletion, while O20 shows 
no CNVs. Other subjects show no extensive deletions or gains, and O2 which was identified by 
FISH as having the deletion was found to have only micro CNVs. From this chromosome it is clear 
that there is more complexity than the Chromowave analysis suggested, though there is a broad 
agreement  with  Chromowave  and  FISH  has  again  been  shown  to  provide  poor  evidence  of 
deletions.
For chromosome 13 there were approximately 8 chromosome wide deletions (AA6, AD13, 
AD14, O10, O2, O3, O30 & O7) and a further deletion identified via FISH (O17). Of those identified 
by Chromowave, subjects AA6 and O2 had chromosome wide deletions, AD13, O3 and O7 had 
deletions  over  the  majority  of  the  chromosome and  O30  and  O10 had  small  deletions.  O17 
identified via FISH was not shown as having a deletion. 
For chromosome 19, 16 subjects were identified by Chromowave as having a 19q deletion 
(7 supported by FISH), of which 14 had CGH analysis. All of these 14 had the 19q deletion except 
for patient AA5 which had a possible highly diluted chromosome wide deletion. Of the subjects not 
identified with the deletion, AD6 possessed the deletion, and AD16 possessed a highly diluted 
possible deletion, and AD16 was close to the boundary on the Chromowave analysis.
5.2.2 Measurements of Loss of Heterozygousity (LOH)
CGH arrays, are also capable of measuring the zygosity of a sample by measuring the strength of 
the different  alleles registered.  Most  genes on an autosomal chromosome,  are present  in  two 
different copies. However, some genes only exist in a single version in a given population. It has 
been suggested that reductions in the homozygosity of some genes, may represent a susceptibility 
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for diseases and in particular for cancer . 
The most  common LOH detection  method is  that  using  Affymetrix  software  (Affymetrix 
2008), which adopts a windowing function to identify regions of low heterozygosity, and a hidden 
Markov model (HMM) to identify regions which are particularly low. HMM are a statistical method 
which represents a noisy data series as existing in a number of 'hidden states'. Each probe in a 
CGH experiment  would  be  assigned  one  of  these  states.  This  makes  the  method  useful  for 
detecting diffuse values. Although this is not the only type of spatial coherence considered in this 
thesis, discrete blocks with a common average do represent one of the most common examples 
discussed here. Consequently HMM represent a primary alternative to the wavelet methods used 
in this thesis. One reason these were not applied to expression analysis is that the noise levels in 
that application are very high. However a potential future work for this thesis is an investigation of 
potential applications of HMM to expression and other data used in this thesis.  Notably this is not 
actually  measuring  a  loss of  heterozygosity,  merely  low  heterozygosity.  It  was  thought  that 
replacing the windowing function with a wavelet  analysis would represent  a more elegant  and 
potentially superior method of detecting either low heterozygosity or the loss of heterozygosity.  
Two related methods for defining the values to denoise were developed. The first simply 
replaces all the homozygous (AA or BB) detections in the genome with the value 0, and all of the 
heterozygous calls (AB or BA) with 1. This is the same formula used in the Affymetrix approach, 
The second method takes the distribution of zygosity for each probe from the normal Hapmap 
subjects. Heterozygous calls (AB or BA) are set to 0 while homozygous detections are assigned a 
probability  given  using  formula  14,  and  Nhet(x) (the  fraction  of  the  probeset  (x),  which  is 
heterozygously detected in the Hapmap samples). that found in the normal subjects and x is the 
probeset. This means that if a probe is homozygous in the sample, and heterozygous in 70% of the 
Hapmap samples, then it is assigned a value of 0.7.
phet (x)=
1
N het ( x)
 (14)
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It was found that this latter method was too sensitive to small regions with extreme values, (see 
figure 57) giving it a noisy profile. This may be due to the small sample size of reference tissue. It 
also made the profiles produced difficult to interpret since the extreme values tended to obscure 
the  larger  more  minor  differences.  Consequently  the  simpler  method  was  developed  and 
investigated.
Figure  57.  Demonstration  of  the  detection  of  LOH by wavelet  denoising using the probability  
method.  The  results  are  difficult  to  interpret,  though  it  can  just  be  seen  there  is  higher  
homozygosity on 1p than 1q, which is due to the 1p deletion. When the results are compared to  
figure  58,  it  can be seen that  the results  from that  method (analysing the same subject  and  
chromosome) is a lot less noisy and easier to interpret.
It  can  be  seen  in  figure  58 that  apart  from  some  errors  at  the  beginning  and  end  of  the 
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chromosome, this wavelet method of detecting LOH is an effective (and easily segmented) method 
of identifying loss of heterozygosity. The edge effects can easily be solved by excluding a small 
number of probes from the two ends of each chromosome. A rough threshold can be determined 
by investigating  a  series  of  samples  without  large deletions  and looking  at  the  distribution  of 
(presumably non-LOH) region values. A rough number is 0.75. Anything above that value can be 
referred to as LOH while anything below is assumed to be normally heterozygous.
Figure 58. Demonstration of the detection of LOH by wavelet denoising. The homozygosity of each  
probe was calculated using the mix of alleles detected via the SNP probe. This was then binarised  
and denoised providing the left illustration, a measure of the homozygosity of the chromosome.  
This can be compared with the second image, which determines the copy number variations over  
the chromosome. It can be seen that the two images match in location and a simple threshold of ~  
0.75 would distinguish between the area with a deletion and those without 
Although it  is  clear  that  wavelets  can be used to improve upon raw LOH signals,  this 
method suffers  from noise or  low detection  percentage depending on the settings  used.  This 
method therefore is not a good method for investigating LOH. Alternative methods (such as those 
based on the B-allele frequency (Staaf et al. 2008)) show higher sensitivity, and so these methods 
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should be preferred to wavelet based methods. It is possible to denoise B-allele frequency using 
wavelets, but this seems to offer no obvious advantage over previous methodologies.
5.2.3 Application of Spatial modelling to Epigenetic data 
In order to apply techniques such as Chromowave to epigenetic data, the data must be organised 
spatially. If this is not the case then the application of wavelets will be extremely sub-optimum and 
there will be no spatially coherent changes. 
To determine whether a dataset is spatially coherent, we make use of the Hurst exponent, a 
common  mathematical  treatment  of  persistence  (Jones,  Lonergan,  and  Mainwaring  1996; 
McCauley, Gunaratne, and Bassler 2007; Hurst 1956). The Hurst exponent (H) can be viewed as a 
measure of the frequency distribution in the signal. Higher exponents refer to larger ratio of low 
frequencies while lower exponents refer to greater ratios of high frequencies. H = 0.5 indicates a 
random walk, with H > 0.5 representing persistent (or coherent) signals and H < 0.5 indicating a 
reverting  process with  a  negative  autocorrelation.  Hurst  analysis  often  uses  a  rescaled  range 
calculation34, and was originally designed to analyse water reservoirs (Hurst 1956), however here 
we apply it to spatial series and the problem of spatial persistence (or coherence) instead. The 
rescaled range starts by calculating the mean value for a time series (ζ) from time (t) = 1 to tau (the 
maximum investigated length of the series). The deviations from this average are then summed for 
all time points and all values of tau (see equation 15). Finally the Rescaled range is calculated by 
taking the difference between the largest and smallest values for this deviation for each value of 
the range tau (see equation 16). As the value of tau goes to infinity (Katsev and L’Heureux 2003) 
the range divided by its standard deviation (rescaled range) becomes a power law. Taking the 
logarithms produces a linear equation with the Hurst exponent as the gradient.
34 Many other estimation methods also exist.  In the next chapter a wavelet based method is applied to 
transcription data. The rescaled range was chosen here partly because it is the most established method 
but also because wavelets were not yet validated for use on epigenetic data. Additionally the initial data 
used was binary in nature, and therefore it was not possible to apply the wavelet method.
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X t , = tu=1 u−〈〉  (15)
R =max  X t ,−minX t , , for 2t  (16)
Hurst  exponent  values  are normally  modelled using either  a  fractional  Brownian motion (fBm) 
model or a fractional Gaussian noise model (fGn) (Eke et al. 2002). However for epigenetic data, 
especially since probes are not uniformly distributed (Wang and Wang 2007), this may not be the 
appropriate  model  (McCauley,  Gunaratne,  and Bassler  2007) and  the statistical  distribution  is 
unknown. Consequently a Monte-Carlo permutation test is used to estimate p-values. By taking 
20,000 permutations of the values for each chromosome for each patient, a statistical distribution 
can be estimated, and p-values approximated. 
Hurst analysis can be applied in two different ways; firstly, it can be applied to the data 
itself, which would then show whether the data is spatially coherent or not. Secondly Hurst analysis 
can be applied to the results of a probe-SVD analysis. The latter answers the question of whether 
the changes in  values are spatially coherent.  While  the former tests whether the data itself  is 
spatially coherent. Together these answer whether a wavelet representation will be successful and 
whether the variations contain a spatial component. 
5.2.3.1 Methylation Values are Spatially Organised
The  Hurst  exponent  was  validated  on  subjects  from  the  tumour  dataset  used  to  validate 
Chromowave. Expression values were used as they are known to be spatially coherent  (Sproul, 
Gilbert, and Bickmore 2005; Fernandez-Ricaud et al. 2009; Jaenisch and Bird 2003) as well as 
containing spatially coherent variation. Firstly, data from chromosome 1 from the normal subjects 
were selected to test whether the expression data is spatially coherent. To further test whether the 
method  can  detect  spatial  coherence  in  the  transcription  variations,  the  whole  set  of  tumour 
samples and normals was analysed with a probe-SVD model. 
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The results for the chromosome test indicate that chromosome 1 in these subjects show a 
small level of persistence (see table 4). The results are only significant in 4 subjects, but values are 
consistently above 0.5. Together these results are significantly more persistent than random noise 
(p = 8 x 10-17, using a z-test). Overall these values represent compelling evidence of there being 
persistence in  the expression data.  This is  as expected,  though the technique is not  sensitive 
enough to show coherence in all patients.
When the test is applied to the results of probe-SVD, it also detects spatial coherence. The 
first  two  eigenvectors  were  analysed  since  they  contained  overlapping  information  about  the 
tumour samples (figures 59 and 60), each describing information relevant to cancer on chr1. The 
first  eigenvector was significantly spatially persistent (H = 0.58,  p = 0.04),  suggesting that this 
would be usefully modelled spatially. The second eigenvector showed higher persistence than the 
first eigenvector (H = 0.72, p = 1.5 x 10-4) and is the more clinically relevant. These results justify 
the original use of Chromowave.
Table 4. Persistence values for chromosome 1 from normal subjects from tumour dataset. P-values 
are estimated using a Monte Carlo resampling test.
Subject Persistence Value Estimated p-Value
N1 0.57 0.08
N2 0.55 0.2
N3 0.55 0.2
N4 0.59 0.03
N5 0.57 0.04
N6 0.59 0.03
N7 0.61 0.01
N8 0.55 0.1
N9 0.55 0.2
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Figure  59, case loadings for the first chr1 probe-SVD eigenvector (54% of variance) for tumour  
data. Tumour case loading values appear to show a bimodal distribution while normal subjects fit  
in between. Eigenvector associated with these case loadings was found to show significant spatial  
persistence (H = 0.5846, p = 0.038), suggesting a role for Chromowave modelling.  
Figure  60. Second case loadings for the first chr1 probe-SVD eigenvector (4% of variance) for  
tumour data. Tumour case loading values show a significant difference between normal subjects  
and cancer  subjects  (p  = 5  x  10-11),  though this  does not  seem to  strongly  represent  the 1p  
deletion.  The  eigenvector  associated  with  these  case  loadings  was  found  to  be  significantly  
spatially persistent ((H = 0.72, p = 1.5 x 10-4) suggesting a role for Chromowave modelling.  
Since the method can determine whether data is spatially persistent,  it  is  interesting to 
apply it to measurements of epigenetic markers such as DNA methylation. The initial dataset is a 
set of methylation sequencer data. This data was chosen as it is both easily available, and, as 
sequencer  data,  contains  many probes per  chromosome (90,000 probes in  total)  giving more 
accurate estimations. Unlike the previous data, this set has previously been binarised. It is known 
that binarisation of the data does not impact strongly on the Hurst exponent  (La Spada and Lillo 
2011) with  the  primary  exception  of  a  systematic  bias.  However,  different  estimators  can  be 
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affected more or less strongly. Consequently some justification of the application of this estimator 
is needed. To this end a simulation of random 100,000 random data series were created. Hurst  
exponents  were  estimated  from each.  Most  had  Hurst  exponent  values  around  0.5,  but  they 
ranged from 0.9-0.3. An estimation of the Hurst exponent for each series was made and recorded. 
The series were then binarised (values above the mean value were set as 1, values below mean 
value was  set  as  0)  and  again  Hurst  exponents  were estimated.  The difference between the 
estimations was calculated and histogrammed (figure 61). It can be seen that these differences are 
unbiased  and  small  (standard  deviation  0.05).  Extreme  values  also  showed  that  these  were 
similarly estimated both binarised and non-binarised.  
Figure  61.  Histogram of  the  difference  between an  estimate  of  the  persistence  value  from a  
continuous data set (of various Hurst values) and binarized versions of the same data. Distribution  
is approximately Gaussian with a small standard deviation (~0.05). indicating that Hurst estimation  
of  binarized  data  is  likely  to  be  similar  to  that  from  the  continuous  variable.  
The data is made up of 16 subjects with 23 chromosomes analysed from each subject 
(chrY was ignored both because its presence is gender specific and because it was represented by 
only  25  probes).  Results  are  included  in  appendix  2,  with  p-values  calculated  using  20,000 
permutations of the data. It can be seen from the results that the vast majority of chromosomes in 
the vast majority of patients show high spatial persistence values with highly significant p-values. A 
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few chromosomes  (e.g.  chr15)  show non-significant  results  in  some subjects.  However  these 
results support the hypothesis that methylation is spatially coherent on all chromosomes. 
To test  whether  inter-individual  variation  from sequencer  data is  spatially  coherent,  the 
Hurst technique was applied to the results of a SVD analysis. The results in table 5 show that the 
the  methylation  values  are  spatially  coherent,  validating  spatial  modelling  as  an  approach  for 
analysing methyl-seq data. This is assumed to be true of methylation data in general, rather than 
being the result of experimental error. The biological meaning of spatial coherence in methylation is 
discussed more later. However, it suggests that methylation in certain regions will vary together. 
This may hint at a role for spatial organisation in maintaining methylation status. Methylation is 
organised spatially in invertebrates and plants (Tweedie et al. 1997; Bird, Taggart, and Smith 1979) 
and this result may hint that some spatial organisation occurs in vertebrates as well. Rather than 
analysing  this  data  in  detail,  in  the  next  few  sections  the  data  analysed  will  originate  from 
methylation arrays, specifically the Infinium HumanMethylation27 BeadChips created by Illumina. 
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Table 5. Table of results from the Hurst analysis of SVD results from methyl-seq data. P-values are  
estimated using a Monte-Carlo test, with the lowest value estimatable being 0.00005. 
Chromosome Hurst estimate Estimated P-value35
1 0.81 < 5 x 10-5
2 0.78 < 5 x 10-5
3 0.66    2 x 10-4
4 0.81 < 5 x 10-5
5 0.79 < 5 x 10-5
6 0.75 < 5 x 10-5
7 0.79 < 5 x 10-5
8 0.81 < 5 x 10-5
9 0.78 < 5 x 10-5
10 0.82 < 5 x 10-5
11 0.75 < 5 x 10-5
12 0.79 < 5 x 10-5
13 0.77 < 5 x 10-5
14 0.8 < 5 x 10-5
15 0.67 < 5 x 10-5
16 0.75 < 5 x 10-5
17 0.77 < 5 x 10-5
18 0.78 < 5 x 10-5
19 0.71 < 5 x 10-5
20 0.75 < 5 x 10-5
21 0.78 < 5 x 10-5
22 0.75    0.0001
X 0.66 < 5 x 10-5
5.2.3.2 Chromowave detects differences in methylation status between colorectal  
cancer samples and adjacent normal mucosa
Since it has been shown that DNA methylation is distributed in a spatial way, it was thought to be 
useful to see whether Chromowave was a useful tool for analysing variations in methylation. An 
investigation  using  the  Illumina  HumanMethylation27  BeadChip  to  investigate  methylation 
differences between colorectal cancer samples and adjacent normal mucosa was selected (Kim et 
35 Cases where no values more extreme than the original were given values of '<5 x 10-5' .
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al. 2011). The alignment data for this platform (GEO GPL8490) was acquired from its GEO page36 
and the data was analysed using Chromowave. 
The case loadings of  the first  eigenvector (67% of  the variance,  see figure  62) have a 
bimodal distribution. With the exception of the 7th pair each sample of normal mucosa carries a 
similar value to that from the tumour sample. Looking at the profile (figure 63), it is clear that the 
case loadings reflect methylation variations on chromosome X (with almost no variation on other 
chromosomes). Given these observations it is likely that this first loading reflects gender specific 
methylation. It is known that women have one X-chromosome inactive (see section 2.2.2.3 Genetic
Dosage and Dosage Control Mechanisms), and it is expected that this is what is being measured. 
The  second  case  loadings  (19%  of  the  variance),  show  a  significant  (p =  2  x  10-10) 
difference between the two groups (paired t-test). Visually the case loadings are associated with 
the differences between the samples  from the tumours  and the  adjacent  normal  mucosa and 
represent  a clear separation of  the two groups. Case loadings for  the second eigenvector are 
shown in figure 64, and the methylation pattern is shown in figure 65. Values are not limited to a 
single chromosome and contain both increased and decreased methylation.
36 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL8490
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Figure 62, primary case loadings (67% of the variance) from the Chromowave global analysis of a  
set of 44 paired methylation samples from colorectal cancer (black bars) and adjacent normal  
mucosa (grey bars). Case loadings are bimodal with pairs having similar values (except 7th pair).  
Analysis  of  the methylation  profiles (figure  63) and the bimodal  subject  specific  case loadings  
suggest  this  vector  represents  gender.                                                   
As in sections  4.2.1.1 Demethylated Lung Tissue and  4.2.1.2 Human Hepatoma Cell  line, it  is 
necessary to compare Chromowave results to those from traditional methods based in real-space, 
to determine whether the Chromowave results are the result of applying the wavelet transform. The 
equivalent of probe-SVD (Alter, Brown, and Botstein 2000) has been applied to methylation data 
previously (Bell et al. 2010) and shown to be a suitable analysis method. Consequently we apply 
this  method  and  use  it  as  a  comparison  to  the  Chromowave  analysis  to  determine  whether 
performing the analysis in wavelet space produces better results than using probe-space. 
Using probe-SVD only the 20th eigenvector  (1% of variance) was significantly (p = 0.004) 
associated with disease state. Because of the multiple comparisons issue, it is likely that this result 
represents a false positive. It was included here only to attempt to show that probe-SVD did not 
capture the difference as well as Chromowave. The result is not as clear at distinguishing between 
the  disease  states  and  also  the  amount  of  variance  explained  with  this  component  is  small.  
Consequently it  appears that  Chromowave is better at modelling these differences than probe-
SVD. 
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Figure  63, First expression pattern (67% of the variance) from 44 paired methylation samples of  
colorectal  cancer  samples  and normal  mucosa.  Pattern  is  driven by ChrX and so is  likely  to  
represent sample gender.
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Figure 64, case loadings from eigenvector 2 (19% of the variance) from the Chromowave global  
analysis of a set of 44 paired samples of methylation data from colorectal cancer samples (dark  
grey bars) and adjacent normal mucosa (light grey bars). Case loadings significantly (p = 2 x 10 -10)  
distinguishes between the methylation states for these two groups. 
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Figure  65,  methylation  pattern  for  the  second  eigenvector  (19%  of  the  variance)  from  a  
Chromowave global analysis of a set of 44 paired methylation samples from Colorectal cancer and 
adjacent normal mucosa. Pattern is significantly (p = 2 x 10-10) different between the groups.
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Figure 66, case loadings from eigenvector 20 (1% of the variance) from the probe-SVD analysis of  
a set of 44 paired samples of methylation data from colorectal cancer samples (dark grey) and  
adjacent normal mucosa (light grey). Case loadings significantly (p = 0.004) distinguish between  
the methylation states for these two groups (when not corrected for multiple comparisons37).
5.2.3.3 Chromowave detects differences between brain tissues
A further dataset was available in the form of methylation data from different brain regions. The 
original  paper  (Gibbs et  al.  2010) demonstrated distinct  differences  between tissues from the 
cerebellum and cortical  regions.  Given the spatial  coherence in  colorectal  cancer data,  it  was 
hypothesised that the differences between tissues may be spatially coherent.  This is useful as 
differences in cancer could be due to copy number variations rather than methylation itself. Also 
this suggests the generality of the findings. 
To test the hypothesis, cerebellar and temporal cortex data from 5 subjects was selected. 
These were then analysed using a Chromowave global analysis. The first methylation eigenvalue 
(83% of variance) represented gender. The profile was driven by chrX and the case loadings were 
significantly associated with gender (p = 0.0001). Methylation differences on ChrX specifically are 
investigated in section 5.2.3.4 ChrX Methylation and Gender. Because this profile was understood, 
37 If multiple comparisons were applied, then this result is unlikely to survive, as it was found only by data  
mining all eigenvectors. This result was included here to further demonstrate that spatial modelling captures 
this difference better than traditional techniques.
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the second set of case loadings were investigated for tissue specific differences. The second set of 
case loadings (14% of variance, figure 67) was significantly different between the two tissues (p = 
0.0002) and showed a clear difference between the two brain regions38.
38 Technically a multiple comparisons correction should be applied. However due to the first component  
being a clear function of gender, and the low p-values (and that only 2 sets of loadings were investigated)  
this was not applied. 
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Figure  67.  Case  loadings  associated  with  second  eigenvector  (14%  of  variance)  from  an 
investigation into spatially coherent methylation differences between temporal cortex (TCRTX) and  
cerebellum data. Case loadings are significantly different between tissues (p = 0.0002). 
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The methylation pattern associated with the second set of case loadings can be found in 
figure  68, and shows a mixture of increased and decreased methylation in the different regions, 
though more are lower in the cerebellum than in the temporal cortex. Using probe-SVD even when 
looking at all the eigenvectors, none were identified as associated with the different tissues, none 
distinguishing between the groups visually or statistically (lowest p-value = 0.3). Clearly even when 
multiple comparisons is ignored, probe-SVD does not capture the relevant information from this 
data.
Another set of independent samples (different individuals from the same investigation) were 
analysed to see whether the results were reproducible. As previously the first set of loadings were 
associated with differences between individuals (and so are not shown), however the second case 
loadings clearly  distinguished between the two groups (p =  0.0008).  This  second set  of  case 
loadings is shown in figure 69. The methylation pattern associated (figure 70) with this set of case 
loadings is also extremely similar to those found in the previous data-set, which shows that this 
result is highly reproducible. As previously probe-SVD showed no association of case loadings with 
tissue types, suggesting that this difference is best modelled in a spatially coherent fashion. The 
technique also showed limited reproducibility, marking out the Chromowave approach.
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Figure 68, methylation pattern for the second eigenvector (29% of variance) from a Chromowave  
global analysis of a set of 10 paired methylation samples from the temporal cortex and cerebella of  
normal subjects. Pattern is significantly (p = 0.003) different between the regions. 
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Figure 69. Case loadings associated with second eigenvector (42% of variance) from the second  
investigation into spatially coherent methylation differences between temporal cortex (TCRTX) and  
cerebellum data. Case loadings are significantly different between tissues (p = 8 x 10-4) on a paired 
analysis. 
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Figure 70, methylation pattern for the second eigenvector (42% of variance) from a Chromowave  
global analysis of a set of 10 paired methylation samples from the temporal cortex and cerebella.  
Pattern is very similar to previous results (figure 68) showing these results are reproducible.
150
5.2.3.4 ChrX Methylation and Gender
It was noticed, in the global analysis of colorectal cancer cells and normals, that ChrX appeared 
strongly in both global analyses with very similar methylation profiles. ChrX, unlike the autosomes, 
is associated with gender specific control mechanisms and it is known that methylation is heavily 
involved in this process (Suzuki and Bird 2008). Consequently it was wondered whether the values 
for chrX (and by consequence a part of the first two global analysis eigenvectors) were associated 
with gender. 
Gender information for the colorectal cancer data was not available and requests for such 
from the originators of the data went unanswered. Chromosome Y methylation values were not 
useful, since the 7 probes available did not partition the paired subjects into two groups. However 
the first  case loadings for ChrX,  do show a seemingly bimodal distribution associated with the 
expression patterns (see figure 71). Similarly there is a good match between the case loadings in 
each pair of samples, with only one appearing in the opposite group, which suggests it is a feature 
of the individuals that is being measured, rather than a truly random noise. 
Figure 71. Case loadings and methylation profile for the first eigenvector (98% of the variance) for  
chromosome X. All case loadings excepting subject 7 (reading left to right) show the same sign as  
their paired sample, suggesting it is a feature of subjects that is being measured. Given expression  
profile and chromosome, it is hypothesised that feature represents gender, however information to  
verify this was not available.
To further  test  the  hypothesis  that  gender  is  associated  with  the  previous  methylation 
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pattern on ChrX, a further dataset was used, made up of samples from the cerebral cortex data, 
from a study into methylation in the Human brain (Gibbs et al. 2010). A total of sixteen samples 
(see materials and methods) were chosen as a set of age and PMI matched male and female 
samples.  This  dataset  was  analysed  using  an  individual  chromosome  Chromowave  analysis, 
applied  to  ChrX.  The  primary  eigenvector  (99%  of  variance)  significantly  (p =  1.2  x  10-11) 
distinguished between the genders (case loadings and methylation pattern shown in figure  72). 
The methylation pattern is very similar to that shown previously for the other dataset, and this more 
than anything seems to validate Chromowave to detect variation in methylation. This result shows 
that women have higher methylation values over almost the entire chromosome, with the exception 
of a region toward the beginning of the Xp end a pattern similar to that found in section 4.2.3.1 Low
X-expression is associated with low concentrations of neurons.
Figure 72. On the left, the case loadings for the first eigenvector of ChrX for the male (dark grey)  
and female (light grey) subjects from an investigation into the methylation of cerebral tissue. The  
associated denoised ChrX methylation profile can be seen on the right. Case loadings significantly  
distinguish between the genders (p = 1 x 10-11), and the methylation profile shows great similarity  
to that in figure 71. 
5.2.3.5 Spatial persistence in H4 acetylation
Given the evidence of spatial coherence in methylation data, it is clearly interesting to look at other 
epigenetic markers. As investigations using these are still relatively rare, most epigenetic markers 
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have no suitable data that can be analysed. An exception to this is data for Histone-H4 acetylation, 
which was used to validate the 'ChIP on SNP-chip' method of measuring acetylation (McCann et 
al.  2007). In the original paper the authors claim that H4-acetylation is clustered at a scale of 
300kb. Hurst analysis was therefore applied to the data to see whether the organisation is spatially 
coherent as suggested by the spatial clustering. 
Because the paper used an old type of SNP chip, the number of probes per chromosome is 
quite small. Consequently only the 3 largest chromosomes were analysed since these had usable 
numbers  of  probes  (~1000)39.  There  are  5  significant  results  showing  persistence  and  one 
significant result showing extreme anti-persistence. This may suggest that any organisation is likely 
to  occur  only  at  small  scales,  which  might  become  confused  with  anti-persistent  data.  An 
alternative  and  more  likely  suggestion  however  may  be  that  the  number  of  probes  on  each 
chromosome were still too low to accurately estimate persistence. For now it remains uncertain 
whether H4 acetylation is spatially coherent.
Table 6 Hurst analysis results from the first 3 chromosomes of the histone H4-acetylation data 
giving persistence value (H) and estimated p-value (p).
Subject Chr1 Chr2 Chr3
1 H = 0.56
P = 0.18
H = 0.62
P = 0.024
H = 0.7
P = 0.0029
2 H = 0.50
P = 0.7
H = 0.45
P = 0.58
H = 0.28
P = 0.0077
3 H = 0.45
P = 0.67
H = 0.54
P = 0.32
H = 0.57
P = 0.29
4 H = 0.51
P = 0.63
H = 0.54
P = 0.35
H = 0.65
P = 0.013
5 H = 0.55 H = 0.57 H = 0.594
39 As  the  Hurst  exponent  is  only  properly  defined  as  the  length  of  the  series  goes  to  ∞  there  is  a 
dependence on length. Only longer series (larger than 1000 points) were included here as these are likely 
to have a reasonable error (Katsev and L’Heureux 2003). 
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P < 5 x 10-5 P = 0.14 P = 0.0824
6 H = 0.47 
P = 0.91
H = 0.46
P = 0.72
H = 0.53
P < 5 x 10-5
5.3 Discussion
This chapter of the thesis aimed at investigating spatial modelling outside of transcriptional data 
and this has been broadly successful. Some data such as CGH are already routinely modelled 
spatially, though it was demonstrated that there is more useful information which can be extracted 
from the values. Other features such as DNA methylation have not normally  thought of as spatially 
organised and so are not  often analysed in  a spatial  way.  An exception  to this  has occurred 
recently (Hansen et al. 2011) whereby it is shown that in solid body cancers there are blocks of 
hypomethylation. This modelling involved the simple use of fixed width spatial filters, and so was 
not as sophisticated as the approaches used here. Also in this work we suggest other sources for 
spatial organisation in methylation. The success of this spatial analysis extends the applicability of 
spatially based modelling (in particular Chromowave) to factors which affect transcription rather 
than just transcription.
Using  the  wavelet  analysis  of  the  CGH data,  It  was  shown  directly  that  Chromowave 
analysis of expression is largely correct when it comes to identifying deletions caused by CNVs, 
and outperforms the FISH method originally used to validate Chromowave. This is a reanalysis of 
the data investigated in section  2.5.4.2.1 Chromowave applied to tumour samples. The earlier 
analysis is not completely correct and there are a few differences between the changes inferred 
through expression and those validated through analysis of CGH. Some of these differences may 
be due to dilution with other tissues. The tumour percentage formula developed here provides a 
useful starting point for analysing the impurities in DNA samples, and these same mixed samples 
are likely to affect the expression analysis. This work may be useful for cytogenetics research and 
allows for corrections to be made to tumour samples which are heavily diluted with normal tissue. 
The identification of highly diluted samples is likely to represent a great advantage of using 
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Chromowave style techniques both in expression and other measures. There are also parallels 
between copy number  variations being diluted with  normal  tissue and the identification  of  the 
neuronal loss pattern in section 4.2.3.1 Low X-expression is associated with low concentrations of
neurons as in  both cases it  is  a mixture of  different  cell  types (neuronal  and non-neuronal  or 
tumour and healthy) which are producing the results. This suggests one of the prime advantages 
for Chromowave and wavelets in general, since it is less likely that samples present in only low 
concentration would be detected using techniques based on individual genes, multiple corrections 
and fold changes, all of which detect individual extreme events rather than broad trends.
A novel part of this chapter is the development of a method of determining which types of  
data show spatial coherence. It seems clear that the regulation of methylation occurs in a spatial  
manner. Of course some hints of this would be the CpG islands, but using this method (and later  
Chromowave) this chapter goes further in showing that the variation that occurs in methylation is 
also spatially coherent. That the regulation of methylation seems to be at least partially spatial, 
helps  to  further  explain  why  Chromowave detects  spatial  changes  in  transcription  due  to 
methylation. It may also help to explain why in section 4.2.1.1 Demethylated Lung Tissue, it was 
observed that changes in methylation had such a large effect on Chromowave. 
The  Hurst  persistence  method  developed  here,  can  identify  data  which  is  organised 
coherently or which shows coherent differences between subjects, but not whether the changes 
are reproducible,  or  if  it  is  useful  to model the data spatially.  By applying  Chromowave to the 
different methylation data-sets however it was possible to gain an idea of how it could be useful to 
analyse spatially coherent methylation data and whether analysing in this way could be relevant 
and reproducible.
The fact  that  Chromowave was  better  at  distinguishing  between colorectal  cancer  and 
normal mucosa than probe-SVD could, suggests that the technique could be modified and applied 
to diagnosing disease samples as well as analysing datasets. The simplest method of modifying 
the Chromowave technique to predict or diagnose samples, would be to project the wavelet pattern 
onto the wavelet transform of the new data, and base diagnosis on the resultant values. Other 
simple  approaches  would  replace  SVD  with  a  technique  such  as  linear  discriminant  analysis 
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(Zhang,  Jing,  and Yang  2006), which  would  have the advantage of  finding  the pattern which 
maximised the differences between (in this instance) tumour and control samples40. Evaluation of 
these techniques would require different statistical approaches to those used here. Use of training 
and  testing  sets  (or  possibly  leave  one  out  cross  validation)  would  enable  estimates  of  the 
classification rate, sensitivity, specificity and predictive values to produced. All of these measures 
are of more interest when dealing with predictive power, than statistical p-values. However, these 
measures are likely to require larger datasets than are used here. One problem with using wavelet  
space methods for diagnosis is that many probes must be used. Although modelling in wavelet 
space has been shown here to have superior performance than equivalent real-space modelling, it 
is possible that a small number of individual probes may have much higher predictive value than 
the majority. If these can be identified, then this would potentially represent a better strategy for 
developing diagnostic methods, given the lower cost and simpler processing techniques. In any 
case,  this  thesis  deals  specifically  with  modelling  spatially  coherent  transcription,  not  with  its 
potential diagnostic uses.
A criticism of  the work  in  cancer  could  be that  since micro-deletions  are common,  the 
reduced methylation could reflect micro-CNVs changing the number of methylated genes rather 
than actual methylation changes. Also no demonstration of the reproducibility of this result was 
possible. It is for these reasons that the investigation into the differences between human brain 
regions  was  useful.  Firstly  this  investigation  demonstrated  that  there  are  spatially  coherent 
differences between different tissues in healthy subjects. This is interesting and suggests spatially 
coherent differences in methylation are quite common. It also showed that these differences are 
highly reproducible, supporting both the method and the discovery. For these reasons it seems 
likely that  Chromowave will  be able to investigate methylation differences in disease, though of 
course  direct  biological  confirmation  of  the  differences  found  here  would  be  important  before 
making any final conclusions on the clinical usefulness of this work. Since the submission of this 
thesis,  biological  confirmation  of  the  spatially  coherent  regions  in  colorectal  cancer  has  been 
40 Other techniques that could be applied in wavelet space and used for prediction include neural network  
approaches and naïve Bayesian classifiers . These approaches all have strengths as well as weaknesses 
and application of these could potentially make up a thesis in themselves.
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provided  (Hansen et al.  2011). In fact spatially coherent regions exist  in a range of solid body 
cancers. They have been linked to 'gene shores', regions near to CpG islands which show high 
levels of methylation and even more recently to lamina associated domains (Berman et al. 2012). 
Unlike the results here however, it was only regions of hypo methylation which were confirmed. 
However, since Chromowave uses wavelets rather than a fixed scale spatial filter, it is likely that 
this modelling is superior. Future work will  require the delineation of similarities and differences 
between  the  approaches  and  their  proper  analysis  and  the  identification  of  any  connection 
between the regions identified in cancer and those tissue specific regions .
The  application  of  chromowave  to  ChrX  methylation  supports  the  previous  finding  on 
methylation showing that women have higher levels of methylation on ChrX (Mohandas, Sparkes, 
and Shapiro  1981;  Venolia  et  al.  1982;  Hellman and Chess  2007), (both  chromosomes show 
methylation, with higher levels apparently on the active X). This helps to validate the application of 
Chromowave to methylation. 
A full understanding of ChrX inactivation may require an investigation of spatial coherence 
in  other  epigenetic  markers.  In  particular  it  has  been  demonstrated  that  there  is  a  spatially 
coherent expression pattern of enrichment of macroH2A1 on the X-chromosome in mice  (Mietton 
et  al.  2009).  No  data  was  available  on this  marker,  however  the  H4  acetylation  marker  was 
investigated.  Results  were  inconclusive,  though  perhaps  suggesting  hints  of  persistence.  A 
potential  reason for  this  is  that  it  is  only  in  the limit  of  n→∞ that  the calculation  becomes 
accurate. The smaller number of probes on this array may have reduced accuracy.
Data from a range of other epigenetic markers and more from H4 acetylation would be 
useful  both  to  judge  any  potential  contributions  to  disease  states  and  to  gain  a  better 
understanding of how these factors operate together to produce spatial coherence, this would be 
important since it is only when all the different factors are analysed that the full picture of spatially 
coherent transcription can be understood.
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6. RESULTS 3: Alternative approaches
6.1 Introduction
It  has  been  shown  that  Chromowave  is  a  useful  tool  for  modelling  spatially  coherent  gene 
expression; however the same spatial covariance can be analyzed by alternative methodologies. 
This  chapter  investigates  a  few  alternatives  and  expounds  their  potential  benefits  and 
disadvantages in this context. To validate these new methods both Huntington’s (HD) and tumour 
data is used from the original Chromowave papers (see section  2.5.4 Chromowave before the
PhD). This data is supplemented in the case of  the persistence data with the results from an 
analysis of brain samples from bipolar disorder subjects and controls (see section 3.3.1.7 Bipolar
Data). As these approaches use mathematical methods not discussed in the introduction chapter, 
these will be introduced in the next two sections.
 6.1.1 Independent Component Analysis
As  described  in  the  introduction,  Chromowave  uses  Singular  Value  Decomposition  (SVD)  to 
identify important components of the data matrix in wavelet space. As an analysis method, SVD is 
now being phased out in favour of the more modern Independent Component Analysis (ICA)41. 
Where SVD decomposes data into orthogonal dimensions, ICA uses statistical independence as a 
criterion for the decomposition. ICA results can therefore be non-orthogonal (yet still independent) 
resulting  in  similar  components  being  separated  in  ICA while  combined  in  SVD.  Because  of 
confounding  factors,  and  non-Gaussian  components,  it  is  expected  that  some  meaningful 
components will become combined in a SVD analysis, while ICA should be able to separate them 
more efficiently.
41 Numerous algorithms exist for performing ICA, here we use the implementation from the fastICA package  
(Hyvarinen and others 1998).
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X=AS  (17)
 The basic equation of the ICA model is found in equation (17). In this equation X represents 
the data matrix, A the mixing matrix (roughly equivalent to the sets of case loadings) and S the 
independent signals (expression-vector equivalents). There are clear similarities between the ICA 
model (equation  (17)) and the Chromowave conceptual model (equation  18). The Chromowave 
conceptual model (equation (17)) includes two terms not present in the ICA model,  σ and η. The 
term  σ represents the non-spatially coherent  signal (e.g.  genes differentially expressed due to 
mechanisms  which  do  not  affect  genes  in  a  spatially  coherent  fashion).  The  second  term  η 
represents the true noise (assumed to be white Gaussian), which is not present in the noiseless 
ICA model shown in equation (17).      
X=A(S+σ)+η  (18)
Chromowave uses SVD to approximate the first term in equation 18 and remove the noise 
η.  Wavelet  thresholding is used to remove  σ. The approximation of  the first  term with SVD is 
equivalent  to  assuming  that  the  different  biological  components  are  orthogonal.  In  real  world 
experiments it is expected that components will often be non-orthogonal. Examples of this were 
seen in section  4.2.3 Effects of Confounding factors on Chromowave. and it is also known that 
post-mortem patient samples frequently have different pH values (Li et al. 2004). Consequentially 
ICA represents a better technique to model the different biological components. 
This ICA model shown in equation (17), is a noiseless model, however noisy ICA models 
have been developed and used  (Beckmann and Smith 2004; Roberts, Roussos, and Choudrey 
2004), with a similar model adopted here. The inclusion of noise into the noiseless ICA model can 
result  in  over  learning results,  including spikes  and  bumps  (Särelä  and  Vigário  2003),  or  the 
splitting  of  single  components  into  several  highly  correlated  components  (McKeown  2000). 
Standard methods of dealing with this form of noise include spatial filtering  (Särelä and Vigário 
2003) and dimension reduction (Beckmann and Smith 2004; McKeown 2000). and these methods 
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are applied here.
Dimension  reduction  via  SVD is  used  to  remove  η  because  the smallest  eigenvectors 
generally  represent  noise.  Choice  of  dimensionality  is  a  largely  unsolved  problem  with  many 
methods suggested in the literature (Horn 1965; Hansen et al. 1999; Minka 2001; Jackson 2003; 
Seghouane  and  Cichocki  2007). Here,  the  dimensionality  was  chosen  by  using  only  those 
eigenvectors which explained no more than 90% of the variance. This simple heuristic serves to 
demonstrate the usefulness of this technique, rather than act as a fully formed methodology for 
investigating gene expression. 
Functionally the non-spatially coherent signal (σ) is the same as the desired signal but is 
not spatially coherent. Consequently σ must be dealt with using spatial filtering. For this reason 
both Chromowave and Chromowave-ICA (CwICA) are applied in wavelet space.  A concern is of 
course whether the ICA model can be correctly applied to a wavelet space representation, and 
whether the assumptions are compatible. Firstly because the wavelet transform is linear, the linear 
ICA model can naturally be applied  (Roberts, Roussos, and Choudrey 2004; Boroomand et al. 
2007). The basic assumption of ICA is that the data can be represented by a summed set of 
statistically independent components. In the case of the FastICA algorithm used here 'statistically 
independent'  can  be  replaced  with  'non-Gaussian'.  Typical  noisy  ICA  models  assume  white 
Gaussian noise added to a non-Gaussian signal (Beckmann and Smith 2004). As discussed in the 
introduction, for a wide range of functions the wavelet transform supplies a sparse, decorrelated 
representation of the signal, while the noise power is distributed amongst all wavelet coefficients. 
Wavelet  denoising  of  the  type  used  here  assumes  that  the  noise  can  be  modeled  as  white 
Gaussian noise, while the signal is highly non-Gaussian (Donoho 1995; Antoniadis, Leporini, and 
Pesquet 2002). The wavelet and ICA models therefore make similar assumptions and are related 
(Donoho  2000).  A  sparse  data  representation  also  improves  the  estimation  of  independent 
components, motivating the use of sparsifying transforms prior to ICA modelling  (Zibulevsky and 
Pearlmutter 2001; Davies and Mitianoudis 2004). The decorrelating behaviour of the transform also 
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helps to improve ICA estimation (Särelä and Vigário 2003; Beckmann and Smith 2004; Boroomand 
et al. 2007), and, in the form of data whitening, decorrelation is a common preprocessing step in 
ICA estimation. From this we can see that the wavelet transform enhances the ICA application 
(Boroomand et al. 2007). Consequently in recent years ICA and wavelets have been combined as 
an analysis  technique in  a variety of  contexts  (Moudden et  al.  2005;  Boroomand et  al.  2007; 
Khullar et al. 2011; Roberts, Roussos, and Choudrey 2004).  
Despite the advantages of working in wavelet space, for noisy applications noise removal is 
paramount  (Boroomand  et  al.  2007).  Consequently  in  this  work,  prior  to  ICA modelling,  both 
dimension reduction (via SVD) and thresholding of the lowest wavelet coefficients (similar to the 
noise models used in (Roberts, Roussos, and Choudrey 2004) and (Boroomand et al. 2007)) are 
applied to the data. Overall this is equivalent to using Chromowave to recreate the wavelet space 
signal, though using a “soft” threshold (Hou 2003), rather than a “hard” threshold. After modelling 
with  ICA,  components  are  ranked  by  estimated  variance  explained  and  the  inverse  wavelet 
transform is applied to bring the results back into real-space.  Sorting ICA components is a non-
trivial procedure. We use the simple method of McKeown et al (McKeown et al. 1998) to estimate 
the variance from the root mean square error per data point for the data reconstructed without that 
component. Other approaches are also possible, including other methods to estimate the relative 
importance (McKeown, Hansen, and Sejnowsk 2003; Beckmann and Smith 2004).
6.1.2 Persistence
Persistence was previously discussed in section 5. RESULTS 2: Application of Spatial modelling to
non-transcriptional data, where it was used to detect spatial coherence in datasets. Work on CGH 
arrays by another group (Hu et al. 2007), has demonstrated increased persistence for samples that 
contain copy-number variations (CNVs),  which fits with the results of  a simple simulation (see 
figure  73).  It  is  likely  that  changes  occurring  in  spatially  coherent  expression  profiles  will  be 
associated with changes in the persistence of those chromosomes. This motivates an alternative 
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model for analysing spatially persistent transcription changes not relying on differences in actual 
expression but on differences in the  extent of spatial coherence.
   
Figure  73, simple simulation of series with different Hurst values. Model had 500 probes with a  
value of zero, and 500 probes with a value of 1, with different amounts of random Gaussian noise  
added. Hurst exponent values were estimated using the rescaled range calculation (Hurst 1956). 
Hurst exponent values (H) were estimated for each simulation and are found in the top left corner  
of each window. For low noise levels, the persistence obtained is much higher, demonstrating that  
the Hurst exponent can be approximately thought of as representing the ratio of spatial signal to  
random Gaussian noise. 
Rather than using resampling as the significance test the  Mann-Whitney U test is used.  
This test is widely considered to have less power than the Student's t-test (Siegel 1957), however it 
does not require the assumption of normality, and while the distribution of persistence values is 
unknown,  it  is  necessary  to  use  non-parametric  tests.  Resampling  methods  could  be  used, 
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however  it  is  more  computationally  efficient  to  use  the  Mann-Whitney  U  test  and  unlike  the 
previous use of the Hurst exponent, there is no pressing reason to use resampling.
6.2 Results:
6.2.1 Chromowave-ICA (CwICA)
6.2.1.1 Application of Chromowave ICA (CwICA) to tumour data
The new Chromowave-iCA based method (CwICA) was tested on the tumour data from the original 
Chromowave paper (Turkheimer et al. 2006).  This is a good test set because this dataset has 
independent validation from the wavelet denoised CGH profiles  (section  5.2.1.3 Comparison of
Chromowave tumour results and Wavelet denoised CGH profiles), allowing for a comparison to be 
made between the Chromowave results and the new CwICA method.
The mixing matrix results from CwICA for chromosomes 4, 13, 15 and 18, match closely 
with the case loadings from Chromowave, and the results from CGH analysis42. Consequently no 
differences in accuracy or detection rate could be discerned between Chromowave and CwICA. 
For chromosomes 1 and 19 (abnormalities 1p and 19q) however differences were observed in 
which patients were identified as possessing the monosomy. Consequently analysis focuses on 
these chromosomes.
On Chromosome 1, patient AA5 showed no evidence of 1p monosomy in the Chromowave 
analysis,  but  does with  the new CwICA analysis.  Patient  AD11 is  classified  as  having the 1p 
monosomy by Chromowave but not by CwICA. For Chromosome 19 CwICA detects patients AA5 
as having no 19q monosomy, whereas Chromowave does.
These  differences  will  be  validated  in  two  ways,  firstly  by  looking  at  the  individual 
expression relative to other subjects and secondly looking at the arrayCGH analysis. Starting with 
chromosome 1, we can see clear expression differences between the p and q halves on patient 
AA5 (figure 55), whereas on AD11 there is no such difference apparent. This supports the CwICA 
42 Given Chromowave effectively assumes Gaussian distribution of components while CwICA assumes non-
Gaussian distribution, the similarities may be surprising. However it should be borne in mind that although 
the SVD analysis assumes a Gaussian distribution, the wavelet denoising assumes that the signal is non-
Gaussian, effectively making it more like the profiles extracted via ICA.
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analysis  over  that  from  Chromowave.  On  chromosome  19  there  is  no  evidence  of  a  19q 
monosomy for patient AA5, again supporting the CwICA analysis.
Looking  at  the  arrayCGH  results  (section  5.2.1.3  Comparison  of  Chromowave  tumour
results and Wavelet denoised CGH profiles, there is no copy number variation on chromosome 1 
for subject AD11. For AA5 however, we see an even clearer demonstration of a difference between 
the two parts of the chromosome. Surprisingly analysis with standard software CNAG (Nannya et 
al. 2005) and CBS (Olshen et al. 2004) segmentation43 detects no copy number variation for either 
patient. This does not prove there is no deletion present however (especially diluted see section 
5.2.1.2 Variations in denoised values represent tumour percentages), and the agreement between 
expression and CGH makes it likely that the abnormality is present on subject AA5.
Looking at the arrayCGH profiles for AA5 on chromosome 19 we see no evidence of a 
monosomy, which must surely suggest that the Chromowave reading is in error, while CwICA has 
correctly determined there is no deletion.
Table 7. Table of the differences between deletions detected via Chromowave, FISH, CGH analysis 
and Chromowave-ICA (CwICA)
Patient Chromosome Chromowave CwICA FISH Copy number44
AA5 1p CN2 CN1 / 1 
AA5 19q CN1 CN2 / 2
AD11 1p CN1 CN2 1 2
Conclusions based on so little data must be uncertain, however it does appear from these results 
that  CwICA  is  capable  of  detecting  this  chromosomal  p/q  difference  more  effectively  than 
Chromowave.
6.2.1.2 Application of Chromowave ICA (CwICA) to Huntington's data
Previous work showed that there were matching profiles in blood and brain which were different 
between  controls  and  those  who  posessed  the  mutation  (in  blood)  and  correlated  with  the 
43 Both analyses were performed by Christophe Poulet.
44 Obtained via arrayCGH.
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Vonsattel  scale  (in  brain)  (Vonsattel  et  al.  1985)).  Since  the  pattern  was  similar  to  that  from 
postmortem  tissue  (see  section  4.2.3.3  Correlation  of  Expression  patterns  with  post-mortem
Interval (PMI)), it was thought this would be a useful application of the new CwICA method.
For  blood  data,  ICA  identified  two  components  (expression  patterns)  which  showed 
significant difference between patients and controls. The first such pattern (38% of variance, figure 
74) can be interpreted differently to Chromowave. It shows highest values for HD patients, lowest 
for  controls  and mid values for  presymptomatics.  This  suggests that  the  pattern represents a 
feature which changes depending on duration or the extent of symptoms. 
The third  identified  pattern  (19% of  variance,  figure  76)  also  shows  a  connection  with 
disease state. However, the expression pattern is similar to that from Chromowave, showing a 
difference between those with the HD mutation (symptomatics and presymptomatics) and those 
without the deletion (controls).
 
Figure 74, primary mixing vector (ICA equivalent to case loadings, estimated at 38% of variance)  
from  a  Chromowave  ICA  (CwICA)  analysis  of  huntington's  disease  (HD)  blood.  Unlike  the  
Chromowave analysis, the presymptomatics (third section, dark grey bars) occupy values between  
those of patients and controls. This suggests a feature related to the progression of the disease,  
rather than the presence of mutation.
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Figure  75,  Expression  pattern  associated  with  primary  mixing  vector  (see  figure  74)  from  a 
Chromowave ICA (CwICA) analysis of huntington's disease (HD) blood. Many chromosomes show 
predominantly increased expression in HD patients, compared with controls or presymtomatics.
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Figure 76, The third mixing vector (ICA equivalent to case loadings, estimated at 19% of variance)  
from a Chromowave ICA (CwICA) analysis of huntington's disease (HD) blood. Unlike the first  
loading  this  mixing  vector  shows  presymptomatics  (third  set,  dark  grey)  to  be  similar  to  HD  
patients. This is similar to the results in the Chromowave analysis (see figure 14 on page 54). 
For the HD brain data (primary mixing matrix, 51% of variance, figure 78), it was found that 
there was a better separation of controls and patients through the ICA mixing matrix than with the 
original Chromowave case loadings (p = 2 x 10-4 compared with  p = 4 x 10-4)45. There is also a 
slightly better match with the Vonsattel scores using the CwICA method (rs = 0.66 p = 0.0075 using 
ICA and rs = 0.62, p = 0.017 using SVD)46. If the pattern of expression is examined (figure 79), it 
can be seen that the pattern is not quite the same as either of the patterns produced from the 
blood. However, the pattern it  is most similar to that from the first component in blood. In both 
cases the activation is predominantly (though not exclusively) increased in patients. In blood this 
pattern was also affected to a lesser extent by the presymptomatics (which were between controls 
and  patients).  This  may  fit  with  the  relationship  to  the  Vonsattel  scale  found  here,  since 
presymptomatics  clearly have low Vonsattel  scores (not  having the neuronal  loss  of  patients). 
However,  not  all  chromosomes  show  similarity  and  the  two  components  may  be  unrelated. 
Perhaps due to the profiles being tissue specific.
45 Calculated using Mann-Whitney U test because ICA produces non-Gaussian data.
46 Calculated using Spearman-rank correlation, because ICA produces non-Gaussian data.
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Figure 77. Denoised expression pattern associated with the third mixing vector (see figure 76) from 
a Chromowave ICA (CwICA) analysis of Huntington's disease (HD) blood. Many chromosomes  
show predominantly lower expression in HD patients/presymptomatics compared with controls.
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Figure 78, Primary mixing vector (equivalent to case loadings, estimated at 50% of variance) from 
a  Chromowave  ICA (CwICA)  analysis  of  huntington's  disease  (HD)  brain.  There  is  a  clear  
distinction between HD sufferers and and controls (p = 2 x 10-4) which is slightly better than that  
identified via Chromowave. Additionally scores for HD sufferers correlate (rs = 0.66 p = 0.0075,  
Spearman rank correlation)  with Vonsattel  scores (red numbers) again slightly  better  than the  
correlation between Vonsattel score and Chromowave case loadings.
Although the differences in the HD brain analysis are not significant on their own, when 
combined with the HD blood analysis and the tumour analysis, the findings suggest that these are 
examples where the CwICA method is superior in identifying relevant components. Although there 
is  scope  for  more  work,  CwICA  should  outperform  Chromowave  when  components  are 
independent but not orthogonal. However the chromowave model is simpler and more stable, and 
so  when  this  orthogonality  is  a  good  approximation  then  Chromowave  should  be  preferred. 
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Figure 79, Denoised expression pattern associated with primary mixing vector from HD brain data  
(figure 78). Pattern shows limited similarities with those from blood, though arguably more with the  
first blood pattern, which showed lower values for presymptomatics as would be expected.
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6.2.2 Variations in Spatial Persistence 
Unlike section  5.2.3 Application of Spatial modelling to Epigenetic data   which used persistence 
simply to detect the presence of spatial coherence, in this chapter the aim is to detect variations in 
the spatial coherence between subjects and conditions. It is therefore not necessary to specify the 
absolute persistence value (i.e. Hurst exponent). Consequently it is possible to avoid the problems 
with determining this value in microarray data that have already been discussed. In this application 
a simpler and more general definition of persistence is used, the median slope of the logarithmic 
wavelet scalogram (Bullmore et al. 2004) (see figure  4 on page  40 for an example of a wavelet 
scalogram).  To  calculate  the  persistence  measure,  the  data  was  first  aligned  to  its  genomic 
location,  and  transformed into  wavelet  space  using the the same methods as  Chromowave. 
Exponential decay of the wavelet coefficients is assumed (from low to high frequencies), and so 
the scalogram coefficients are squared and logged. These values are then plotted against the log 
of the ordinal number of each band. A linear fit is performed and the median slope for these sets of 
coefficients is calculated47. The median is used because it is more robust to statistical outliers than 
the mean. Depending on the model of the data, this can be used to estimate the Hurst exponent 
(Jones, Lonergan, and Mainwaring 1996). 
There are two potential advantages of this method compared with Chromowave (or CwICA) 
analysis methods. Chromowave cannot distinguish between for example an increase in expression 
due to a mechanism increasing the activity of those genes (for example, a chromosomal gain), or a 
region of low expression becoming less tightly bound. However, the persistence model should be 
able to distinguish between these cases. There is a difference between imposing a region of non-
average expression.  which  would  increase persistence and losing  such a  region which  would 
cause a reduction (see figure 73). 
Additionally since persistence is effectively measuring the ratio of low frequency changes to 
high frequency changes, variations associated with changes on the individual gene level, which do 
not affect the spatial organisation may be detected using this method, but not using Chromowave. 
47 This wavelet method could not be applied to binarised data as used in the previous chapter.  The wavelet 
technique was found to be more sensitive in simulations and expression analysis than the r/s calculation  
employed in the previous chapter. A final reason for using it was its similarity to Chromowave which was 
appropriate for data which Chromowave has been validated for.
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When determining  significance  for  differences  in  persistence  between groups,  it  is  not 
possible to rely on the distribution being normal. Consequently, while the p-values quoted are from 
Mann-Whitney tests (p ≤ 0.05). 
6.2.2.1 Persistence Changes caused by copy number variations
This persistence method was applied to tumour sample data from the original Chromowave paper. 
The CGH data (analysed via the wavelet denoising methods discussed in section 5.2.1 Application
to SNP arrays) was used to validate which patients showed copy number variations (CNVs). Three 
different partial CNVs were investigated, two were partial deletions, the third a partial gain all CNVs 
are expected to increase the persistence values (see section 6.1.2 Persistence). The deletions are 
found on chromosomes 1 and 19 and are common deletions in oligodendrogliomas (Barbashina et 
al.  2005).  Gains  are  rarer  than  deletions,  however  two  patients  showed  partial  deletions  on 
chromosome 21  (21q).  On both  chromosomes 1  and  19 there  were  subjects  who  carried  no 
deletions,  however  for  chromosome  21,  there  were  micro-deletions  and  gains  present  in  all 
subjects and so only normals could be used.
For chromosome 1, a significant difference was found between those cases with the 1p 
deletion and those without (p = 3 x 10-6) (see figure  80). Cases with the deletion were found to 
have higher median persistence values than those without.  The separation using Chromowave 
was  found to  be (p  =  8  x  10-6)  a  very similar  value,  however  there  were  two  outliers  in  the 
Chromowave analysis and only one in the persistence analysis.
For chromosome 19 there was also a significant difference (p = 9 x10-6) between cases with 
the 19q deletion and those without. Cases with the deletion had higher median persistence values 
(see figure 81). A Chromowave analysis shows a similar separation (p = 1 x 10-5). 
For chromosome 21 there was also a significant difference (p = 1.2x10-2) between cases 
with the C21 gain and normals with higher persistence for  those with the gains.  If  instead all  
tumour  cases with  evidence of  CNVs are  contrasted with  normals  then there  is  also  a  good 
separation between the two groups (p = 7 x 10-7), again with higher persistence for those with 
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CNVs (see figure 82). This clearly shows that both deletions and gains are associated with higher 
persistence as expected.  
 
Figure 80. Boxplot of persistence values of chromosome 1, for 18 subjects without the  1p deletion  
and 16 cancer patients with the deletion.  Persistence is  significantly higher for  those with the  
deletion (p =  4.9x10-9). 
Figure  81.  Boxplot  of  persistence values of  chromosome 19,  for  20 subjects  without  the 19q  
deletion and 15 cancer patients with the deletion. Persistence is significantly higher for those with  
the deletion (p =  1.5 x 10-6). 
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Figure 82. Boxplot of persistence values of chromosome 21, for 10 normal subjects without the  1p  
deletion and 16 cancer patients with the deletion. Persistence is significantly higher for those with  
the deletion (p =  4.9 x 10-9). 
6.2.2.2 Persistence differences between Patients, Controls and Pre-
symptomatic carriers of Huntington's disease  in Huntington's Disease 
Blood Samples
In the Huntington's disease blood data. We find spatial persistence values are significantly lower in 
HD patients than in controls for chromosomes 1 (p = 3.2 x 10-10), 11 (p = 4.2 x 10-7), 12 (p = 3.5 x 
10-11),  2 (p = 2.5x10-8), 3 (p = 4.9 x 10-8), 4 (p = 3 x 10-3), 5 (p = 3.7 x 10-7), 6 (p = 3 x 10-4), 7 (1 x 
10-4), 8 (5.4 x 10-6) & 9 (3 x 10-2). 
For Many chromosomes presymptomatics have significantly lower spatial persistence than 
controls, these are chromosomes 1 (p = 2 x 10-4), 3 (p = 1 x 10-3), 5 (p = 1 x 10-4), 6 (p = 3.2 x 10-2), 
7 (p = 6.9 x 10-3), 8 (p = 7.2 x 10-4), 11 (p = 8 x 10-4), 12 (p = 1 x 10-4) & 15 (p = 7 x 10-4). 
Further more 3 chromosomes show significantly lower spatial persistence values for HD 
patients  than presymptomatics.  These are  chromosomes 1 (p = 0.0163).  chromosome 2 (p = 
0.0214) and chromosome 9 (p =  0.0052).
No  Chromosomes  showed  significantly  higher  persistence  in  patients  than  controls  or 
presymptomatics. Nor significantly higher persistence in presymptomatics than controls.
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6.2.2.3 Persistence differences between Patients and Controls in 
Huntington's Disease Brain Samples
The  brain  samples  show  a  more  mixed  picture  than  the  blood  samples.  However  we  find 
significantly lower spatial persistence values in patients than in controls for chromosomes 1 (p 
=0.04), 12 (p =0.03), 13 (p =0.01), 14 (p =8x10 -5), 20 (p =0.01) & 5 (p =0.004). Additionally we find 
the  following  chromosomes  have  significantly  higher  persistence  in  patients  than  controls, 
Chromosome 15 (p = 0.02), 16 (p = 0.004), 17 (p = 0.01), 6 (p = 0.005).
6.2.2.4 Persistence Differences between Brain samples in Bipolar 
disorder
After demonstrating that similar results could represent different types of changes in persistence it 
was decided to apply the method to a set of data which had no apparent significant result in a 
Chromowave analysis. As the example, ChrX in bipolar brain data was chosen, since there were 
multiple studies available,  several  of  which had been analysed previously (see section  3.3.1.7
Bipolar Data) and there was no significant association with ChrX. 
In  the  large  bipolar  dataset  there  was  a  significant  (p  =  0.0014)  separation  of  the 
persistence values from controls and patients. Persistence values were larger in bipolar subjects.
In the smaller set of bipolar patients (from the same study, but a different cohort and brain 
region)  there  was  also  a  significant  (p  =  0.049)  difference between the persistence values of 
chromosome X between controls and patients. 
In the dataset of bipolar data from the BA46 region of the brain there was a non-significant 
difference (t-test p = 0.08, Mann-Whitney p = 0.06) using both the t-test and the Mann-Whitney 
test. However, the results did again show that persistence was higher in bipolar patients agreeing 
in trend with the previous results.
6.2.3 Anti-Chromowave
This PhD focusses on spatially coherent expression changes however it is possible (albeit unlikely) 
that these are actually the result  of  systematic  errors in the microarray platforms.  Alternatively 
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there  may  be  situations  where  investigating  the  spatially  coherent  aspect  of  expression  is 
undesirable  and  only  the  individual  variation  wanted  (e.g.  pathway  analysis).  In  the  case  of 
traditional  analysis,  (section  2.4.1 Traditional  Microarray  Analysis),  expression  values for  each 
probe  individually  are  analysed.  These  values  however  are  the  combination  of  the  spatially 
persistent data and the individual gene components. This may mean that a method for removing 
the spatial coherence is useful. 
To extract the non-spatial component of expression a new method was developed based on 
the Chromowave wavelet decomposition, but instead of denoising the wavelet coefficients it zeros 
all the coefficients of wavelet scales above 4 probes. Large scale structure in the chromosomes is 
thus removed. Smaller scale structure is allowed through because some genes are represented in 
microarrays using multiple adjacent probes. Some spatial coherence will be allowed through, but it 
is  likely  the  majority  of  it  will  be  due  to  multiple  overlapping  probes  rather  than  true  spatial  
coherence. Once the wavelet coefficients are zeroed the data is transformed back into real space 
and the data analysed using any standard method (probe-SVD, SAM etc). To test the output of this 
method  compared  with  standard  methods,  both  t-tests  and  probe-SVD  were  applied  to  anti-
Chromowave data and normal unprocessed data. Huntington's (HD) blood data was chosen to test 
whether the two approaches are equivalent. 
In the HD blood data, removing the spatially coherent genes meant that 523 new probes 
became  significant  (after  FDR  multiple  correction),  while  1366  other  probes  had  lost  their 
significance  and  a  total  of  1727  probes  were  common  to  both  analyses.  Ignoring  multiple 
comparison correction, there are a total of 6500 significant genes (p < 0.05) in the normal analysis 
and 5736 in the non-spatially coherent analysis. 1289 of these probes are unique to latter analysis, 
while 2053 are significant only in the normal analysis. This means that only 68% of the genes from 
a normal analysis are still 'significant' if spatial coherence is removed. The probe-SVD results for 
the two analyses show similar but differing case loadings, none of which appear to be strongly 
associated with the disease state.
The results in this section show that spatial coherence is a significant component of the 
variation  in  individual  gene  expression.  Consequently  this  must  be  taken  into  account  when 
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investigating the significance of individual genes. Whether it is the individual gene component or 
the combined spatially coherent and individual components that are important may depend on the 
situation. It is beyond the scope of this PhD to investigate this in detail, both because biological 
validation would be necessary and because this strays far from modelling spatial coherence. It can 
be concluded however, that whether spatial coherence represents poor normalisation or relevant 
biology, it should not be ignored whatever the spatial scale of modelling.
6.3 Discussion
This thesis has focussed on the Chromowave methodology and there are good reasons for this. 
Chromowave and WAGE were the tools available at the start of the PhD for investigating spatially 
coherent  expression  differences  between  groups.  This  chapter  investigated  some  alternative 
models based on extensions to the Chromowave method (e.g. CwICA) or on a different model 
such as persistence. 
Chromowave-ICA (CwICA) is an extension to the Chromowave model. The use of ICA in 
wavelet space represents a surprisingly natural combination. However the removal of noise for the 
noiseless ICA model, is difficult and represents the greatest unsolved issue with this work. The 
method applied here appears to provide superior  results  on application to tumour data.  Better 
performance may be due to normalisation issues confounded with disease state (perhaps because 
of  large  numbers  of  deleted  genes).  CwICA identified  uniform  chromosome  wide  expression 
variation between subjects, which Chromowave presumably combined into the CNV pattern. When 
applied to HD data CwICA also provides separation between different components which are non-
orthogonal. These can be interpreted as differences between changes which occur because of the 
mutation and those which occur only when symptoms occur. The latter pattern was not detected 
via Chromowave.
The persistence model represents a very different model for spatially coherent changes. It 
does  not  identify  specific  regions  which  vary,  rather  identifying  the  existence  of  variations. 
Detection of differences in HD and tumour samples was similar to that from Chromowave, however 
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importantly these changes differed in direction. In the HD blood there was decreased persistence 
in multiple chromosomes and these were replicated in brain chromosomes. These findings fit both 
with the expectation that CNVs would increase persistence and also that the changes in HD are 
caused  by disruption  of  the  epigenetic  mechanisms.  These disruptions  reduce persistence by 
disrupting regions of similar expression causing an increase in high frequency variation. Those 
chromosomes in brain which did not show reduced persistence were not identified as being similar 
to  blood in  previous work  (section  2.5.4.2.2 Chromowave applied to Huntington's  disease and 
(Anderson et al. 2008)) suggesting different mechanisms operate in blood and brain. 
The ability to distinguish between CNVs and epigenetics show that the persistence model 
represents  a  complementary  modelling  strategy  to  Chromowave.  The  persistence  model  also 
detected  consistently  larger  persistence  values  in  bipolar  subjects,  with  no  associated 
Chromowave finding. This may suggest either that the location of the differences causing this vary 
between subjects, or that it is due to a reduction in individual gene variation. In either case there is 
scope for using this model in cases where Chromowave cannot detect any variation.
None  of  these  methods  are  without  their  flaws.  The  CwICA model  can  lose  important 
components due to the noise removal methods, and is not robust to noise remaining in the data. It 
also needs to be applied to more datasets to see if the improvements in detection are real and 
general features. Similarly the persistence model does not show differences in expression levels, 
only the ratio of different scales, and the anti-chromowave model is confused by duplicate probes. 
However,  each  model  may have  its  specific  use.  CwICA is  better  at  separating  similar  (non-
orthogonal)  components  than  Chromowave,  the  persistence  model  can  uncover  results  which 
Chromowave  would  miss  and  the  anti-Chromowave  method  looks  at  non-spatially  coherent 
expression.
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7. RESULTS 4: Combined modelling of multiple types of data
7.1 Introduction
The aim of this PhD has been to investigate spatially coherent changes in transcription. However, 
spatial coherence also exists in some epigenetic markers (chapter 5. RESULTS 2: Application of
Spatial modelling to non-transcriptional data) and the same tools can be used to analyse these. 
This  chapter  aims to combine the modelling of  transcription with the modelling of  these other 
features. In particular the focus is on modelling the spatial components of transcription and the 
spatial components of epigenetic markers and CGH data. 
Combining multiple modalities into one study is becoming more common, but is still rare. 
Consequently there are relatively few available datasets suitable for this analysis. In this chapter,  
only two datasets are used. The first dataset is made up of the tumour expression data used in the 
original Chromowave paper, combined with the CGH analysis of the same subjects. The second 
dataset  comes  from  an  investigation  into  different  brain  regions  (Gibbs  et  al.  2010),  partially 
investigated in section 5.2.3.3 Chromowave detects differences between brain tissues. It is made 
up of both methylation and transcription data.
Although this chapter uses many standard analysis techniques, it also includes a technique 
known as Simultaneous Component Analysis (SCA) introduced in the next section.
7.1.1 Simultaneous Component Analysis
SCA is  a new family of  methods  (Van Deun et  al.  2009;  van den Berg et  al.  2009).  Multiple 
techniques exist, producing similar (though not identical) results (Van Deun et al. 2009; Wilderjans 
et al. 2010). Here we apply sum-PCA (Van Deun et al. 2009) since it resembles, and can be solved 
using SVD, an important part  of Chromowave.
The general equation of SCA (Van Deun et al. 2009) is found in equation 19. Each of the 
179
datasets (Xk) are individually modelled with a PCA style model. The kth dataset is the product of the 
components (Tk) and the transposed case loadings (PkT), plus some residuals Ek. To allow for the 
simultaneous modelling of the datasets, an individual weighting factor (wk) is used to avoid biasing.
w k X k=T k Pk
T+E k  (19)
Because  we  are  looking  at  simultaneous  modelling  of  data  blocks  involving  the  same 
subjects, the case loadings (Pk) for each dataset are assumed to be the same, leading to equation 
20. This is  the requirement that  the components from each dataset  have the same behaviour 
between individuals (they share subjects). An alternative not explored here would be to look at 
data sharing probes, but different individuals.
w k X k=T k P
T+E k  (20)
The model in equation  20 is then solved optimising the constraint in equation  21, which 
provides solutions of a useful form (i.e. least squares minimising of residuals48). Similarly to PCA 
and SVD the components are required to be orthogonal and sorted in order of variance explained. 
minT , P k Σk∥wk X k−T k P
T∥2  (21)
The SCA model can be solved using SVD of the weighted concatenated data matrix and 
the identities in equations 22 and 23, where Vi is the ith eigenvector from the SVD analysis of the 
concatenated  data  matrix,  Si the  ith singular  value  and  Ui the  ith set  of  case loadings.  These 
identities provide orthonormal case loadings (see Van Deun et al. 2009 for more detail).
P i=V i S i  (22)
T i=U i  (23)
48 Maximum likelihood methods are also possible (Van Deun et al. 2009).
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The SUM-PCA model is equivalent to applying PCA to a combined data matrix made up of 
all the data, after the different data blocks have been appropriately weighted and scaled (Van Deun 
et al. 2009). SCA has previously been applied to gene expression data (Nueda et al. 2007) as well 
as metabolomics (Van Deun et al. 2009; Smilde et al. 2005) and non-biological data (Ge and Song 
2008). There are several different weighting and scaling schemes, however the one used here is 
that developed for Sum-PCA (Van Deun et al. 2009). Rather than explicitly weighting the model, 
the blocks are demeaned and set to have sum of squares equal to 1. This means that each block 
should have the same weight giving no bias towards either dataset. In this work we apply the SCA 
method in wavelet space to investigate the spatial component. Essentially this is an extension of 
Chromowave modelling into multiple data types simultaneously.
7.2 Results
7.2.1 Chromowave-SCA 
There are clear similarities between SVD and the SCA technique.  The replacement of SVD with 
SCA in Chromowave allows for the spatially coherent components of different types of data to be 
modelled  together.  SCA is  applied  in  wavelet  space  and the  profiles  are  then  denoised  and 
transformed back into real space.
SCA can be applied to data sharing subjects or sharing objects. Subject mode has data 
types linked by being taken from the same subjects. For example, it may be a series of individuals 
investigated using both expression and methylation.  Object  mode analysis  has the data types 
linked by the object of interest, e.g. gene probes. 
The focus in this chapter is on subject mode. There are several reasons to expect this to be 
superior in the case of probe analysis (such as object mode needing probes to be combined and 
removed, making it lossy). However the primary reason for applying subject mode SCA is that the 
aim  is  to  combine  the  data  to  improve  identification  of  subjects  rather  than  investigating  the 
differences between datatypes. 
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In  Subject  mode  Chromowave-SCA the  data  is  wavelet  transformed,  as  in  standard 
Chromowave and then run through the SCA model. As a side note, there is no requirement for all 
data blocks to be transformed in the same way,  and so it  is  possible to include both wavelet  
transformed and non-transformed data. Although this is not investigated here, this has the potential 
to be useful in future investigations.
7.2.1.1 Application of subject-mode SCA to Expression-CGH in the tumour dataset
The tumour dataset represents the best known set of paired data. The CGH is matched both in 
subject mode and potentially in object mode. Chromosome one was analysed for a set of the data 
using subject mode Chromowave-SCA. The case loadings for this can be seen in figure 83. The 
expression and CGH profiles associated with these case loadings can be seen in figure 84. 
It can be seen from figure 84, that the major profile (97% of the variance) represents a 1p 
deletion and the case loadings for the first eigenvector suggest that subject AD11 does not carry a 
deletion which agrees with the analysis in section  5.2.1.3 Comparison of Chromowave tumour
results and Wavelet denoised CGH profiles. However, the SCA-analysis also suggests that patient 
AA5 does not  carry the deletion,  which disagrees with the ICA work.  The explanation for  this 
difference may be identified by looking at the second eigenvector. The case loadings (figure  85) 
and profile (figure 86) show a 1p/1q difference, however this represents a gain on 1q rather than a 
deletion  on  1p.  Both  interpretations  appear  to  fit  the  data,  some  form  of  further  biological 
verification would be needed to determine which interpretation is correct.
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Figure  83. Case loadings from first eigenvector (97% of variance) of the application of SCA to  
chromosome 1 of  tumour  samples.  Compared to  previous  analyses the profile  appears  more  
bivariate.  Unlike  Chromowave  analysis  this  shows  AD11  as  not  containing  the  deletion.  
Interestingly subject AA5 is shown as not carrying the deletion either differing from the analysis in  
section  5.2.1.3 Comparison of Chromowave tumour results and Wavelet denoised CGH profiles, 
which suggested AA5 had a 1p deletion. This can be explained by investigating the second set of  
case loadings (see figure 85). 
Figure  84.  SCA profiles  for  the  primary  eigenvector  with  expression  (left)  and  Comparative  
Genomic Hybridisation (right) modelled at the same time. Profiles show a 1p abnormality which  
represents the common deletion. Profiles are extremely similar showing that SCA was successful.
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Figure 85 case loadings for the second eigenvector (1.5% of variance) of the application of subject  
SCA to chromosome 1 of tumour samples. Subject AA5 shows the largest value, and this explains  
why there was no identification of AA5 as having the 1p deletion since the expression profile (see  
figure 86), shows a similar 1p/1q difference though in this case it appears more like a 1q gain than  
a 1p deletion.
Figure 86, SCA profiles for the secondary eigenvector (1.5% of the variance) with expression (left)  
and Comparative Genomic Hybridisation (CGH, right) modelled at the same time. There is a good  
visual match between the profiles, giving us confidence that this is modelling a real expression–
CGH link. The profile shows a similar 1p/1q difference, however it seems that this profile instead  
represents an increase in expression and copy number on the 1q end.
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7.2.1.2 Application of subject mode SCA to methylation-Expression.
A further dataset which this can be applied to is the methylation dataset for the two different brain 
regions described in section 5.2.3.3 Chromowave detects differences between brain tissues. It was 
decided to focus on only a couple of chromosomes to determine whether there is an effect, with 
the largest two chromosomes chosen due to their larger amount of data. Applying SCA to this data 
produced the result  shown in figure  87,  with the case loadings shown in figure  88. The case 
loadings clearly distinguish between the two data groups (p = 2 x 10-5) however the expression and 
methylation profiles show no real similarities. However, there are some possible relationships. It is 
notable for example that the 1p and 1q regions nearest to the centromere, are regions of high 
differential methylation and expression. The direction of this difference is exclusively positive on the 
expression,  and  mostly  negative  on  the  methylation.  This  suggests  the  well  known  inverse 
correlation between methylation and expression. Similarly the rest of the 1q region shows positive 
expression and mostly negative methylation. However, the region on the 1p side show a less clear 
distinction and possibly even negative methylation associated with negative expression. This is 
difficult  to  connect  with  the previous  observations,  though  it  is  notable  that  a  small  region of 
reduced methylation and the telomeric  1q end is  associated with a  small  region of  increased 
expression.
The expression values on this analysis are extremely low, which may suggest that perhaps 
the difference is too small to reliably measure with Chromowave, or indeed it may suggest that 
spatial methylation does not cause spatial expression. 
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Figure  87. Subject SCA analysis in wavelet space of methylation (top) and expression (bottom).  
Unlike the work on CGH there is no clear similarity between these patterns, though the regions  
around the centromere (~1.2-1.4 x 108 bps) do show extensive positive expression and negative  
methylation.  This  anti-correlation would be the expected result  from a methylation experiment,  
however in both profiles there is a region towards the beginning of the chromosome which shows  
differential activity, but the directions (and locations) of each do not tally with the other data.
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Figure  88.  Chr1  Case  loadings  from  SCA analysis  of  methylation  and  expression  data  from 
temporal  cortex  and  cerebellum tissue.  The  tissues  show clear  separation  showing  that  SCA 
identifies meaningful case loadings. Associated patterns were shown in figure 87.
Figure  89.  Chr2  case  loadings  from  SCA  analysis  of  methylation  and  expression  data  from  
temporal cortex and cerebellum tissue. Tissues show clear separation showing that SCA identifies  
meaningful case loadings. Patterns associated with these loadings are shown in figure 90.
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Figure 90. Subject SCA analysis of methylation (top) and expression (bottom) data. Although case 
loadings (see figure  89) are significantly  different  between brain regions,  there is  no similarity  
between these patterns. This was also the finding for chr1. This may be due to the high noise  
levels in the expression data or due to there being no connection between coherent methylation  
and coherent expression. 
Looking at chromosome 2, we have similar results to the previous work. The component is 
clearly  related  to  the  difference  in  tissues  (case  loadings  in  figure  89),  but  shows  different 
expression and methylation patterns (see figure 90). However, whereas previously it appeared that 
the areas showing the most differential expression on the methylation analysis also showed high 
levels  of  differential  expression  on  the  expression  analysis,  in  this  chromosome  there  is  no 
connection with the locations on each plot. This could be due to the low expression differences 
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detected, however there may be no connection between the spatial patterns detected. This could 
reflect a more complex relationship between spatial expression and spatial methylation than exists 
in the CNV work or even that non-spatial methylation is more important in spatial expression than 
the spatial part. It could also be however that high noise or poor signal due to the extremely small 
differences found in the expression data obscure the real results. 
7.3 Discussion 
In recent years it has become more common to publish studies investigating multiple data types 
using the same subjects  (Gibbs et  al.  2010;  Lehman et  al.  2010), often analysed using basic 
methods. It is still not routine to publish investigations using mixtures of data types, however some 
of these investigations are also now available in public databases. Modelling these mixed data is 
still  new,  and  the  application  of  Chromowave  type  spatial  modelling  represents  a  unique 
development. It was shown in chapter 4, that Chromowave could model various data types, and 
the  new Chromowave-SCA represent  a  natural  way of  combining  these.  Here  we  specifically 
looked at the spatially coherent components of both the epigenetic and transcription data. However 
it is not necessary for both data types to be spatially organised, provided that SCA is conducted in 
subject mode any data could be used (with the wavelet transform only applied to the spatial data). 
It  is  interesting  to  speculate  on  whether  this  could  model  Genome Wide  Association  Studies 
(GWAS) for example. Ultimately this could well lead to complete modelling solution for spatially 
organised transcription in disease. Combining CGH data with expression was successful, however 
the work with methylation performed so far  is  not  convincing and no link between the spatial 
components of methylation and expression was found. Future work would investigate combining 
spatially analysed with non-spatially analysed data, and also investigating other datasets and data 
types. 
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8. DISCUSSION
The overall aims of this project were to investigate spatial coherence in gene expression and to 
develop  techniques  to  model  this  phenomenon  better.  To  this  end  spatial  coherence  was 
investigated in numerous expression datasets as well as in data related to expression. This has 
helped elucidate several examples of spatial coherence, both associated with diseases and with 
confounding factors. To investigate spatial coherence associated with gene expression more, some 
of the mechanisms underlying coherent gene expression were probed and modelled spatially. This 
has  been  shown to  be  a  successful  modelling  strategy worthy of  future  research.  In  addition 
softwares have been developed to extend or supplement spatial modelling. 
During this thesis, the investigation into modelling spatial coherence was hampered by the 
lack  of  a  validation  set  with  known  variations.  As  part  of  the  investigation  into  mechanisms 
underlying  spatially  coherent  gene  expression,  the  tumour  dataset  published  previously 
(Turkheimer et al, 2006) has been better characterised. Using an analysis of CGH data from the 
same  samples  it  was  shown  that  Chromowave  results  were  largely  correct  at  inferring  copy 
number  from  expression  values.  This  makes  it  the  closest  to  a  validation  set  which  exists. 
Consequently it was reused to test newer methodologies. 
There are also no gold standard methods for analysing spatial coherence in expression 
datasets. Chromowave was used as it is the only method published shown to be able to identify 
copy number variations and distinguish between disease states in Huntington's.  As part  of  the 
future work, other methods based on non-wavelet techniques could be tried (e.g. Hidden Markov 
Modelling  (HMM))  however  these  methods  are  unproven  in  this  field,  while  Chromowave  is, 
consequently wavelet based methods were a large focus of this thesis.
Although there is  crossover,  the results  from this  thesis  can be broadly separated into 
biological and methodological results. Consequently the rest of this discussion will be separated 
into these categories.
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8.1 Biological
Biologically,  one of the first important steps that needed to be performed was the validation of 
Chromowave modelling for epigenetic data. Previous attempts results relied on assumptions about 
the pathogenesis of Huntington's disease and so more direct investigations were needed. It was 
shown that the application of demethylation agents and deacetylation inhibitors to cell lines was 
associated with coherent expression changes detected using Chromowave. The results were also 
more associated with the treatment  than the equivalent  non-spatial  technique,  suggesting that 
spatial modelling captured the differences better.  The differences in transcription associated with 
demethylation agents were largely positive, fitting with theory, however some doubt was cast on  
the detection of the epigenetic signature of deacetylation inhibitors. This doubt was due to treated 
data showing generally lower gene transcription levels than the untreated, while higher expression 
was expected. It was also shown that Chromowave could distinguish between cell lines with and 
without  Hutchinson-Gilford  Progeria,  associating  them with  widespread  expression  differences. 
However although many abnormalities were found in the expression profile of Progeria subjects, 
there was no greater difference in lamina-associated domains (LADs) than other regions. Given 
the biology described in the introduction, it might be expected that LADs would show extensive 
increases in expression. 
All  of  these  investigations  used  cell  line  data. The  chief  advantage  of  this  is  that  the  
identical samples can be carefully controlled under laboratory conditions. However cell lines are  
immortalised to make them useful, which involves genetic and epigenetic changes being made. 
Cell lines can differ widely from Human samples, making their relevance questionable. This could  
explain both the negative findings for lamina associated domains in the Progeria samples and the 
unexpected  decreased  expression  from  the  deacetylation  inhibitors49.  Another  issue  with  the 
deacetylation  inhibitors  in  particular  is  that  the  biological  effects  of  the  treatments  is  not  fully 
understood. As discussed in the chapter, the agents used to activate the silenced genes can have 
multiple  effects  on  DNA. The  differences  detected  by  Chromowave may  reflect  these  other 
49 Though there are many reasons that  could  be suggested,  and the results are only tentative without  
replication.  For  LAD  work  it  may  also  be  that  these  are  made  of  the  wrong  tissues,  however  no 
information on which tissues these were from was available.
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mechanisms  rather  than  those  due  to  epigenetic  changes. This  is  a  common  problem  with  
biological samples, being due to incomplete understanding of the processes involved. 
There  are also  indications  of  the  difficulties  in  analysing disease samples.  A variety of 
different tissues appeared to show similar spatial changes associated with post-mortem interval 
(PMI), which could sometimes be interpreted as disease related. Looking at different tissues, for  
this investigation, rather than sticking with a single tissue type, was necessitated by the absence of 
data with associated PMI information. However,  the expression patterns  found in  the  different  
tissues were similar, and was found to have an association (not always significant) with PMI. A 
generic non-tissue specific expression pattern is of interest, especially as it may be associated with 
a confounding variable. Often this profile varied between disease states. Highlighting examples of 
poor  scientific  practice  as for  some datasets  there  are  significant  differences in  PMI  between 
disease groups50. It is likely this is due to the difficulty in obtaining matched samples, but it is still a 
disadvantage of many of these datasets. It is also sometimes true that confounding factors are 
unavoidable. In neurological diseases the ratio of neuronal:non-neuronal tissue reduces,  and it 
was found that this was associated with lower expression on chrX. This result fits with the known 
higher chrX expression in brain, suggesting that it is primarily neurons which show this increased 
expression.  This  investigation  was  necessarily  indirect,  using  reporter  genes  as  a  proxy  for 
measurements that were not  originally performed. Future work would attempt to independently 
validate this  interpretation,  however  it  seems certain  that  there is  a reduction in  X-expression 
associated  with  neurological  disorders.  It  is  also  likely  that  the  it  is  related  to  tissue  specific 
variations, either due to microglial activation or neurons. Consequentially it appears that certain 
tissues are associated with coherent expression patterns.
Spatially  coherent  differences between tissues were also  investigated in  the context  of 
methylation. With coherent differences found associated with disease state (colorectal cancer) and 
different brain regions (temporal cortex and cerebellum). That there are tissue specific differences 
is  interesting  and suggests  that  spatial  coherence is  a  general  feature of  methylation  (and is 
50 Obviously there are sophisticated ways of dealing with this, and these were applied in the original work. 
However, the spatially coherent components showed no connection with disease state  when PMI was 
included as a covariate.
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unexpected).  The actual meaning of this is currently unclear.  The results in cancer have been 
linked to the recently identified 'CpG shores'  and it  may be that  the tissue specific methylatin 
differences are also related to this. It is possible that spatial regulation of some form is involved in 
the maintaining methylation status however this is outside of the scope of this thesis. Future work 
investigating this is clearly justified. Analysing methylation data spatially was justified using a novel 
test  based on the Hurst  exponent,  which can be used to detect  spatial  organisation in  future 
datasets, making it biologically interesting. 
8.2 Methodological
Some  methodological  considerations  have  been  ignored  in  this  thesis.  For  example,  in  the 
introduction  it  was  said  that  when  using  Chromowave only  the  primary eigenvector  would  be 
considered. Although generally this was followed, it was not universally applied in this thesis. In 
most cases however there were reasons for this. Chromowave analysis of secondary eigenvectors 
was  only  performed  when  the  primary  eigenvector  reflected  a  known  biological  feature.  For 
example,  gender  in  the  case  of  methylation  investigations.  For  probe-SVD  analyses  all 
eigenvectors were investigated. Probe-SVD was included primarily as a control technique, and 
simply showing that the first  eigenvector was not associated with variables of interest was not 
thought sufficient to show that the technique did not capture the important information. In most 
cases,  when  the  relevant  variables  were  captured  in  a  single  component,  this  component 
explained less variance than the Chromowave result and was less significantly associated with the 
variables of  interest.  This highlights the advantages of  the spatial  modelling both because the 
variables are captured better, and there is smaller multiple comparisons problem. With other similar 
techniques  (e.g.  CwICA)  primary  components  were  sometimes  associated  with  normalisation 
errors. The multiple comparisons issue here was ignored out of convenience. There were however 
only a very small number of components, while the results were highly significant, so the issue is 
not of much practical importance. In the case of CwICA, there were also issues of results sorting 
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which has a bearing on which components should be looked at.
The issue of multiple comparisons leads to concerns about the truth and relevance of the 
results. As this thesis lacks direct biological experiments the 'truth' of the results cannot be defined 
that way. Instead it was generally considered to be correct when the results matched hypothesis or 
when it was reproducible in multiple experiments. When this does not happen the results are left as 
inconclusive, and are sometimes argued to be wrong, though it is also possible that the hypothesis 
is  wrong.  Ultimately  future  direct  experiments  will  be  needed  to  verify  the  findings  and 
interpretations presented in this thesis as well as to build a better understanding of anything found. 
Another concern with this thesis is the reliance of most of the results on wavelet analysis. 
Other techniques have been used to analyse spatial organisation in other fields, for example HMM 
are widely used. Wavelets were used because of the high noise levels, and that they had already 
been validated for Chromowave. Future work would include investigating different approaches and 
assessing their  strengths  and weaknesses.  One disadvantage of  the wavelet  approach is  the 
difficulty in interpreting the biological meaning of the wavelet coefficients. Other problems include 
the difficulties of assigning significance to individual probes. Normal microarray analysis includes 
the significance of single probes, however in wavelet transformed data this is a difficult problem. 
Some solutions to this could either revolve around a different form of analysis (see  Van De Ville et  
al. 2007 for an example)) or the usage of HMM. This latter approach being a more statistically 
developed way of analysing space. A final problem with the use of wavelets is that their denoising 
relies on the noise being Gaussian.  This factor  also helps to explain the usage of  parametric 
statistics for large parts of this thesis.
The first truly new methodology mentioned in this thesis is the previously mentioned Hurst 
test for spatial coherence. Rather than model specific locations which change together, this models 
data which is similar for nearby values. Applied to raw data, a persistent dataset is likely to be 
better modelled using wavelets than a non persistent (or anti-persistent) dataset. Applied to the 
SVD application  it  demonstrates  that  nearby  values  are  related  to  each  other,  suggesting  an 
unmodelled spatial component. The model is not the same as that of Chromowave, but fits with the 
aim of investigating spatial coherence and provides a clear way of detecting spatial trends in the 
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data. A similar method was used again to investigate differences in expression, and was shown to 
distinguish between differences due to copy number variations (increased persistence in tumour 
patients) and those in Huntington's disease (decreased persistence in patients). This demonstrates 
that different information can be extracted from the data using new models. It may also suggest 
that  mechanistic  underpinnings of  spatially coherent  differences can be inferred based on this 
model. However much more work is needed to investigate this properly. 
The  demonstration  that  methylation  has  a  coherent  component  also  allowed  for 
Chromowave to be applied directly to this epigenetic data. It was demonstrated that profiles were 
reproducible and available in both disease samples (cancer) and tissue differentiation, suggesting 
this  form  of  modelling  will  be  widely  applicable.  Ultimately  it  was  attempted  to  combine  this 
methylation  modelling  with  expression  modelling,  using  simultaneous  component  modelling. 
Although this approach worked for modelling similarities between CGH and expression profiles, no 
connection  between  methylation  and  expression  was  found.  Whether  this  was  due  to  spatial 
methylation not being strongly connected with expression (as opposed to methylation in general) or 
problems with the specific data, such as high noise levels, requires further work to clarify. It is also 
possible to apply this modelling in different ways, and there is potential to apply it to non-spatial  
data concurrently with spatial. This is another area left unexplored in this thesis but which could be 
a fascinating area for further work. 
A model which was applied only to expression,  and was similar  to  Chromowave is  the 
CwICA model.  From the CwICA perspective,  the application  of  the wavelet  transform has the 
benefit of improving match between the data and the ICA model. It can therefore be seen as a 
simple transform to improve data analysis. This suggests an alternative justification for the model 
as  an  attempt  to  improve  ICA modelling  of  gene  transcription  using  a  transform  which  also 
enhances its spatial component. The ICA model allows for examples where the components are 
not normally distributed or when they are not independent. There is ample motivation for this from 
the biology section which includes several examples of confounds which can be interpreted as 
differences between disease groups. Investigation into this model showed that it produced results 
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which fitted known results in the tumour data better than Chromowave, and that it produced results 
which could be interpreted as more interesting in the Huntington's disease data. However, more 
research would be needed to gain a better judgement on how sensitive and powerful this method 
is. There was also one attempt made to move away from spatial coherence altogether. Using this 
technique  it  was  demonstrated  that  normal  expression  modelling  was  affected  by  the  spatial 
component.  Although no biological verification of  this was sought,  it  appears that if  the spatial 
component is considered a confound, or is just not wanted for whatever reason, its removal is 
possible using the 'anti-Chromowave' method. 
With particular reference to the ICA work, it may be wondered why unsupervised methods 
make up such a large part of this thesis. It is probably more common to apply direct modelling (e.g. 
t-test  or  regression)  to  wavelet  space  problems  and  problems  in  general.  There  are  several 
reasons for this choice. Firstly by using data driven approaches it is possible to look at the results 
and determine whether they are actually to be believed, or whether they may be the result  of 
another factor. However a more important feature when it comes to the epigenetic literature is that 
linking wavelet analyses to p-values is a non-trivial problem. By applying appropriate statistical 
tests to case loadings (in Chromowave) or mixing matrices (in CwICA) a straightforward p-value is 
obtained. This allows for results to be packaged in a way thought to be more acceptable to other  
researchers.
8.3 Future work
Areas for future work exist in all sections of this thesis. Biologically an area for more investigation is 
the apparent  higher expression of  ChrX in neurons.  Not  only can this be directly validated by 
looking at the expression of laser dissected neurons versus other brain tissues but if it is validated, 
the  potential  epigenetic  mechanisms  and  relationship  to  X-dosage  control  can  be  further 
investigated. Investigations of differences in spatial methylation and other markers being a possible 
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investigation route.  Similarly if  new data with information on confounds could be acquired, the 
pattern associated with PMI can be investigated. It would then be possible to investigate the lack of 
tissue  specificity  thoroughly.                                                      
Other  biological  investigations  would  include  deeper  analysis  of  tissue  specific  spatial 
methylation. In particular the tissues used here were brain regions, and it might be expected that 
non-brain regions, or different cell  types would show a larger difference. The location of tissue 
specific differential methylation could also be investigated and in particular compared with that from 
cancer.   These  features  may  relate  to  'CpG  shores'  or  other  features  such  as  LADs.  Other 
epigenetic markers (such as various histone acetylations etc) could also be investigated, to see if  
they  have  spatial  components.  Chromowave-SCA  could  be  used  to  investigate  the  joint 
organisation of these marks, whether they are spatial or not.
The  methodological  work  in  this  paper  could  mainly  benefit  in  being  applied  to  new 
datasets. More understanding of the role of spatial coherence in methylation, would produce a 
better understanding of its importance and generality. An important piece of work for CwICA and 
the Hurst techniques would be to determine their power and sensitivity, while is is important to 
demonstrate  whether  anti-chromowave is  is  reproducible.  As  discussed  in  that  section, 
Chromowave-SCA could be extended to  include data which has not been wavelet transformed, or 
to other types of data such as genome wide association studies. Other mathematical models could 
also be applied in wavelet space to see if better analytical tools than those developed here could 
be produced.
    Another useful area for further work, would be to investigate whether spatial modelling could be 
used for prediction or diagnosis. Many approaches exist which could be investigated. SVD could 
be applied by projecting the results onto the wavelet transform of the data, but it would probably be 
better to make use of dedicated prediction techniques, such as machine learning or data mining 
techniques.  This  would require the segmentation  of  the data into  training and testing  sets (or 
possibly cross validation techniques where data is more limited). This would enable estimates of 
the classification rate, sensitivity, specificity and predictive values to be produced. An advantage of 
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this type of technique is that it may be possible to use wavelet techniques as an aid to diagnosis.  
This would be particularly useful for diseases such as Parkinson's or Alzheimer's which are hard to 
diagnose (not for diseases such as Huntington's where there is already a simple diagnostic test). 
However, no evidence of disease specific changes were found for these in this thesis. A further 
disadvantage of this sort of approach is that it does not necessarily tell you anything about the 
disease mechanisms or potential confounds, which may be obtained using modelling techniques 
investigated here.  Another  important  consideration would be that  a large number  of  probes is 
required to develop the wavelet space profile. Although Chromowave outperformed probe-SVD in 
all cases in this thesis, there is no guarantee that a small number of probes don't capture the 
differences between diseases better than  Chromowave. Given the cost implications of scanning 
massive numbers of genes, attempting to identify a small number of reporter genes may be a 
better direction to investigate for prediction. However, the averages of large numbers of genes are 
likely to be more stable and less noisy and so perhaps there is room for spatial modelling.
An area which combines biological and methodological work for future work, is the inclusion 
of bioinformatics tools into the spatial modelling. Prior knowledge of the ontology and pathways 
analysis can potentially help with informing the understanding. 
As already mentioned, a final area for future work is to investigate alternative methods of 
modelling space. Almost all the models in this thesis required the wavelet transform, while other 
techniques  (e.g.  HMM)  have  been  used  in  other  fields.  In  addition  other  versions  of  spatial 
coherence (for example that involved in the spiral organisation of DNA or 3D coherence) would be 
suitable for future investigations. This is especially true given the newer types of data which are 
beginning to appear (e.g. Hi-C and ChIA data (Rusk 2009; Swami 2009)). These methods probe 
the 3D chromatin structure in far more detail than has been possible previously. Such data was not 
available during the majority of  this  thesis,  but  as more is  collected new models are likely  to 
become possible. 
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APPENDICES 
Appendix 1: List of genes acting as neuronal proxies
PPT1
CDH2
PACSIN2
NAV1
ACCN2
CALN1
SMNDC1
ANK2
SIP1
CLN3
NENF
NPAS3
ENO2
NRCAM
CLN5
CHRNB2
NPAS3
NAV2
PUNC
LRRN5
CLN6
ANK2
SLC1A1
NPAS2
LRRTM2
210
CLN8
NAV3
CPNE6
PACSIN3
LRRN1
ACCN1
LRRN3
CALN1
SMN1
LRRN6D
LOC390667
NOS1AP
PACSIN1
NPTX2
LRRTM3
INA
SLC22A3
TMOD2
NNAT
LRRN6A
ACCN1
LRRN6C
LRRTM4
NPTXR
NPAS4
NEGR1
SMN2
NPAS1
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CHRNA2
NPTX1
NGEF
LRRTM1
NOS1
LRRN5
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Appendix 2: Spatial persistence in methyl-seq data
Chromosome 1
Subject Hurst estimate Estimated p-value51
1 0.73 < 5 x 10-5
2 0.73 < 5 x 10-5
3 0.72 < 5 x 10-5
4 0.81 < 5 x 10-5
5 0.81 < 5 x 10-5
6 0.81 < 5 x 10-5
7 0.81 < 5 x 10-5
8 0.81 < 5 x 10-5
9 0.81 < 5 x 10-5
10 0.8 < 5 x 10-5
11 0.81 < 5 x 10-5
12 0.81 < 5 x 10-5
13 0.8 < 5 x 10-5
14 0.79 < 5 x 10-5
15 0.76 < 5 x 10-5
16 0.73 < 5 x 10-5
Chromosome 2
Subject Hurst estimate Estimated p-value
1 0.67 < 5 x 10-5
2 0.68 < 5 x 10-5
3 0.69 < 5 x 10-5
4 0.78 < 5 x 10-5
5 0.78 < 5 x 10-5
6 0.78 < 5 x 10-5
7 0.78 < 5 x 10-5
8 0.78 < 5 x 10-5
9 0.78 < 5 x 10-5
10 0.78 < 5 x 10-5
11 0.78 < 5 x 10-5
12 0.78 < 5 x 10-5
13 0.78 < 5 x 10-5
14 0.78 < 5 x 10-5
15 0.78 < 5 x 10-5
16 0.78 < 5 x 10-5
51 P-values were estimated using 20,000 permutations of data. Examples where no permutations gave results as extreme as the Hurst 
estimate are given the marker “< 5 x 10-5”, these examples are clearly denoted as significant.
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Chromosome 3
Subject Hurst estimate Estimated p-value
1 0.6 0.01
2 0.6 0.01
3 0.54 0.21
4 0.68 < 5 x 10-5
5 0.68 < 5 x 10-5
6 0.67 < 5 x 10-5
7 0.67 < 5 x 10-5
8 0.67 < 5 x 10-5
9 0.68 < 5 x 10-5
10 0.66 < 5 x 10-5
11 0.68 < 5 x 10-5
12 0.67 < 5 x 10-5
13 0.66 < 5 x 10-5
14 0.62 < 5 x 10-5
15 0.62 < 5 x 10-5
16 0.61 < 5 x 10-5
Chromosome 4
Subject Hurst estimate Estimated p-value
1 0.75 0.01
2 0.74 0.01
3 0.74 0.21
4 0.82 < 5 x 10-5
5 0.82 < 5 x 10-5
6 0.82 < 5 x 10-5
7 0.82 < 5 x 10-5
8 0.82 < 5 x 10-5
9 0.82 < 5 x 10-5
10 0.8 < 5 x 10-5
11 0.81 < 5 x 10-5
12 0.81 < 5 x 10-5
13 0.8 < 5 x 10-5
14 0.78 < 5 x 10-5
15 0.74 < 5 x 10-5
16 0.75 < 5 x 10-5
214
Chromosome 5
Subject Hurst estimate Estimated p-value
1 0.71 0.05
2 0.71 < 5 x 10-5
3 0.72 < 5 x 10-5
4 0.79 < 5 x 10-5
5 0.8 < 5 x 10-5
6 0.79 < 5 x 10-5
7 0.79 < 5 x 10-5
8 0.79 < 5 x 10-5
9 0.8 < 5 x 10-5
10 0.79 < 5 x 10-5
11 0.8 < 5 x 10-5
12 0.8 < 5 x 10-5
13 0.79 < 5 x 10-5
14 0.79 < 5 x 10-5
15 0.77 < 5 x 10-5
16 0.74 < 5 x 10-5
Chromosome 6
Subject Hurst estimate Estimated p-value
1 0.69 0.05
2 0.69 < 5 x 10-5
3 0.67 < 5 x 10-5
4 0.75 < 5 x 10-5
5 0.75 < 5 x 10-5
6 0.75 < 5 x 10-5
7 0.75 < 5 x 10-5
8 0.75 < 5 x 10-5
9 0.75 < 5 x 10-5
10 0.75 < 5 x 10-5
11 0.75 < 5 x 10-5
12 0.75 < 5 x 10-5
13 0.75 < 5 x 10-5
14 0.73 < 5 x 10-5
15 0.73 < 5 x 10-5
16 0.73 < 5 x 10-5
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Chromosome 7
Subject Hurst estimate Estimated p-value
1 0.73 < 5 x 10-5
2 0.73 < 5 x 10-5
3 0.7 < 5 x 10-5
4 0.8 < 5 x 10-5
5 0.8 < 5 x 10-5
6 0.8 < 5 x 10-5
7 0.8 < 5 x 10-5
8 0.8 < 5 x 10-5
9 0.8 < 5 x 10-5
10 0.79 < 5 x 10-5
11 0.8 < 5 x 10-5
12 0.79 < 5 x 10-5
13 0.78 < 5 x 10-5
14 0.76 < 5 x 10-5
15 0.74 < 5 x 10-5
16 0.73 < 5 x 10-5
Chromosome 8
Subject Hurst estimate Estimated p-value
1 0.7 0.05
2 0.7 0.05
3 0.73 < 5 x 10-5
4 0.82 < 5 x 10-5
5 0.81 < 5 x 10-5
6 0.81 < 5 x 10-5
7 0.81 < 5 x 10-5
8 0.81 < 5 x 10-5
9 0.81 < 5 x 10-5
10 0.81 < 5 x 10-5
11 0.82 < 5 x 10-5
12 0.81 < 5 x 10-5
13 0.81 < 5 x 10-5
14 0.78 < 5 x 10-5
15 0.76 < 5 x 10-5
16 0.73 < 5 x 10-5
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Chromosome 9
Subject Hurst estimate Estimated p-value
1 0.7 0.05
2 0.71 0.05
3 0.73 < 5 x 10-5
4 0.79 < 5 x 10-5
5 0.79 < 5 x 10-5
6 0.79 < 5 x 10-5
7 0.79 < 5 x 10-5
8 0.79 < 5 x 10-5
9 0.79 < 5 x 10-5
10 0.79 < 5 x 10-5
11 0.79 < 5 x 10-5
12 0.79 < 5 x 10-5
13 0.77 < 5 x 10-5
14 0.75 < 5 x 10-5
15 0.7 < 5 x 10-5
16 0.64 0.0002
Chromosome 10
Subject Hurst estimate Estimated p-value
1 0.69 < 5 x 10-5
2 0.7 < 5 x 10-5
3 0.6 < 5 x 10-5
4 0.81 < 5 x 10-5
5 0.81 < 5 x 10-5
6 0.81 < 5 x 10-5
7 0.81 < 5 x 10-5
8 0.81 < 5 x 10-5
9 0.81 < 5 x 10-5
10 0.81 < 5 x 10-5
11 0.82 < 5 x 10-5
12 0.82 < 5 x 10-5
13 0.82 < 5 x 10-5
14 0.81 < 5 x 10-5
15 0.8 < 5 x 10-5
16 0.78 < 5 x 10-5
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Chromosome 11
Subject Hurst estimate Estimated p-value
1 0.69 < 5 x 10-5
2 0.7 < 5 x 10-5
3 0.68 < 5 x 10-5
4 0.76 < 5 x 10-5
5 0.75 < 5 x 10-5
6 0.75 < 5 x 10-5
7 0.75 < 5 x 10-5
8 0.76 < 5 x 10-5
9 0.75 < 5 x 10-5
10 0.75 < 5 x 10-5
11 0.76 < 5 x 10-5
12 0.75 < 5 x 10-5
13 0.74 < 5 x 10-5
14 0.73 < 5 x 10-5
15 0.7 < 5 x 10-5
16 0.66 < 5 x 10-5
Chromosome 12
Subject Hurst estimate Estimated p-value
1 0.72 0.05
2 0.72 < 5 x 10-5
3 0.73 < 5 x 10-5
4 0.8 < 5 x 10-5
5 0.8 < 5 x 10-5
6 0.8 < 5 x 10-5
7 0.8 < 5 x 10-5
8 0.8 < 5 x 10-5
9 0.8 < 5 x 10-5
10 0.79 < 5 x 10-5
11 0.79 < 5 x 10-5
12 0.79 < 5 x 10-5
13 0.79 < 5 x 10-5
14 0.76 < 5 x 10-5
15 0.74 < 5 x 10-5
16 0.75 < 5 x 10-5
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Chromosome 13
Subject Hurst estimate Estimated p-value
1 0.7 < 5 x 10-5
2 0.69 < 5 x 10-5
3 0.66 < 5 x 10-5
4 0.77 < 5 x 10-5
5 0.76 < 5 x 10-5
6 0.77 < 5 x 10-5
7 0.77 < 5 x 10-5
8 0.77 < 5 x 10-5
9 0.76 < 5 x 10-5
10 0.77 < 5 x 10-5
11 0.77 < 5 x 10-5
12 0.77 < 5 x 10-5
13 0.77 < 5 x 10-5
14 0.75 < 5 x 10-5
15 0.73 < 5 x 10-5
16 0.73 < 5 x 10-5
Chromosome 14
Subject Hurst estimate Estimated p-value
1 0.72 0.05
2 0.72 < 5 x 10-5
3 0.71 0.05
4 0.8 < 5 x 10-5
5 0.8 < 5 x 10-5
6 0.8 < 5 x 10-5
7 0.81 < 5 x 10-5
8 0.81 < 5 x 10-5
9 0.8 < 5 x 10-5
10 0.79 < 5 x 10-5
11 0.8 < 5 x 10-5
12 0.8 < 5 x 10-5
13 0.79 < 5 x 10-5
14 0.76 < 5 x 10-5
15 0.7 0.00015
16 0.69 0.00025
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Chromosome 15
Subject Hurst estimate Estimated p-value
1 0.55 0.13
2 0.53 0.36
3 0.57 0.05
4 0.69 < 5 x 10-5
5 0.69 < 5 x 10-5
6 0.69 < 5 x 10-5
7 0.68 < 5 x 10-5
8 0.69 < 5 x 10-5
9 0.69 < 5 x 10-5
10 0.69 < 5 x 10-5
11 0.67 < 5 x 10-5
12 0.64 < 5 x 10-5
13 0.66 < 5 x 10-5
14 0.66 < 5 x 10-5
15 0.65 0.00015
16 0.62 0.00025
Chromosome 16
Subject Hurst estimate Estimated p-value
1 0.71 < 5 x 10-5
2 0.71 < 5 x 10-5
3 0.74 < 5 x 10-5
4 0.76 < 5 x 10-5
5 0.76 < 5 x 10-5
6 0.76 < 5 x 10-5
7 0.76 < 5 x 10-5
8 0.76 < 5 x 10-5
9 0.76 < 5 x 10-5
10 0.75 < 5 x 10-5
11 0.75 < 5 x 10-5
12 0.76 < 5 x 10-5
13 0.71 0.0001
14 0.68 0.0003
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Chromosome 17
Subject Hurst estimate Estimated p-value
1 0.68 0.0002
2 0.68 0.0001
3 0.72 < 5 x 10-5
4 0.78 < 5 x 10-5
5 0.69 < 5 x 10-5
6 0.67 < 5 x 10-5
7 0.7 < 5 x 10-5
8 0.78 < 5 x 10-5
9 0.77 < 5 x 10-5
10 0.77 < 5 x 10-5
11 0.77 < 5 x 10-5
12 0.77 < 5 x 10-5
13 0.76 < 5 x 10-5
14 0.76 < 5 x 10-5
15 0.75 < 5 x 10-5
16 0.72 < 5 x 10-5
Chromosome 18
Subject Hurst estimate Estimated p-value
1 0.69 < 5 x 10-5
2 0.67 0.0006
3 0.7 0.0001
4 0.78 < 5 x 10-5
5 0.77 < 5 x 10-5
6 0.77 < 5 x 10-5
7 0.78 < 5 x 10-5
8 0.77 < 5 x 10-5
9 0.78 < 5 x 10-5
10 0.77 < 5 x 10-5
11 0.79 < 5 x 10-5
12 0.78 < 5 x 10-5
13 0.78 < 5 x 10-5
14 0.77 < 5 x 10-5
15 0.76 0.0001
16 0.7 0.0001
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Chromosome 19
Subject Hurst estimate Estimated p-value
1 0.63 0.0004
2 0.64 0.0004
3 0.67 < 5 x 10-5
4 0.72 < 5 x 10-5
5 0.72 < 5 x 10-5
6 0.71 < 5 x 10-5
7 0.71 < 5 x 10-5
8 0.72 < 5 x 10-5
9 0.73 0.0001
10 0.7 < 5 x 10-5
11 0.71 < 5 x 10-5
12 0.71 < 5 x 10-5
13 0.69 0.0001
14 0.68 0.0001
15 0.66 0.0001
16 0.66 0.0001
Chromosome 20
Subject Hurst estimate Estimated p-value
1 0.65 0.0007
2 0.66 0.0006
3 0.72 < 5 x 10-5
4 0.76 < 5 x 10-5
5 0.76 < 5 x 10-5
6 0.76 < 5 x 10-5
7 0.75 < 5 x 10-5
8 0.76 < 5 x 10-5
9 0.76 < 5 x 10-5
10 0.75 < 5 x 10-5
11 0.76 < 5 x 10-5
12 0.75 < 5 x 10-5
13 0.75 < 5 x 10-5
14 0.74 < 5 x 10-5
15 0.72 < 5 x 10-5
16 0.65 0.0006
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Chromosome 21
Subject Hurst estimate Estimated p-value
1 0.75 < 5 x 10-5
2 0.76 < 5 x 10-5
3 0.74 < 5 x 10-5
4 0.77 < 5 x 10-5
5 0.79 < 5 x 10-5
6 0.78 < 5 x 10-5
7 0.78 < 5 x 10-5
8 0.79 < 5 x 10-5
9 0.78 < 5 x 10-5
10 0.79 < 5 x 10-5
11 0.77 < 5 x 10-5
12 0.79 < 5 x 10-5
13 0.76 < 5 x 10-5
14 0.73 < 5 x 10-5
15 0.69 < 5 x 10-5
16 0.65 < 5 x 10-5
Chromosome 22
Subject Hurst estimate Estimated p-value
1 0.63 0.0046
2 0.64 0.0024
3 0.65 0.0013
4 0.75 < 5 x 10-5
5 0.75 < 5 x 10-5
6 0.75 < 5 x 10-5
7 0.75 < 5 x 10-5
8 0.75 < 5 x 10-5
9 0.75 0.0001
10 0.74 0.0001
11 0.76 < 5 x 10-5
12 0.74 < 5 x 10-5
13 0.74 0.0001
14 0.75 < 5 x 10-5
15 0.74 < 5 x 10-5
16 0.68 0.0004
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Chromosome X
Subject Hurst estimate Estimated p-value
1 0.63 0.0053
2 0.65 0.0025
3 0.56 0.1099
4 0.66 0.0014
5 0.66 0.0017
6 0.65 0.0019
7 0.65 0.0022
8 0.66 0.0015
9 0.66 0.0017
10 0.65 0.0031
11 0.66 0.0014
12 0.64 0.0031
13 0.64 0.0040
14 0.65 0.0029
15 0.64 0.0022
16 0.63 0.0044
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